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12. Conducting science in a place where tectonic plates collide, gives additional 
meaning to the notion "earth-shocking discoveries". 
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'Mouse'. By Rogier (l'A years old) 
CHAPTER 1 
Introduction 
1.1. Hematopoietic development; a brief overview 
Hematopoiesis in higher vertebrates is a complex and accurately controlled process. Blood cells 
originate from a population of totipotent hematopoietic stem cells, which retain proliferative and regenera-
tive capacity, and underlie the continuously renewing hematopoietic system (Broxmeyer, 1991; Tavassoli, 
1991). 
A myriad of cytokines, acting either alone or in concert, are capable of stimulating proliferation of 
hematopoietic stem cells and progenitor cells and/or promoting their subsequent differentiation in vitro 
and in vivo. These factors are at the basis of a dynamically regulated hematopoietic homeostasis, which 
allows an organism to adequately respond to altered demands (Sachs, 1987; Metcalf, 1989; Harmening, 
1992). 
1.2. Leukemia 
Leukemia is a blood disease characterized by a great increase in numbers of abnormal white blood 
cells. Uncontrolled production of leukocytes is caused by cancerous mutation of a myelogenous or a 
lymphogenous cell. Usually, the more undifferentiated the cell type, the more acute the leukemia is, often 
leading to death within a few months if left untreated (Guyton, 1991). 
Leukemia is accompanied by metastatic growth of leukemic cells in abnormal areas of the body. 
Leukemic cells of the bone marrow may be produced in such great numbers that they invade surrounding 
bone, causing pain and a tendency to easy fracture. Almost all leukemias spread to the spleen, lymph 
nodes and other well vascularized regions, regardless of whether the origin of the leukemia is in the bone 
marrow or in the lymph nodes. The rapidly growing cells invade the surrounding tissue, depleting these 
tissues of metabolic elements and consequently causing tissue destruction and metabolic wasting of the 
organism. 
Increased susceptibility to infection, as a result of immune system failure, severe anemia and bleeding 
tendency caused by thrombocytopenia (lack of platelets) are all very common effects in leukemia and 
result mainly from displacement of the bone marrow by non-functional leukemic cells. 
1 3 . Genetic basis of human cancer 
Most cancers in human are of genetic origin: accumulation of multiple mutations within the DNA of 
a single somatic cell cause the cell to lose growth control (Hopkins, 1987). The concept of somatic 
mutation of cancers was proposed early this century (Boveri, 1929) and later specified (Nowell, 1970; 
Knudson, 1975). Karyotypically visible abnormalities have been known to occur in neoplasias (Von 
Hansemann, 1890; Boveri, 1914) since the turn of the last century. For many years it had been suspected, 
that such abnormalities might cause cancer by alteration of specific genes or their expression. Only in the 
last decades, due to introduction and continuous improvement of cytogenetic and molecular techniques, 
has the significance of chromosomal aberrations in the onset and progression of cancers become clear: 
analysis of recurrent cytogenetic abnormalities in cancer has led to the identification of many oncogenes, 
genes involved in the development of cancer (Bishop, 1991; Rabbitts, 1994). 
• Cellular oncogenes in cancer; viral origin 
A significant part of current conceptual understanding of carcinogenesis in vertebrates is derived from 
virologie research: cellular oncogenes were first discovered as cellular counterparts of transforming 
oncogenes found in retroviruses. At the beginning of this century it was shown that some avian leukemias 
and sarcomas were transmissible in cell-free extracts (Ellerman and Bang, 1908; Rous, 1910). This pointed 
to an infectious nature of certain cancers. Following the isolation of mammalian tumor viruses in the 
early 60's, interest in oncogenic viruses was greatly enhanced. At present, viruses that can cause cancer 
and transform cells in culture include several DNA tumor viruses (families: Papovaviridae, Adenoviridae 
and Herpetoviridae) and RNA containing viruses (family: Retroviridae). All oncogenic viruses of the latter 
family belong to the subfamily Oncovirinae. Among these oncornaviruses, C-type virus particles are 
equipped with the ability to transduce genes of cellular origin onto their own genome. These so-called viral 
oncogenes (v-onc) are, due to altered expression and/or acquired genetic mutation(s) of the cellular genes, 
responsible for initiation and maintenance of malignant cellular transformation. The cellular counterparts 
of v-oncs appear to be evolutionary conserved sequences and are, under normal circumstances, often 
implicated in growth control. These genes are referred to as cellular (proto-)oncogenes (c-onc). Since the 
first isolation of Rous sarcoma virus from avian sarcomas, many more oncornaviruses have been found in 
chicken, turkey, mice, rats, cats and monkeys. To date, over 30 different viral oncogenes are known 
(Varmus, 1989; Bishop, 1991), a number which is still increasing. 
While numerous transforming viruses have been isolated, viral carcinogenesis in animals is a relatively 
rare process and even more so in human. There are several examples where tumor viruses may be 
implicated in human cancer, such as hepatitis B (and C) in hepatocellular carcinoma, human papilloma 
virus in anogenital cancers, Epstein-Barr virus in nasopharyngeal carcinoma and Burkitt's lymphoma, 
human T-cell leukemia/Iymphoma viruses in adult T-cell leukemia/lymphoma. These are nonetheless rare 
cases, and the mechanism(s) by which the viruses cause the disease are often not understood (Hopkins, 
1987). Since the discovery of proto-oncogenes in the mammalian genome, however, it has become clear 
that, analogous to the role of v-oncs in viral carcinogenesis, these c-oncs play a key role in human car-
cinogenesis as well (reviewed by: Varmus 1989; Bishop, 1991). The development of a fully malignant 
tumor involves the activation or altered expression of oncogenes, or the inactivation of tumor suppressor 
genes that control normal cellular development. It generally is accepted that approximately 80% of all 
cancers have an environmental component (Higginson, 1993): the majority of human cancers arises by 
chance, as a result of (accumulation of) mutation(s) through exposure to various occupational or 
environmental genotoxins (e.g. tobacco, asbestos and radon (lung cancer), UV light (melanoma), ionizing 
radiation (leukemia)). Only in a few instances are inherited predisposing mutations known to be responsible 
for tumorigenesis (e.g. Wilms' tumor; retinoblastoma). 
• Mechanisms of oncogenic activation 
Among cytogenetic changes known to be at the basis of oncogenic transformation, are: point mutations 
(such as those in RAS, P53, Rb genes in various cancers; reviewed by Bishop, 1991), deletions (often 
resulting in loss of tumor suppressor genes, like the Rb gene in retinoblastoma; reviewed by Marshal, 
1991), gene amplifications (among the best characterized are the MYC gene amplifications in 
neuroblastomas and RAS gene amplifications in primary lung, bladder, colon and rectum carcinoma; 
reviewed by Bishop, 1991), and gene inversions and translocations (reviewed by Rabbitts, 1994). Among 
the latter group, mutations consistently found in certain tumor types (specific), and those found in isolated 
cases (idiopathic) are distinguished. 
Historically, much information has been gathered from studying chromosomal aberrations in leukemias, 
because of easy access to primary tumor cells. Leukemia often results from specific chromosomal transloca-
tions and inversions, that cause activation of proto-oncogene products (through positioning of a T-cell 
receptor gene or an immunoglobulin gene in close proximity to a proto-oncogene) or, more commonly, 
creation of tumor specific fusion proteins (chimaeric oncoproteins). Affected genes in both categories often 
involve transcription factors. In solid tumors, the majority of translocations results in the formation of 
chimaeric oncoproteins. The combined cytogenetic and molecular biological findings suggest that protein 
fusion may prove to be a general theme in malignant chromosomal translocation (Rabbitts, 1994). 
1.4. The Philadelphia chromosome in leukemia 
One chromosomal abnormality in particular has served as a paradigm for investigation of human 
leukemia and of other forms of malignant disease. Not only was the Philadelphia chromosome (Ph ) the 
first recognized cytogenetic aberration consistently associated with a specific form of cancer, cytogenetic 
and molecular dissection of the breakpoint on chromosomes 22 and 9 and its gene-fusion product have 
been pivotal in outlining and understanding some of the current mechanistic concepts that underlie 
oncogenic transformation. The Philadelphia translocation in specific types of leukemia and the genes 
involved will be discussed in detail below. 
9 9q+ 
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Figure 1. The Philadelphia (Ph) translocation. (Left) The chromosomes involved in the Ph translocation, chromosomes 
9 and 22, and the resulting abnormal chromosomes 9q* and 22q~. (Right) A schematic drawing of this chromosomal 
translocation with the approximate locations of the abl and sis oncogenes. Arrows indicate the positions of the 
chromosomal breakpoints (figure taken from Heisterkamp and Groffen, 1991). 
Chronic myelogenous leukemia (CML) was first recognized as a clinical entity around the middle 
of the last century. In the ensuing years the disease was distinguished from other myeloproliferative 
disorders on the ground of its distinct clinical and pathological features. The first real clue to its patho-
genesis was the landmark discovery of an abnormally small chromosome in 1960 (Nowell and Hungerford, 
1960). The Philadelphia chromosome (Ph), named in honor of the city in which it was discovered, was 
the first specific chromosomal abnormality to be consistently associated with one particular form of human 
cancer. 
A decade after the first description of the iVi-chromosome, it was identified as a modified chromosome 
22 (Caspersson et al. 1970). Subsequently, it was shown that the abnormal chromosome was the product 
of a translocation, [t(9:22)(q34;qll)], between chromosome 22 and chromosome 9 (Rowley et al., 1973), 
in which the distal portion of the long arm of chromosome 22 (22qll.21 to qter region) had become joined 
to chromosome 9 at band q34 (Fig. 1). Despite the general assumption that the translocation was 
reciprocal, this was not confirmed at the molecular level until 10 years later when it was shown, that a 
gene (ABL) encoded on a small segment of chromosome 9 (q34.1 to qter), moved to chromosome 22 at 
band q l l (De Klein et al., 1982; Bartram et al, 1983; Groffen et al., 1984). 
The association between the presence of the /"^-chromosome and CML is well established: over 95% 
of all patients have this chromosome in their leukemic cells. Although literature has customarily referred 
to P/t-positive and .P/z-negative CML, some of the remaining 5% of patients were found to have 'Ph-
translocations', which were often not microscopically visible, but which could be detected using molecular 
techniques (reviewed by: Mitelman, 1993). In recent years it has been suggested that the remaining class 
of CML patients lacking this chromosomal translocation altogether do not have true CML but rather 
suffer from other myeloproliferative disorders (reviewed by: Clarkson and Strife, 1991). The Ph-
chromosome is also found in a low percentage of acute myeloid leukemia (AML; also referred to as 
acute non-lymphocytic leukemia; ANLL) and in adult and childhood acute lymphoblastic leukemia 
(ALL). The percentage of ALL patients reported to have a TVi-chromosome varies from 2-6% in children 
to 17-25% in adults (Priest et al., 1980; Champlin et al., 1985). 
• Origin and pathogenesis of ALL and CML 
Acute lymphoblastic leukemia (ALL) is the major subtype of pediatric cancer in developed countries. 
ALL is a biologically diverse disease and is divided into broad subgroups, according to immunological and 
karyotypic criteria. These subtypes correspond roughly to T and B-cell precursor populations. The target 
cell for ALL is either a multi-potential stem cell or a lymphoid (T or B) stem cell. Childhood and adult 
.P/i-positive ALL are acute in onset and invariably of pre-B lymphoblastic origin. Despite advances in 
understanding of cell and molecular biology of ALL, the etiology of ALL remains elusive. Some 
leukemogenic factors have been defined, however, including exposure to high levels of radiation, Down's 
syndrome and other chromosome fragility disorders (Greaves, 1990). 
The distinctive and diverse chromosomal abnormalities associated with ALL subtypes most probably 
reflect important components of the etiological mechanisms involved. The Philadelphia translocation is 
the most common chromosomal abnormality in ALL. ALL has been referred to as clinically remarkable 
in that a substantial portion of cases are curable with relatively modest doses of chemotherapy and prophy-
lactic CNS radiation. However, the cytogenetic P/i-marker is associated with a very poor clinical prognosis: 
patients with P h + ALL are rarely cured (Fletcher et al, 1991; Greaves, 1990). 
The incidence of CML in most Western countries is about 1.5 per 100.000 population per year and 
accounts for about 15 percent of all cases of leukemia. About 3500 new cases are diagnosed in the USA 
each year. The cause of CML and the mechanisms, which determine its progression, are presently 
unknown. It is an acquired disease, but there are no clues to its etiology other than an increased incidence 
in individuals with exposure to increasing doses of ionizing radiation. This has been noted following chronic 
exposure in radiologists, who practiced without adequate shielding, in patients submitted to radiation 
treatment, and in individuals exposed to a high doses of radiation from the detonation of nuclear weapons 
such as in Japan in 1945. 
CML is a clonal myeloproliferative disorder, arising from neoplastic transformation of a hematopoietic 
progenitor cell and is characterized clinically by clonal expansion of the myeloid compartment, involving 
neutrophils and their direct precursors. This chronic phase is characterized by marked hyperplasia of 
myeloid cells, that maintain their maturation capacity, and is easily controlled with therapy. 
The disease goes through an accelerated phase during which the myeloid cells gradually lose their 
capacity for terminal differentiation. Basophilia, thrombocytosis, and cytogenetic clonal evolutions also 
appear. Ultimately the disease undergoes a transition to a more aggressive type leukemia (blastic phase 
or blast crisis) on average four years after diagnosis (i.e. chronic phase). At this point, /Vi-positive cells 
appear to have lost their capacity to differentiate and the rapid accumulation of cells, that retain a 'blast' 
morphology and are highly resistant to therapy, is directly or indirectly responsible for the invariably fatal 
outcome of the cancer. Blast crisis can be classified as myeloid, lymphoid or undifferentiated, based on 
morphologic, cytochemical and immunologic features of the cells (reviewed by: Kantarjian et al., 1991). 
Treatment has been attempted for over 60 years. Currently, the most promising protocols are bone 
marrow transplantation, for which only a select group of patients is eligible, and interferon treatment. 
The presence of the P/i-chromosome in erythrocyte, granulocyte, monocyte, lymphocyte and 
megakaryocyte precursors in CML seems to point to the original genetic mutation having occurred in an 
ancestral cell common to these cell types, but the exact location of the transforming event within the 
progenitor cell lineages remains unclear. Usually, all nucleated cells in the bone marrow are Ph-positive 
at the time of diagnosis. .P/z-negative normal cells persist, but their growth is apparently suppressed by 
the leukemic cells. The Ph-chromosome is absent in the majority of mature lymphocytes, although in 
about 20-25% of patients in chronic phase some B cells contain the /Vi-marker and early B cell progenitors 
predominate in about 25% of patients in blastic transformation (Champlin and Golde, 1985). T lymphocyte 
involvement has only rarely been reported, although recent findings would indicate that bilineal (T lym-
phoid/myeloid) .P/i-positive progenitors may be implicated in some cases of blastic transformation (Akashi 
et al, 1993). 
Tumor progression is a fundamental feature of cancer biology. Cancers do not arise de novo in their 
final form, but begin as small indolent growths, which gradually acquire characteristics associated with 
malignancy. Most leukemias, as is also the case with solid tumors, undergo clonal development and 
karyotypic evolution. As a result of the original leukemic clones acquiring additional genetic abnormalities, 
a proliferative advantage is conferred on subclones, which become increasingly malignant. About 10% of 
CML patients present at diagnosis with other chromosomal abnormalities in addition to the Ph-
chromosome (Clarkson and Strife, 1991). At the time of blast crisis, approximately 8 out of 10 CML 
patients show additional chromosome abnormalities. Non-random translocations are most common, but 
additions, deletions, inversions, duplications and other structural chromosome abnormalities also occur 
frequently (Clarkson and Strife, 1991). In /%-positive ALL, more than 90% of cases have identifiable 
chromosomal abnormalities at diagnosis, with structural changes occurring more frequently than numerical 
changes (75% vs. 60%). In addition, often other chromosome translocations are present besides the Ph-
chromosome (Williams et al., 1990). 
1.5. Molecular insight into the Philadelphia translocation 
A cellular oncogene designated ABL is located on chromosome 9 in band 9q34. The possibility of 
ABL involvement in the /Vi-translocation was substantiated, when translocation breakpoints were 
discovered within its 5' region (De Klein et al., 1982; Heisterkamp et al., 1983, 1983a; Groffen et al, 
1987). In the P/i-translocation, part of it is moved to chromosome 22 (Heisterkamp and Groffen, 1991; 
Heisterkamp et al., 1993a). The majority of breakpoints in ABL occurs in the large intron between the 
two alternative first exons, IB and 1A, and in that between 1A and 2 (Fig. 2). Some breakpoints occur 
in the main body of exons, sporadically upstream of exon IB (Morris et al., 1990, and references therein). 
The location of the breakpoint is directly responsible for what happens on a molecular level in the Ph-
translocation: a truncated ABL proto-oncogene, missing its regulatory promoter region, is joined to 
sequences on chromosome 22 (Fig. 3). 
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Fi&ae 2 The human ABL locus. The genomic DNA of the ABL locus is represented by the horizontal lane, with the 
bracket and the solid lines indicating the regions not cloned and cloned to date. The alternative exons lb and la and the 
common exon II are marked, as well as the exon containing the phosphotyrosine acceptor site (tyr; Groffen et al., 1983). 
Arrows below the graph point to the position of chromosomal breakpoints on chromosome 9 in 5 CML patient DNAs. 
The arrow above the map indicates the position of the breakpoint in the CML cell line K562, which has been used in 
numerous in vitro studies (figure taken from Heisterkamp and Groffen, 1991). 
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Figure 3. The human BCR locus and its chimaeric translational products. (A) More than 95% of breakpoints in CML 
are located within the M-bcr. In a subclass ofPh* ALL, breakpoints are found within m-bçr. Exons are indicated with 
boxed areas in the restriction map. E = EcoRl, E denotes a polymorphic EcoRI site. (B) The chimaeric Bcr/Abl 
oncoproteins are shown schematically; the Abl moiety is the same in both types of patients, whereas the contribution of 
Bcr domains varies (see also Fig. 5; figure taken from Heisterkamp and Groffen, 1991). 
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The breakpoints on chromosome 22 are restricted to relatively limited regions of DNA located within 
a gene designated BCR (breakpoint cluster region; Fig. 3). The BCR gene is oriented with its 5' end 
toward the centromere of chromosome 22. Breakpoints occur within certain introns; as a consequence, 
what remains on chromosome 22 is part of a gene still containing its promoter and a varying number of 
5' exons. The 3' exons are usually translocated to chromosome 9; their relevance for leukemogenesis is 
thought to be minor. The juxtaposition of the promoterless part olABL to the 5' BCR segment seems 
to be the crucial event. More complex and variant translocations occur, in which the 5' BCR/3' ABL 
sequences are found on other chromosomes, or on an apparently normal chromosome 22. In all these 
cases, however, the unifying common event is the joining of BCR and ABL (reviewed in Heisterkamp 
and Groffen, 1991). 
Because of their orientation with respect to each other, the two genes can be transcribed as one 
single chimaeric BCR/ABL gene (Shtivelman et al., 1985). The number of ABL exons found in the 
chimaeric transcript is relatively invariant (Fig.3). The contribution of the BCR gene to the chimaeric 
BCR/ABL oncogene differs. When the breakpoint lies within the first intron of BCR (within the minor 
breakpoint cluster region, or m-bcr), the hybrid transcript contains only BCR exon 1. In other instances, 
the break occurs within the major breakpoint cluster region (M-bcr) between exons 10 and 14 (or, by 
convention designated: M-BCR exons 1-5). Exon 1 of BCR as well as M-BCR exons 2 and 3 end after 
the first nucleotide of a triplet; since ABL exon 2 starts with the second nucleotide of a triplet, a correct 
open reading frame is maintained upon splicing of these BCR exons to ABL exon 2 (with the exception 
of the codon joining the two genes). The short, 7 kb BCR/ABL mRNA, that contains only BCR exon 1, 
encodes a protein 185,000-190,000 Dalton, and is designated P185 or P190 correspondingly. When the 
breakpoint is located in the M-bcr region, the messenger RNA's are around 8.5 kb in length. The 
corresponding proteins are 210.000 Dalton in size and referred to as P210. P190 is mainly found in juvenile 
and adult ALL, although it has occasionally been found in blastic phase of CML (Grosveld, 1990). The 
P210 is present in both CML and ALL. 
• The ABL proto-oncogene 
The ABL proto-oncogene was first identified in the mammalian genome (Goff et al., 1980) by its 
homology to the oncogene of Abelson murine leukemia virus (A-MuLV; Abelson and Rabstein, 1970). 
It has since been found to generate two more oncogenes, one of which is the v-abl of Hardy-Zuckerman 
feline sarcoma virus (HZ2) FeSV; Hardy-Zuckerman, 1970: Besmer et al., 1983). In the early 1980's ABL 
was implicated in human cancer for the first time, when it was shown that the proto-oncogene was 
translocated to the Philadelphia chromosome in CML (De Klein et al., 1982; Heisterkamp et al., 1983, 
1983a; Groffen et al., 1987). This discovery, as was the case for BCR, heralded the beginning of intensive 
research into the molecular biology of the ABL gene. 
The ABL proto-oncogene extends a region of at least 200 kb of DNA, its 3' end pointed toward the 
telomere of chromosome 9. The ABL gene has two alternative first exons, IB and 1A, which are separated 
by a large 175 kb intron. The second intron is 17 kb. The main body of ABL exons spans only 32 kb. 
The product of the c-ABL proto-oncogene is a non-receptor protein-tyrosine kinase that is ubiquitously 
expressed in mammalian cells. ABL homologs are found in different animal species and together constitute 
the abl family of tyrosine kinases (reviewed by Wang, 1993). The tyrosine specific protein kinase family 
includes transmembrane growth factor receptors like epidermal growth factor (EGF) receptor, insulin 
growth factor (IGF) receptor, platelet derived growth factor (PDGF) receptor and colony stimulating 
factor-1 (CSF-1, M-CSF, c-fms) receptor (Sefton et al, 1981; Groffen et al., 1983; Reddy et al., 1983). 
These receptors have the capacity to phosphorylate themselves (auto-phosphorylation). Abl is closely 
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related to a group of cytoplasmic or membrane associated tyrosine kinases that lack a transmembrane 
and/or extracellular domain, including proteins encoded by proto-oncogenes such as SRC, ARG and 
FES/FPS. However, the protein kinases are targeted to cellular membranes through N-myristoylation of 
an N-terminal sequence in the protein (reviewed by Resh, 1990) 
The c-Abl protein contains at least four functional domains (Fig. 4): An N-terminal variable domain, 
encoded by two alternative exons (called Type I and IV in mouse c-abl (Meijer et al., 1987; Oppi et al, 
1987), or Type la and lb in human c-abl (Ben-Neriah et al., 1986; Shtivelman et al., 1986), a kinase 
regulatory domain which includes two Src homologous regions (SH3 and SH2), the tyrosine kinase or 
SHI domain (this region harbors the enzymatic domain common to the oncogene family) and a large C-
terminal segment that is unique to the Abl family of tyrosine kinases. Deletion of N-terminal domains 
within Abl activates the Abl-kinase (Franz et al., 1989; for further discussion see: 'Molecular mechanisms 
for BCR/ABL mediated leukemogenesis'; this paragraph), as do a myriad of other mutations (Rees-
Jones and Goff, 1988). SH2 domains recognize short peptide motifs bearing phosphotyrosine residues and 
function in protein-protein interactions (Koch et al. 1991; Pawson, 1995). Although SH2 domains are not 
required for catalytic activity, specific point mutations within these modules can inactivate the Abl-kinase 
(Mayer et al, 1992). SH3 domains are, like SH2 domains, also involved in signal transduction, through 
recognition of proline residues in peptide motifs, although their exact biological function is unclear (Koch 
et al., 1991; Pawson, 1995). In c-Abl(IV), deletion of the SH3 domain activates the kinase activity of Abl 
(Franz et al., 1989), as does insertional mutation in the region between the SH3 and the SH2 domain. This 
suggested that the spatial orientation of both domains is critical for regulation (Jackson and Baltimore, 
1989) and that somehow the SH3 domain serves as a inhibitory regulator of the tyrosine kinase. Whether 
this inhibition is trans (through inhibitors) or cis (through intramolecular interaction) in nature, is currently 
not known (reviewed by Wang, 1993). 
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• 
P190 
A 
P210 
c-Abl 
v SH3 SH2 
• 
P190 
P210 
Y-kinase NTS DB F-actin 
Figure 4. Schematic depiction of structural domains within the Bcr protein (upper) and the Abl protein (lower). In pl6tPcr 
the N-terminal oligomerization domain (oligo), the approximate region responsible for the serine/threonine kinase activity 
in the protein (SIT-kinase), the Dbl-homology domain (Dbl), the pleckstrin homology domain (PH) and the C-terminal 
GAP domain (GAP) are indicated 7» pi45*°l, the variable domain (v) is encoded by two alternatively spliced first exons 
(see text). Five additional domains include the Src homology domains SH3 (SH3), SH2 (SH2) and SHI, which is the 
tyrosine kinase domain (Y-kinase), a DNA binding domain (DB) and an F-actin binding domain (F-actinB). The putative 
nuclear translocation signal is marked with NTS. Arrows in the figure indicate the approximate positions in the Bcr protein 
and in the Abl protein, N-terminal and C-terminal of which, respectively, domains are included in the chimaeric Bcr/Abl 
P190 and P210 oncoproteins; the contribution of Bcr to Bcr/Abl in P190 and P210 differs, while the Abl moiety in both 
Bcr/Abl oncoproteins is identical (see also: Fig. 3). 
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The c-Abl proto-oncoprotein is localized in both the cytoplasm, where it is weakly associated with F-
actin, and the nucleus, where it co-localizes with chromatin. Nuclear translocation, DNA-binding, and F-
actin binding are mediated by the large, non-catalytic C-terminal segment of the protein (Kipreos and 
Wang, 1992; McWirther and Wang, 1993a; Van Etten et al., 1989). The nuclear translocation of Abl is 
cell cycle dependent and corresponds to phosphorylation of serine/threonine residues in the protein. The 
DNA binding function of Abl is regulated by cell cycle-dependent cyclin 2 (cdc2)-mediated 
phosphorylation (Kipreos and Wang, 1990; Kipreos and Wang, 1992). 
The non-receptor tyrosine kinase p l 4 ^ negatively regulates cell growth when overexpressed in 
fibroblasts (Sawyers et al, 1994), a function which contrasts with that of abl fusion oncogenes such as 
x-abl and BCR/ABL. ABL null-mutant mice are runted and die within 2 weeks after birth for unknown 
reasons. In addition, many show B and T cell lymphopenia, the cause of which also remains unknown 
(Tybulewic et al., 1991; Schwartzberg et al., 1991). 
Although it seems clear that the Abl protein is involved in cell cycle regulation, at present, neither 
the mechanisms that regulate the normal c-Abl function nor the signal transduction pathways, that Abl 
is part of, are well understood. 
. The BCR gene 
The clustering of chromosomal breakpoints in a specific region of chromosome 22 (Groff en et al., 
1984) in blood cells of leukemic patients, led to the discovery the BCR gene (Heisterkamp et al. 1985). 
In human, the BCR gene is ubiquitously expressed. In the mouse, bcr expression is detectable as early 
as the zygote stage, continues throughout embryogenesis (unpublished observations) and is found in most 
adult tissues examined with a relatively high expression in brain (Heisterkamp et al., 1993). 
The BCR gene encodes a 160 kDa cytoplasmic protein with several functional domains (Fig. 4). The 
N-terminal domain encoded by BCR exon 1 has an (associated) serine/threonine kinase activity in vitro 
(Maru and Witte, 1991), can oligomerize (McWirther and Wang, 1993), and is capable of binding other 
protein factors, among which pl45^ (Sawyers et al, 1991; McWirther et al., 1993). Bcr itself is 
phosphorylated on serine and threonine residues, the significance of which is currently not understood. 
The central part of Bcr has homology to the Dbl proto-oncogene, a guanine nucleotide-exchange factor 
(GEF) for human CDC42 (Eva and Aaronson, 1985; Hart et al., 1991), suggesting a similar catalytic 
activity for Bcr. The biological significance of the pleckstrin-homology domain in Bcr is as of yet unclear 
(Boguski and McCormick, 1994; Cohen et al., 1995). 
In vitro, the C-terminal end of p l ó O ^ harbors GTPase activating protein (GAP) activity toward the 
small GTP-binding proteins Racl and Rac2 and CDC42 (Diekmann et al., 1991; Hart et al., 1992). Racl 
and Rac2 belong to the Rho family of small p21"aMike GTPases, members of which are involved in cyto-
skeletal organization. Racl is required for growth-factor-induced membrane ruffling of Swiss 3T3 fibroblasts. 
Bcr can regulate this Racl-mediated process in vitro, since microinjection of the purified Bcr GAP domain 
abolishes ruffling (Ridley et al, 1993). A number of other proteins are also GAPs towards Racl and Rac2 
in vitro, including rhoGAP, ß-chimerin, n-chimerin, ABR and P190 (Diekmann et al., 1991; Leung et al, 
1994; Ahmed et al., 1994; Heisterkamp et al., 1993b; Ridley et al., 1993). 
Based on the information described above, Bcr is likely to play a role in signal transduction. To date, 
no naturally occurring mutants have been identified, other than the truncated Bcr in the Bcr/Abl fusion 
oncoprotein. 
• Molecular mechanisms for BCR/ABL mediated leukemogenesis 
Currently, at least three different c-abl derived oncogenes have been identified in oncogenic retroviruses 
known to cause cancer in mouse and cat (A-MuLV and (HZ2) FeSV respectively) and from human 
neoplasias (BCR/ABL in ALL and CML). In all of these oncogenic proteins, the Abl tyrosine kinase is 
constitutively activated. The mechanisms for oncogenic activation are different for the three oncogenic 
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forms. Activation of v-abl involves deletion of both the SH3 domain or the C-terminal part (A-MuLV 
or (HZ2) FeSV respectively) and fusion with viral protein (Gag) sequences. Activation of the transforming 
potential of Gag-v-Abl is primarily due to deletion of the SH3 domain (Fig. 5); additional mutations in the 
Abl moiety may contribute to the oncogenicity of Gag-v-Abl (Rees-Jones and Goff, 1988). 
SH3 SH2 SH1 c-abl p145 
v-abl pl60 
Qbl bcr-abl p210 
BCR 
bcr-abl p190 
BCR 
Figure 5. Schematic representation of structural domains in the normal c-Abl protein and the chimaeric oncoproteins, 
Gag-v-Abl, P190 Bcr-ABl and P210 Bcr-Abl. In c-Abl, the SH3, SH2 and SHI (kinase function) domains are marked 
The presence of a viral (gag) and the variable Bcr amino acid sequences, in Gag-v-Abl and the chimaeric oncoproteins 
Bcr/Abl P210 and P190 respectively, are indicated in the lower three maps (N-terminal); note the presence of the Bcr 
DBL-homology domain in the Bcr/Abl P210 oncoprotein, but not in P190 (figure adapted from Grosveld, 1990). 
The c-abl gene is activated by a different mechanism in Philadelphia chromosome-positive leukemia. 
Fusion of BCR on chromosome 22 to c-ABL on chromosome 9, replaces N-terminal sequences of Abl 
with those of Bcr (Heisterkamp et al., 1983; Shtivelman et al., 1985; Hermans et al., 1987). The chimaeric 
Bcr/Abl oncoproteins differ in two ways from the Gag-v-Abl: their SH3 regions are still intact and they 
are not N-myristoylated (Fig. 5). No additional mutations are found in the Abl moiety of Bcr/Abl. Bcr/Abl 
oncoproteins are confined to the cytoplasm, in contrast to c-Abl or Gag-v-Abl. The chimaeric BCR/ABL 
oncoproteins have acquired a strong auto-phosphorylation activity, which is readily detectable in vitro. 
This is true for both v-abl and chimaeric BCR/ABL oncogenes. In Bcr/Abl, two regions in the first 
domain of Bcr are responsible for activating the Abl kinase in the chimaeric BCR/ABL gene product. 
One region, mapped to amino acids 28-68, deregulates the Abl tyrosine kinase activity and enhances the 
actin-binding function of Abl (McWhirter and Wang, 1991). The second region in the first Bcr domain, 
amino acids 176-242, may contribute to the deregulation of the catalytic activity through intrinsic binding 
to the AW-SH2 domain (Konopka et al, 1984; Muller et al., 1991; McWhirter and Wang, 1991); it has 
been proposed that this deregulation involves interference with the putative negative-regulatory function 
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of the SH3 domain (Pendergast et al., 1991). 
Although controversial (Groffen et al., unpublished results), there is some evidence that, unlike v-abl, 
BCR/ABL does not transform murine fibroblasts (NIH-3T3 cells; Daley et al., 1987). The weaker 
oncogenic activity of Bcr/Abl proteins is believed to relate at least in part to the subcellular localization 
of the different oncogenic forms of Abl (Wang, 1993). BCR/ABL can cooperate with the myc oncogene 
to transform Rat-1 fibroblasts, albeit with a much lower efficiency than v-abl. Similar in vitro assays have 
also indicated a difference in transforming ability between BCR/ABL PI90 and BCR/ABL P210, which 
correlated with differences in auto-phosphorylation activity (Lugo and Witte, 1989; Lugo et al., 1990). 
The (auto-)phosphorylation activity of Abl in vitro is relatively weak; overexpression of c-abl is not 
transforming (Wang, 1993 + references therein). 
1.6. In vitro studies of BCR/ABL 
To decipher cellular mechanisms that underlie tumorigenic transformation of hematopoietic cells by 
BCR/ABL chimaeric oncoproteins, researchers have often resorted to the use of in vitro assay systems. 
A classical method to examine the transforming (oncogenic) potential of a proto-oncogene is the NIH-
3T3 transfection assay, in which the gene of interest is introduced into an immortalized cell line. Most 
NIH-3T3 transforming genes from human tumors appeared to be ras oncogenes. The assay is known to 
be relatively insensitive to morphological transformation by other oncogenes, such as myc and myb. The 
hybrid BCR/ABL oncoproteins do not, or at best poorly (Groffen et al, unpublished results), transform 
these mouse fibroblasts (Daley et al., 1987). However, in concert with another oncogene, myc, it they cause 
full transformation in Rat-1 fibroblasts (Lugo and Witte, 1990). 
More important to the etiology of leukemia is the effect of BCR/ABL oncogenes on cells of 
hematopoietic origin. Lymphoid and myeloid cells can be transformed in vitro with retroviral constructs 
harboring BCR/ABL oncogenes (McLaughlin et al., 1987; Young and Witte, 1988; Daley et al., 1988). 
Both BCR/ABL P190 and P210 stimulate growth of immature lymphoid cells. These studies also indicated 
that BCR/ABL P190 is a more potent stimulator than BCR/ABL P210 (Lugo and Witte, 1990). BCR/ABL 
P210 expression abrogates the requirement for interleukin 3 (IL-3) of murine factor-dependent lympho-
blastoid or myeloid cell lines (Daley et al., 1988). Similarly, leukemic B-cell progenitor cells, derived from 
BCR/ABL PI90 transgenic mice, could be cultured independent of exogenous growths factors and stroma 
(Griffiths et al., 1992). 
Recent studies, however, indicate that growth factor independence is probably not an early acquired 
trait of leukemic cells in human CML: neither human Philadelphia-positive hematopoietic progenitors nor 
chronic phase CML cells loose their growth factor requirement and normal proliferative responses to 
growth factors (Moore et al, 1973; Goldman et al., 1974; Metcalf et al., 1974; Lansdorp et al., 1985). It 
was suggested that BCR/ABL expression in chronic myelogenous leukemia alters the normal develop-
mental controls in leukemic progenitor cells by suppression of apoptosis under conditions of limiting 
growth factor. This notion was corroborated by in vitro experimentation with hematopoietic cell cultures 
and temperature sensitive mutants of v-abl and BCR/ABL (Evans et al. 1993; Bedi et al., 1994a; Bedi 
et al., 1994b; Carlesso et al, 1994; Laneuville et al., 1994; McGahon et al., 1994; Kabarowski et al., 1994), 
suggesting that myeloid expansion is the result of prolonged cell survival rather than uncontrolled 
proliferation. 
• Cellular interactions of Bcr, Abl and Bcr/Abl 
Which molecular mechanisms and factors partake in cellular transformation, once BCR/ABL is 
expressed inside hematopoietic cells, has been the focus of research over recent years. A large number 
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of studies describes protein-protein interactions with Bcr, Bcr/Abl and/or Abl in vitro or in cultured cells. 
Proteins interacting with Abl include 3BP-1 (Cicchetti et al., 1992), Rb (Welch and Wang, 1993), Crk 
(Feller et al., 1994; Ren et al, 1994), Crkl (Ten Hoeve et al., 1994), Grb-2 (Ren et al., 1994; Pendergast 
et al., 1993; Puil et al., 1994), Nek (Ren et al, 1994), and actin (McWirther and Wang, 1993a). In addition, 
Abl has been shown to bind DNA (Kipreos and Wang, 1992). Bcr interacts with p21racl/2 (Diekman et 
al, 1991; Ridley et al., 1993), CDC42Hs (Hart et al., 1992), Abl (Pendergast et al. 1993) and proteins of 
the 14-3-3 family (Reuther et al., 19940. Bcr/Abl binds and/or phosphorylates Bcr (Campbell et al., 1990; 
Lu et al., 1993), Grb-2 (Pendergast et al., 1994), ph-p53 (Campbell et al., 1990), Fes (Ernst et al., 1994), 
She (Puil et al, 1994; Matsuguchi et al., 1994), rasGAP, pl90, p62 (Druker et al., 1992), the phosphatase 
Syp (Tauchi et al., 1994), c-cbl (Andoniou et al., 1994) and Crkl (Ten Hoeve et al., 1994b; Nichols et al, 
1994; Oda et al., 1994). Some of these factors are specific to hematopoietic cells, others are not. Some 
factors engage in interactions with domains in the parental molecules, which are missing in the chimaeric 
Bcr/Abl oncoprotein. It is as of yet unclear whether such factors play a major role in transformation. 
Moreover, although many of these interactions are likely to be significant in an experimental setting, it is 
questionable that they all contribute equally in vivo to the process of Bcr/Abl mediated tumorigenesis in 
the hematopoietic cells of /%-positive leukemia patients. 
1.7. Animal studies in iVt-positive leukemia 
Historically, a lot of information about gene function has been obtained through genetic analysis of 
mutant organisms (e.g. fruit fly, mouse). Whereas the discovery of mutant animals was merely governed 
by chance, recent revolutionary technical advances in mammalian genetics have made it possible to create 
animals with predetermined alterations in their genome. These techniques have already had a significant 
impact on our understanding of fundamental biology, in such areas as the developmental regulation of 
gene expression, cell lineage interaction and the effect of gene expression or ablation in the context of 
an intact organism. In the biomedical field, the opportunity has been created to generate animal models 
for human disease, to genetically engineer animals for production of proteins of therapeutic importance, 
and to develop human somatic gene therapy techniques. In agriculture, introduction of genetically 
manipulated species has been directed at optimizing quantitative yield and qualitative food product 
composition and enhancement of adaptation to adverse environments. 
One of the first techniques aimed at germline alteration makes use of introduction of exogenous DNA 
sequences, transgenes, into the mouse genome (Fig. 6). This can either be achieved by microinjection of 
pronuclei of fertilized mouse eggs or retroviral infection of early embryos (Jaenisch, 1988). These embryos 
are transplanted into pseudopregnant female mice, and, with exception of when embryonically lethal 
transgene constructs are used, develop into transgenic animals. 
A conceptually different strategy modifies endogenous DNA sequences in the mouse genome, rather 
than adding exogenous sequences. This technique is known as gene targeting or targeted mutagenesis. 
The advantage of this approach is that integration and integration site can be controlled. In transgenic 
technique, genomic integration is random rather than directed, and often in the form of tandemly 
integrated copies. Gene targeting relies on homologous recombination of cloned and altered (e.g., mutated 
or interrupted) DNA sequences with complementary sequences in the endogenous locus. In an initial step, 
one (or both) allele(s) of a particular gene is genetically altered in embryonal stem (ES) cells by means 
of a targeting vector (Capecchi, 1989). ES cells, although grown in culture, have retained their full 
developmental potential: ES cell contribution to all tissues is found, including the germline, upon injection 
of the cells in developing mouse blastulas (Evans and Kaufman, 1981; Martin, 1981;, Bradley et al., 1984). 
The injected embryos will be born as genetically mosaic (chimaeric) mice and transmit the targeted allele 
to their progeny (Fig. 7). Through interbreeding of fully heterozygous descendants, the gene of interest 
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can be fully inactivated or mutated. These animals are known as null mutants or, colloquially, knock-out 
mice. 
TG DNA 
1 cell stage zygote 
foster mouse 
non-transgenic offspring transgenic offspring 
Figure 6. Generation of transgenic animals through micro-injection of 1 cell stage embryos. The figure (above) depicts 
the micro-injection of the largest of two pronuclei in fertilized mouse eggs, with a DNA solution containing the transgene 
(TG) of interest. The transgene will randomly integrate into the mouse genome, and, from hereon, every newly formed cell 
in the dividing embryo will carry the transgene, including the germ line cells. Injected embryos are surgically transferred 
into the fallopian tube of pseudopregnant recipient female mice (foster mouse) and allowed to pass through gestation. 
Newborn mice are either transgenic or non-transgenic, depending on whether integration of the transgene occurred. 
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blastocyst 
foster mouse 
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chimaerlc mouse 
host blastocyst-derived offspring ES cell-derived offspring 
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Figure 7. Generation of mouse germ-line chimeras by introducing embryonal stem (ES) cells into mouse blastocysts. First, 
ES cells, in which one allele of a particular gene is genetically altered by the experimenter, are micro-injected into the 
blastocoel of a 4.5 day old host embryo (blastocyst; above). The injected ES cells (grey) combine with the existing 
embryonal stem cells (black) in the inner cell mass (ICM) to form a mosaic ICM, from which a chimaeric embryo will 
develop. The injected blastocysts are surgically transferred into the uterus of a pseudopregnant mouse and development 
is allowed to progress to birth. Above, the ES cells are derived from a mouse homozygous for a dominant agouti coat 
colour allele and the recipient blastocyst from a mouse homozygous for the recessive black allele. The chimaeric mice are 
composed of cells of both genotypes and therefore display coats with patches of each colour. When germ line transmission 
occurs, the dominant agouti coat colour gene, which was ES cell derived, and the mutated allele will be passed on from 
the chimaeric mice to offspring thereby generating animals uniformly heterozygous (+/-) for the introduced mutation. 
Offspring from matings between heterozygous animals will consist of wildtype (+/+; not mutated), heterozygous (+/-; one 
allele mutated in every cell) and null-mutant animals (-/-), the latter of which no longer carry a normal functional gene 
(Le. both alleles of the gene of interest are mutated). 
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The importance of in vivo models to study Philadelphia-positive leukemia is manifold. A well defined 
mouse model provides a means by which tumorigenesis can be studied from its earliest stages onward and 
factors and mechanisms that eventually contribute to malignant progression of the leukemic cells can be 
uncovered. Besides an 'unlimited' provision of tumor material for analysis, more importantly, the availability 
of a mouse model provides a means by which cancer treatment regimes can be tested. In addition, 
identification of cellular components and/or pathways that contribute to the onset or progression of 
leukemia may eventually lead to the discovery and development of new drugs. 
Two conceptionally different approaches have made use of transplantation of BC/î/ABL-positive 
murine bone marrow cells into syngeneic recipients or microinjection of BCR/ABL transgenes into 
fertilized oocytes respectively. 
• Chronic myeloid leukemia; retroviral approach 
Over the most recent years, attempts to generate a reliable animal model for the study of CML have 
been thwarted by lack of reliability and reproducibility (Daley, 1993). Several investigators have tried to 
create a mouse model for CML through reconstitution of irradiated recipient mice with BCR/ABL-positive 
bone marrow (Elefanty et al., 1990, Kelliher et al, 1990, Daley et al., 1990, Daley et al., 1991; Gishizky 
et al. 1993). Mouse bone marrow cells were infected with retroviral vectors bearing BCR/ABL coding 
regions. Although some mice were obtained that developed leukemia, the kinetics and the nature of the 
induced disease were, shown to depend largely on infection conditions, retroviral and internal regulatory 
sequences used, and also on genetic background of the irradiated recipient mice. In essence, the outcome 
of the disease depended on which hematopoietic progenitor cell was targeted by retroviral vectors (Elefanty 
et al. 1992; Kelliher et al., 1993). Myeloproliferative disorders could be obtained by manipulating these 
experimental conditions. However, myeloid disease develops in only a small number of transplanted mice 
(Daley, 1993); the myeloproliferative disorder in these mice was referred to as CML-like rather than CML 
(Elefanty and Cory, 1990; Gishizky et al., 1993). BCR/ABL P190 and P210 were found to cause similar 
disease in a retroviral setting (Kelliher et al., 1991). Even with v-abl, which under natural conditions 
exclusively induces pre-B cell leukemia in mice, myeloproliferative illness could be produced (Kelliher et 
al., 1990). All in all, the disease pattern resulting from retroviral infections appears very difficult to 
reproduce (Daley, 1993 and personal communication). A major obstacle in retroviral technology is to target 
the infection to stem cells. This is essential, since CML is thought to be a clonal disease originating in the 
hematopoietic stem cell (Fialkow et al.'77). 
• Transgenic mouse models for CML and ALL 
Transgenic mouse technology was first introduced in 1980 (Palmiter and Brinster, 1985). Essentially, 
a transgene is micro-injected into a one-cell stage zygote, and will consequently be integrated into the 
genome of the developing embryo. The advantage of a transgenic model as an alternative to retrovirally 
infected bone marrow transplantation becomes immediately apparent: once integrated into the genome 
of a 1-cell stage zygote, a transgene is per definition present in all derived cells, including the hemato-
poietic stem cell. Transgenic technology is a powerful experimental tool in the study of gene function in 
development and disease. 
In BCR/ABL transgenic animals, every cell including hematopoietic stem cells will contain a BCR/ABL 
transgene. Development of disease is independent of influences of retroviral sequences or other 
experimental factors, such as infection and bone marrow culture conditions. Hence, a transgenic mouse 
model solely reflects the tumorigenic properties of BCR/ABL oncoproteins. An initial study was carried 
out with a hybrid BCR-v-abl transgene (Hariharan et al., 1989) in mice. Depending on the choice of 
regulatory sequences, mainly T lymphomas and few pre-B lymphomas (promoter sequence: immunoglobulin 
heavy chain enhancer, E/n) or exclusively T lymphomas (promoter sequence: myeloproliferative sarcoma 
virus long terminal repeat; MPSV-LTR) were found. However, the \-abl oncogene in BCR-v-aW has 
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accumulated a multitude of mutations in the structural part of the abl oncogene, that do not occur in 
either the human ABL or the BCR/ABL oncogene (Rees-Jones and Goff, 1988; Groffen et al., 1992). 
These mutations contribute to the transforming ability of v-abl. Besides the fact that v-abl causes a 
hematopoietic disease distinct from that caused by BCR/ABL (Scott et al., 1991), the hybrid BCR/v-abl 
protein does not exist outside the laboratory. These observations complicated interpretation and comparison 
of results with those of others who did use BCR/ABL in for example retrovirus-infected bone marrow 
studies. 
In an attempt to generate a true transgenic mouse model for CML, a 'minigene' had been designed 
(Heisterkamp et al., 1993c), in which expression of a P210 or P190 transgene was controlled by the human 
BCR promoter, as is the case in the Philadelphia translocation. With these constructs, however, no live 
transgenic progeny were ever obtained: although a small number of 'expressing' transgenic embryos 
apparently passed through development normally up to term, embryonic malformation and resorption were 
found significantly more frequent than in control pregnancies (Heisterkamp et al., 1993c). The observed 
effects presumably directly related to BCR promoter activity during development, as well as to yet 
unknown pleiotropic lethal effects of the P210 fusion protein on embryogenesis. 
To circumvent the problem of embryonic lethality a different promoter system was chosen: metallo-
thionein (MT) promoters are inducible and transcriptionally active in a non-tissue specific manner (Mayo 
and Palmiter, 1981; Durnam and Palmiter, 1981; Stuart et al, 1984). The first construct made was one 
that encoded a Bcr/Abl P190 oncoprotein. Although transgene expression was detectable without induction, 
it did not interfere with embryogenesis: transgenic founder animals were born in relatively large numbers. 
Within two months after birth the animals quite rapidly developed a pathological condition: 80% of the 
founder animals died of acute leukemia. Predominant disease was clinically classified as pre-B cell ALL 
and was indistinguishable from human ALL (Heisterkamp et al., 1990). Hence, this animal model unambig-
uously demonstrated the specific relation between BCR/ABL P190 oncogene expression and the 
development of pre-B cell leukemia. 
1.8. Scope of this thesis 
The availability of primary human tumor material for study is often restricted. Moreover, such tissues 
represent terminally advanced stages of tumorigenesis, and do not provide any insight into early events 
in tumorigenesis. To decipher cellular mechanisms that underlie tumorigenic transformation of 
hematopoietic cells by BCR/ABL chimaeric oncoproteins, researchers have often resorted to the use of 
in vitro assay systems. Unfortunately, the chosen assay conditions are not always relevant to human 
leukemia. Therefore, the availability of in vivo models to study Philadelphia-positive leukemia is 
paramount: a well defined mouse model provides a means by which tumorigenesis can be studied, from 
its earliest stages onward, and factors and mechanisms, that eventually contribute to malignant progression 
of the leukemic cells, can be uncovered. Besides an 'unlimited' provision of tumor material for analysis, 
more importantly, the availability of a mouse model provides a means by which cancer treatment regimes 
can be tested. In addition, identification of cellular components and/or pathways that contribute to the 
onset or progression of leukemia may eventually lead to the discovery and development of new drugs. 
In 1990, the group of Groffen and Heisterkamp reported on a transgenic mouse model for 
Philadelphia-positive acute lymphoblastic leukemia (ALL). The disease that developed in the BCR/ABL 
P190 transgenic mice resembled the human disease closely. With the establishment of a model for leukemia 
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in an in vivo setting, the possibility was created to investigate the development of a 'human' leukemia 
from its earliest stages onward, and to study factors and mechanisms that eventually contribute to malignant 
progression of the disease. Part of this graduate study focussed on initiating a detailed biological analysis 
of this and other mouse models for Ph + leukemia: tumor evolution, a common feature of cancer biology, 
was studied by cytogenetic analysis of leukemia, and oncogenic specificity of BCR/ABL P190 and 
differences in oncogenicity between the BCR/ABL P190 and P210 oncogenes, were investigated using de 
novo generated transgenic animals (Chapters 2, 3, 4 and 5). A start was made with the evaluation of 
relatively simple anti-cancer treatment protocols by us (Chapter 6) and by other groups. 
The biochemical reason why cellular transformation occurs in Philadelphia-positive leukemia has been 
known for quite some time now: the Abl tyrosine kinase, which is under normal circumstances implicated 
in cell cycle regulation, becomes constitutively activated through fusion to Bcr sequences as a result of 
the t(9:22)(q34;qll) translocation. The reason why, on a (molecular) biological level, cells lose growth 
control, remains elusive. The role of Bcr in the disease, other than that the fused sequences somehow 
activate the Abl kinase, is unclear. At the beginning of this graduate study, nothing was known about the 
normal cellular function(s) of the plóCr0- protein. In 1991, it was discovered that Bcr retains a GTPase 
activating protein (GAP) function toward certain small GTP-binding proteins of the p21 subfamily 
p2iRac/Kho Subsequently it was found that the Racl protein plays a role in mitogen stimulated membrane 
ruffling in fibroblasts, indicating a possible role for Bcr in cell growth regulation. At approximately the 
same time, Racl and Rac2 were connected in vitro with the respiratory burst (NADPH) oxidase, a catalytic 
system that is responsible for bactericidal oxygen radical production in neutrophils and macrophages, and 
in B-cells. The Bcr protein was meanwhile unfolding as a complex multidomain protein, harboring sequence 
homology with the Dbl oncogene, a guanidine-nucleotide exchange factor (GEF) for the small GTP-
binding protein CDC42, pleckstrin, the major substrate for protein kinase C in platelets, with ß-chimerin, 
n-chimerin, ABR, rhoGAP and pl90, all proteins with an overlapping in vitro GAP activity toward Racl 
and Rac2. Besides, Bcr harbors a unique serine/threonine kinase activity, is capable of oligomerization and 
was shown to interact with several cellular factors in vitro. Although in vitro the BcrGAP activity showed 
overlap with a whole myriad of biochemically related proteins, the biological relevance of this regulatory 
domain was not clear. Recently it was speculated that the BCR gene plays a role in normal hematopoiesis 
and is also implicated P/z-positive leukemia. On the basis of the data described above, and more 
importantly, because of its connection to P/i-positive leukemia, we set off to generate bcr null-mutant mice 
to examine the function of plÄr*7- in normal and leukemic cell in the context of the whole organism 
(Chapter 7). To this end, the innovative gene targeting technology was used. 
The bcr gene is highly expressed in mammalian brain. The expression pattern of a biochemically related 
protein, n-chimerin, overlaps with that of bcr. N-chimerin was shown to be involved in certain cognitive 
processes in birds and possibly in mice as well. Notwithstanding the function of Bcr in cells of 
hematopoietic origin, these observations suggest a possible different function for this protein in brain. In 
an attempt to further delineate a putative function of Bcr in the brain we have studied the regional 
expression and developmental expression kinetics of bcr in rodent brain (Chapter 8). 
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Two "mouses"'. By Mia (3) 
CHAPTER 2 
Clonal Development and Karyotype Evolution during Leukemogenesis 
of BCRIABL Transgenic Mice 
This chapter has been published as: Voncken J.W., Morris C, Pattengale P.K., Dennert G., Kikly C, Groffen J., 
and Heisterkamp N.: Clonal development and karyotype evolution during leukemogenesis of BCRIABL transgenic 
mice. Blood 79 (1992) 1029-1036. 
Clonal Development and Karyotype Evolution During Leukemogenesis of 
BCR/ABL Transgenic Mice 
By Jan Willem Voncken, Christine Morris, Paul Pattengale, Günther Dennert, Christie Kikly, John Groffen, 
and Nora Heisterkamp 
The Philadelphia (Ph) translocation is responsible fpr the 
generation of the chimeric BCR/ABL oncogene. The Ph 
chromosome constitutes the earliest detectable chromo-
some abnormality in chronic myelogenous leukemia and is 
also found in acute lymphoblastic leukemia. Mice transgenic 
for a P190 BCR/ABL-producing DNA construct develop lym-
phoblastic leukemia/lymphoma and provide an opportunity 
to study early stages of the disease as well as progression. In 
this study, we have karyotyped the bone marrow of 10 
19-day-old BCR/ABL P190 transgenic mice from a line that 
reproducibly develops leukemia/lymphoma. Leukemic cells 
from 17 terminally ill transgenic founders and progeny were 
THE PHILADELPHIA (Ph) chromosome, specifically found in chronic myelogenous leukemia (CML) and 
Ph-positive acute lymphoblastic leukemia (ALL), is the 
result of a reciprocal translocation between chromosomes 9 
and 22 . " The translocation causes the ABL oncogene from 
chromosome 9 to fuse with part of the BCR gene located on 
chromosome 22. In approximately half of cases of Ph-
positive ALL this chimeric gene produces a P190 BCR/ 
ABL fusion protein, containing only those amino acids 
encoded by the first exon of the BCR gene; in the remaining 
cases of Ph-positive ALL and in CML a fusion protein with 
a larger BCR gene contribution, P210, is found." The 
oncogenic role of these fusion proteins is suggested by the 
fact that the Ph chromosome is a consistent abnormality 
present at the time of diagnosis in the leukemic cells of 
CML and ALL patients, and also by the oncogenic outcome 
of transgenic and other in vivo experiments using the 
BCR/ABL fusion gene.'10 
Cancer is thought to be a multistep process that passes 
through different stages, each accompanied by gene muta-
tions."12 This process is exemplified by CML. Debate 
continues as to whether a predisposed leukemic cell, which 
lacks the Ph chromosome, exists in CML,1314 but the Ph 
chromosome is always found at diagnosis, usually as the 
sole karyotypic abnormality.15 With progression of the 
disease, additional chromosome aberrations are observed 
in as many as 80% of patients after the transition from 
chronic to acute stage.16" ALL is often accompanied by 
nonrandom chromosome abnormalities at presentation, 
among which the Ph chromosome is one of the most 
frequently seen.18 
To investigate the role of BCR/ABL in leukemia, we 
have generated mice transgenic for a DNA construct that 
produces the P190 protein. Eight founder mice rapidly 
succumbed to leukemia (both myeloid and lymphoid) 
within a short period (58 days) after birth, demonstrating 
the leukemogenic activity of the activated ABL oncogene.10 
In the present study, we have asked whether the onset and 
progression of BCR/ABL P190-generated leukemia in 
transgenic mice is accompanied by the appearance of 
chromosome abnormalities such as those found in humans. 
Our results show a normal karyotype in initial stages and 
support the assumption that the activated BCR/ABL gene 
also karyotyped as well as bone marrow transplant recipi-
ents of leukemic donor marrow. Karyotypically visible aberra-
tions were absent from the early stages of BCR/ABL P190-
generated leukemia and normal metaphases could be found 
even in the terminal stages of the disease. A high frequency 
of aneuploidy was found in advanced leukemia, with a 
marked preference for the gain of mouse chromosomes 12, 
14, or 17. These results point to a primary role for BCR/ABL 
in leukemogenesis and suggest a destabilizing effect of the 
BCR/ABL gene on the regulation of cell division. 
© 1992 by The American Society of Hematology. 
alone plays a key role in the development of leukemia. 
Later stages of the disease are characterized by nonrandom 
numerical changes of mouse chromosomes that have a 
genetic analogy to human chromosomes involved in leuke-
mia. 
MATERIALS AND METHODS 
Transgenic mice. Transgenic mice were generated as previously 
described10 using a BCR/ABL construct encoding the P190 fusion 
protein. In different lines the transgenic DNA construct is ex-
pected to have been integrated independently on different chromo-
somes. In cases in which the copy number of the transgene was 
higher than one, integration most often occurs in a tandem, 
head-to-tail fashion in one particular locus. There is no evidence 
that integration of transgene DNA into the mouse genome exhibits 
site-specificity.19 
Founder animals were the offspring of matings between C57B1/ 
CBA F, animals. Transgenic progeny were the result of matings 
between founders and C57B1 x CBA F, mice. Successive genera-
tions were the result of similar matings. Mice identification 
numbers have three, six, nine, or 12 digits and indicate founders, 
Fl, F2, and F3 animals. Pathologic analysis was performed on 
autopsy material obtained at killing from mice that were generally 
terminally ill. Mice were diagnosed with lymphoblastic lymphoma/ 
leukemia (LL) or ALL alone. Of all founder and progeny trans-
genic mice (n = 100), 50% had died of leukemia/lymphoma before 
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70 days of age. Of the line established from founder no. 623, 
animals died of or were killed with terminal disease on an average 
of 68 days after birth (range, 41 to 147 days). A more detailed 
characterization of these mice will be presented elsewhere (manu-
script in preparation). 
Bone marrow (BM) transplants. BM from founder no. 713 and 
from progeny animal no. 623-844-1037 (both transgenic BCR/ 
ABL, P190) was collected from femurs and transplanted into 
C57B1 x CBA Fj animals that had received a lethal radiation dosis 
of 1,000 rad (recipient S.2-3) or a sublethal dosis of 500 rad (all 
other recipients). Animal no. 713 was diagnosed with ALL and 
killed at 64 days. Its terminal white blood cell count (WBC) was 
28 x 10VL. Donor no. 623-844-1037 was diagnosed with LL. 
Transplants were performed as indicated in Fig 1. 
Cytogenetics. Karyotypic analysis was performed directly on 
material collected at autopsy. A clone was defined as two cells 
having trisomy or a structural change and three cells having 
monosomy of a particular chromosome. Heparinized peripheral 
blood (PB) or BM was collected in RPMI 1640 medium supple-
mented with 15% fetal bovine serum. PB cells were used only when 
WBCs were higher than 50 x 10*/L; nonleukemic blood and blood 
containing less lymphoblasts did not yield sufficient metaphases 
under these culture conditions. Cells were washed once, then 
incubated with 100 ng/mL colcemid (GIBCO, Grand Island, NY) 
for 1 hour at 37°C, given a hypotonic shock in 0.075 mol/L KCl for 
20 minutes at 37°C, and fixed and washed with cold 1:3 (vol/vol) 
acetic acid:methanol. Chromosomes were trypsin G-banded accord-
ing to Seabright.20 Chromosome banding terminology was as 
described by Nesbitt and Franke.21 
Southern blot analysis. DNAs were isolated from spleen, lymph 
nodes, muscle, blood, and kidney as described.10 DNAs digested 
with £coRI were run on 0.7% gels, blotted to nitrocellulose, and 
hybridized to a 1.2-kb Msp 1/EcoRl JH probe. Posthybridization 
washings were at 0.1X SSC at 65°C. 
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Fig 1. Transplant strategy and 
karyotype findings for recipients 
of BM or splenocyte (SPL) cells 
from leukemic mouse donors no. 
713 {series 1) and 623-844-1037 
{series 2). The number of cells 
that had a particular karyotype is 
in brackets. 
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RESULTS 
The transgenic mice expressing P190 BCR/ABL de-
scribed previously10 all succumbed to leukemia before 
progeny was obtained. New transgenic founders were made 
and progeny was obtained from some of these. Animals 
developed LL and were evaluated karyotypically at dif-
ferent stages of disease. 
Karyotypes of transgenic BCR/ABL P190 founder mice and 
their progeny. A total of 17 mice were analyzed cytogeneti-
cally. Karyotypic findings in leukemic cells isolated in the 
terminal stages of disease are detailed in Table 1 and 
summarized in Table 2 for the three founder animals (nos. 
529, 538, and 632) and 14 progeny animals derived from 
founders no. 632,629,626, and 623. 
Abnormal karyotypes were found in 15 of the 17 animals 
analyzed and ranged from 10% to 100% of metaphase cells 
scored. Trisomy predominated and was nonrandom with a 
preference for chromosomes 10,12,14, and 17 (Table 1, Fig 
2A through E). Founder animal no. 538 showed a t(12;16). 
Two of the 17 animals analyzed had normal karyotypes. The 
first animal (no. 626-729) had a leukemic BM, but lymph 
nodes and PB were normal. The second animal (no. 
623-844-1035) was diagnosed with lymphoblastic lym-
phoma. 
Karyotypically normal cells were found in eight of the 
animals, even in those mice with a high WBC. For example, 
mice no. 529, 632-767, and 623-844-1037, all with a WBC 
above 100 x 10', had at least 80% normal metaphases 
(Table 1). These high WBCs suggest that the karyotypically 
normal cells were leukemic. 
Nine of the 17 animals showed evidence of clonal 
evolution. For example, animals no. 623-881 and 623-844 
showed normal metaphases as well as two or three abnor-
mal clones, which seem to have been derived through the 
sequential gain of chromosomes (Table 1). There was also 
evidence of independent clone formation. For example, 
mouse no. 626-730 had five apparently unrelated abnormal 
karyotypes, in addition to normal metaphases (Table 1). 
Animal no. 623-844-1051 showed evolution within clones as 
well as independent clone formation (Table 1). 
Karyotypes of leukemic BM transplant recipients. BM 
transplant procedures were used to investigate cytogenetic 
changes during tumor progression. The transplant strategy 
is outlined in Fig 1. Survival times were from 16 to 48 days 
and WBCs were elevated at least fourfold (not shown). 
Karyotype analysis was performed on material collected at 
autopsy. 
Sublethally irradiated C57B1 x CBA hosts were trans-
planted with leukemic BM or spleen cells from two dif-
ferent BCR/ABL P190 transgenic mice. BM or splenocytes 
from founder mouse no. 713 that had ALL were trans-
planted into four recipients. Two of these recipients, R.l 
and R.2, developed ALL after 48 and 69 days, respectively. 
Transplantation of the leukemic cells of R.l to three 
secondary recipients resulted in the rapid development of 
disease with death at 15 or 16 days. Serial transfers to 
tertiary recipients resulted in an increasingly aggressive 
type of leukemia with a short latency period (9 days; results 
not shown). 
Founder mouse no. 713 was not karyotyped. The primary 
recipient R.l had an extra chromosome 12 in all leukemic 
cells, and R.2 had an extra chromosome 14 in one clone and 
an extra chromosome 12 and 14 in a second clone (Fig 1). 
The three secondary recipients of R.l all had the trisomy 12 
clone of R.l and a second clone with a small marker 
chromosome, the origin of which could not be identified, 
but which was identical in all three animals (Fig 1). 
We also used Southern blot hybridization of different 
transgenic tissue DNAs to an Ig JH probe to follow tumor 
progression in the transplant series. The spleen of the 
original donor (no. 713) showed a germline £coRI frag-
ment, a less intense rearranged band of approximately 5.5 
kb, and two intense rearranged bands of approximately 4.3 
and 3 kb (Fig 3). This finding suggested the presence of 
more than one major dominant clone in this animal. DNA 
from spleen and an affected lymph node of recipient R.l 
showed both 4.3- and 3-kb rearranged bands, with lymph 
node DNA containing only a faint germline band. Splenic 
DNA of R.2 lacked the 4.3- and 3-kb rearranged bands but 
showed two bands of approximately 6.5 and 4 kb. Splenic 
DNA from animals R.l-1, 1-2, and 1-3 exhibited the same 
pattern as seen in the donor R. 1 (Fig 3). Recipients of R. 1 -1 
BM (animals R.l-1-land 1-1-2) had a prominent 4.3-kb 
band and a weak 3-kb band (Fig 3). The lack of novel 
rearranged bands suggests that the clone containing the 
marker chromosome originated from the trisomy 12 clone. 
The second transplant donor (no. 623-844-1037) had only 
one abnormal clone, containing an extra chromosome 12 in 
10% of its leukemic cells (Table 1). Spleen DNA, however, 
exhibited at least seven rearranged bands with a JH probe 
(data not shown). Consistent with this finding, transplanted 
animals S.l-1, 1-2, and 2-3 (all primary recipients) showed 
six different cytogenetic clones, including the trisomy 12 
clone (Fig 1). Clones characterized by trisomies 10 and 12 
and by trisomies 9 and 17 were found in more than one of 
the recipients and were presumably present as a minority, 
undetected clone in the original donor mouse. The trisomy 
9 and 17 clone appeared to have a selective advantage in 
transplanted cells because it was present in all the trans-
planted animals of this series, ie, in both recipients of S.l-1 
BM (animals 3-5 and 3-6), and as the dominant clone in 
both recipients of S.l-2 BM (animals S.4-7 and 4-8; Figs 1 
and 2F). 
Thus, Southern blot analysis of the BM transplant series 
suggested distinct clonal patterns, and supported the pre-
sumed presence of unrelated clones, as seen cytogeneti-
cally. 
Early stages ofP190 leukemia. The cytogenetics studies 
we have described above were based on leukemic samples 
taken from animals in late to very advanced stages of the 
disease. It was possible that the karyotype changes detected 
were present early in the disease and, together with the 
BCR/ABL gene product, were jointly responsible for the 
development of overt leukemia. Alternatively, their appear-
ance could have been associated predominantly with dis-
ease progression. To investigate these possibilities, we 
examined the karyotype of mice early in the development of 
leukemia. For this purpose, a breeding line of animals 
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Table 1. Karyotype of Transgenic P190 BCR/ABL Leukemic Founders and Progeny 
Mouse No." 
626-7295 
623-844-10351 
529 
632-767 
623-881 
623-844 
623-844-1037 
623-844-1061 
538 
632 
632-749 
632-753 
629-719 
629-723 
626-730 
623-884 
623-844-1035-1087 
Srct 
BM 
BM 
PB 
PB 
BM 
BM 
PB 
PB 
PB 
PB 
PB 
PB 
BM 
BM 
PB 
BM 
PB 
No. of Cells 
50 
20 
4 
16 
1 
2 
3 
24 
3 
5 
12 
2 
4 
10 
14 
2 
18 
1 
1 
2 
2 
5 
9 
20 
1 
1 
2 
4 
22 
7 
23 
25 
1 
1 
1 
8 
8 
10 
20 
1 
1 
2 
2 
5 
5 
1 
1 
18 
1 
1 
9 
Karyotype 
40.XX 
40.XY 
41.XY.+5 
40.XY 
41.XX. + 10 
42,XX, + 10, + 17 
41,XX,+?19 
40.XX 
40.XX 
42,XX,+ 10,+ 14 
43,XX,+10,+ 12,+14 
43,XX, + 12,+ 14,+mar 
41.XX. + 14 
42,XX,+12,+14 
40.XX 
41,XX,+12 
40.XX 
40.XX 
43,XX,+10,+12,+18 
42,XX,+12,+ 12 
42,XX,+10,+12 
41.XX.+12 
42,XX, + 10,+ 14 
40,XY,t(12;16)(F1;B5) 
42,XY,-H2,+ 12 
42,XY,+12,+mar, 
42,XY,+10, + 12 
42,XY,+12,+mar, 
41,XY,+12 
42,XY,+?13, + 17 
43,XY,+10,+?13,+ 17, 
41.XX.+14 
41.XX. + 17 
43,XX,+5. + 17,+17 
4 2 , X , - X , - 1 9 , + 14,+17,+mar,+mar ! 
40.XX 
4 2 , X , - X , - 1 9 , + 14,+ 17,+mar,+mar2,+mar3 
42,XX,+17,+ 17 
42,XX,+5,+ 17,del(6)(B1;B3) 
41.XY.+9 
41,XY,+mar 
42,XY,+mar,+mar 
40,XY,t(5;12)(B;F1) 
40.XY 
41.XY.+12 
44,XY,+1,+ 10,+ 14,+17 
45,XY,+1,+10,+12,-1-14,-1-17 
43,XY,+1,+14,+ 17 
42,XY,+12,+12 
42,XY,+14,+17 
41.XY.+12 
Age (d)* 
70 
143 
43 
68 
46 
52 
41 
66 
38 
79 
43 
60 
99 
39 
56 
147 
45 
WBC UO'/LI 
2 
23 
347 
301 
127 
22 
120 
127 
196 
163 
55 
376 
7 
4 
60 
47 
187 
*The first three-digit numbers indicate distinct transgenic mouse lines; subsequent three-digit and four-digit numbers indicate Fl progeny and F2 
progeny, and so on. 
tSource of lymphoblasts. 
tAge at which animal was killed with terminal disease. 
sAnimal had evolving lymphoblastic leukemia at death, with no lymph node but some marrow involvement. 
IIAnimal was diagnosed with lymphoblastic lymphoma, with apparent soft tissue involvement. 
founded by mouse no. 623 was used. These animals showed 
an average age of death due to overt leukemia similar to 
that found in the other P190 BCR/ABL transgenic mice. 
The appearance of BCR/ABL-expressing cells in PB was 
taken as a measure for the development of leukemia, and 
trial samples were taken from a test group to determine the 
earliest appearance of such cells in the circulation (data not 
shown). PB samples of 3 uXwere drawn at regular intervals 
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Table 2. Summary of BCR/ABL Mice With Terminal Disease 
Founders 3 
Progeny 14 
Total no. of animals analyzed 17 
No. of animals with normal karyotype 2 
No. of animals with karyotypically normal 
and abnormal cells 8 
No. of animals with only karyotypically ab-
normal cells 7 
Total no. of animals analyzed 17 
and assayed for BCR/ABL expression using reverse tran-
scriptase and the polymerase chain reaction.22 Based on 
these data, 10 transgenic animals, all progeny of mouse no. 
623-844-1035, were killed at 19 days of age and their BM 
evaluated. The course of the disease in additional progeny 
of animal no. 623-844-1035 was identical to that in other 
transgenic lines. At 19 days, the peripheral WBC was 
normal, there was no evidence for the development of 
lymphomas, and the BM showed normal development. In 
these particular animals BCR/ABL expression was de-
tected in the BM of all and in the PB of four. Of these 10 
animals, only one, no. 1118 (Table 3), had chromosome 
abnormalities; all other animals had a normal karyotype. 
There was a low level of apparently random aneuploidy in 
no. 1118, with four different cells showing a gain of a 
different chromosome. These data show that clones charac-
terized by chromosome change develop in later stages of 
the leukemia. 
DISCUSSION 
Previous experiments suggested that the activated BCR/ 
ABL oncogene was the primary factor causing LL in our 
transgenic mice."1 We can assume that the presence of the 
activated oncogene in many lymphoid cells would lead to 
multiple leukemias in single mice. Our present results 
support those concepts. The prime role of BCR/ABL in 
causing leukemia was supported by the early leukemia 
studies (Table 3). Only one of 10 animals had chromosomal 
abnormalities and none showed clonal growth. Later-stage 
leukemias, including those with large numbers of leukemic 
cells, showed many normal metaphases (39% of the total 
scored) and 8 of the 15 animals with chromosome abnormal-
ities showed some normal metaphases (Tables 2 and 4). 
These findings are a strong argument for the expansion of a 
pool of early leukemic cells that have BCR/ABL as a sole 
mutation. However, we can not exclude the possibility that 
cooperation between BCR/ABL and other oncogenes is 
necessary to generate overt leukemia. Such oncogenes 
could have been activated by mutations, not visible cytoge-
netically, of a similar form to structural alterations of the 
p53 gene present in more advanced stages of CML.23,24 
The idea of a multiple origin of the leukemia is supported 
by the transplantation of the BM of donor no. 623-844-
1037, which gave rise, in different recipients, to indepen-
dent clones characterized by IgH gene change or abnormal 
chromosome number. Other animals also showed evidence 
for independently derived leukemic clones. These multiple 
clones probably reflected the development of separate 
leukemias from different BCR/ABL-transformed lymphoid 
cells in single mice. Further cytogenetic/genetic-based 
progression of these clones, and their competition with 
each other, could be expected. There was no evidence of a 
common, specific cytogenetic change that was essential for 
the development of leukemias. 
A high frequency of chromosome aneuploidy was noted 
in the advanced leukemias. The four cells showing gain of a 
different chromosome in the early leukemic mouse no. 1118 
(Table 3) may represent a pool of cytogenetic variation 
from which cells with proliferative advantage become 
dominant and form clones. It is of interest that one of the 
abnormal cells in that animal had an extra chromosome 12, 
Fig 2. Partial karyotypes of 
abnormal clones detected in leu-
kemic cells of (A) mouse no. 632 
[41.XY.+12]; |B) mouse no. 629-
723 [42.XX.+5.+ 17,del|6)(B1B3)]; 
(C) mouse no. 623-844-1051 
[42,XX.+10,+14]; (D) mouse no. 
623-881 [43,XX,+ 10,+ 12,+14]; 
(E| mouse no. 623-884 [43.XY, 
+1.+ 14.+17]; and (F) BM trans-
plant recipient no. S.3-5 [42.XX, 
+9,+17]. The arrowhead marks 
the deleted chromosome 6 in 
mouse no. 629-723. 
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Fig 3. Ig JH rearrangements in leukemic BM transplant recipients. Individual mice (D, donor no. 713; see text for other mice} are indicated 
above the lanes. Arrows and the two asterisks point to the germline and two rearranged 4.3- and 3-kb £coRI fragments, respectively. The source 
of DNA is indicated above the figure: S, spleen; L, lymph node; K, kidney; M, muscle; B, blood. 
one of the common trisomies found in advanced leukemia 
in other P190 BCR/ABL mice. 
The chromosome changes tended to be nonrandom in 
occurrence (Table 4). Most prominent was the acquisition 
of extra copies 10, 12, 14, and 17, either alone or in 
combination. The gain of chromosomes 10, 12, and 17 was 
also found in the second BM transplant series (Fig 1), 
although the original donor showed only trisomy 12 in 10% 
of its cells. The first BM transplant series showed gain of 
chromosomes 12 and 14. The chromosomes involved in 
these nonrandom gains carry a number of loci known to be 
associated with cancer, cell growth, and development. 
Chromosome 10 carries the Steel locus, the bcr gene, the 
myb proto-oncogene, Ahi-l (a site of MoMuLV integration 
in Abelson murine leukemia virus-induced pre-B-cell lym-
Table 3. Karyotype of BCR/ABL P190 Mice Killed at 19 Days 
Mouse Age WBC 
No.* (d| (109/L) 
No. of 
Cells Karyotype 
1116 
1117 
1118 
1119 
1120 
1121 
1122 
1123 
1124 
1125 
19 
19 
19 
19 
19 
19 
19 
19 
19 
19 
0.8 
2.1 
0.6 
1.8 
1.8 
1.6 
1.3 
1.6 
1.0 
0.6 
BM 
BM 
BM 
BM 
BM 
BM 
BM 
BM 
BM 
BM 
20 
20 
1 
1 
1 
1 
16 
21 
21 
20 
20 
14 
20 
20 
40.XX 
40.XX 
41,XX,+?6 
41,XX,+12 
41.XX.+16 
41,XX,+mar 
40.XX 
40.XX 
40.XX 
40.XX 
40.XY 
40.XY 
40.XY 
40.XY 
phomas), fyn, ros-l, and Braf.25 Mouse chromosome 10 
exhibits four main regions of synteny with human chromo-
somes: 6q, 10, 12q, and 21q.M Mouse chromosome 12 
contains several MoMuLV integration sites, as well as the 
fos proto-oncogene, the transforming growth factor-ß3 
(TGF-ß3) locus, N-myc, L-mycl, and the Ig heavy chain 
locus. This chromosome has main regions homologous to 
human chromosomes 2p (N-MYC) and 14q (TGF-ß3, FOS, 
IgH). Mouse chromosome 14 also contains MoMuLV 
integration sites, the T-cell receptor-a (TCR-a) and -8 loci 
and the Rb-1 gene, and has synteny with human chromo-
somes 10, 13q (RB-1), and 14q (TCR-a and -8). Finally, 
mouse chromosome 17 has MoMuLV integration sites, the 
Pim-l gene, tumor necrosis factor-ot (TNF-a) and -ß, the 
H-2 complex, and shows significant homology with human 
chromosome 6p (PIM, TNF-a, TNF-ß, HLA).2627 
How do these data compare with chromosome abnormal-
ities found in human ALL? The leukemic cells of patients 
Table 4. Nonrandom Chromosome Duplications In BCR/ABL P190 
Leukemic Mice 
Chromosome 
Abnormality 
No. of 
Cells* 
No. of Different 
Animalst 
+5 
+ 10 
+ 12 
+ 14 
+ 17 
None 
25 
59 
81 
97 
94 
159 
6 
14 
20 
24 
23 
39 
3|2) 
6(2) 
7(3) 
7(3) 
6(3) 
10(5) 
17 
28 
44 
39 
33 
61 
•Full designation of these mice is 623-844-1035-(number shown); all 
eG3. 
'Total number of metaphases analyzed is 411 and includes all 
animals in Table 1. 
tTotal number of different animals is 17; the numbers in parentheses 
reflect the number of different transgenic lines examined (ie, breeding 
lines derived from different founders; of a total of 6) in which this 
abnormality was seen. 
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with ALL show a high incidence of clonal chromosome 
abnormalities, often complex, and including both structural 
and numerical changes.16 Hyperdiploidy is frequently seen, 
and chromosome numbers usually range from 50 to 60. 
Identical karyotypes are rare between cases, but the addi-
tion of chromosomes 4, 6, 10, 14, 17, 18, 21, or X is 
commonly seen."28 Interestingly, the homologs of some of 
these chromosomes were involved in the transgenic mice: 
human chromosome 6 (mouse chromosome 10 and 17) and 
human chromosome 14.(mouse chromosome 12 and 14) 
were the most obvious of these. This correlation between 
findings in the two species could indicate the presence of 
genes on these chromosomes, such as those described 
above, and others yet unidentified that are associated with 
an increase in proliferative potential. Structural changes 
are found in approximately one-third of human ALL 
patients. Specific translocations include the t(9;22), which 
is found in 2% to 6% of childhood and 19% to 30% of adult 
cases when leukemia is diagnosed. Chromosome abnormal-
ities, in addition to the Ph chromosome, tend to be 
variable.16 In this respect, the nonrandom chromosome 
changes and clonal evolution of our BCR/ABL P190 mice 
is more comparable with the nonrandom chromosome 
changes of human blast-phase CML;'6 
It has been argued that the initial development of 
Ph-positive CML in humans is unrelated to the presence of 
the Ph chromosome,"14 and that a primary Ph-negative 
leukemic clone(s) has an increased susceptibility, of an 
unknown nature, to acquire chromosomal abnormalities. 
This instability leads to the t(9;22) translocation and CML 
develops. The data described in this study provide no 
support for such model. In our mice, it is clear that 
expression of BCR/ABL precedes the development of 
chromosome abnormalities. 
Cytogenetic variation is a marked feature of most forms 
of cancer, particularly their advanced stages, and is inter-
preted as a consequence of neoplasia. It has been postu-
lated that the basic defect in Ph-positive CML lies in 
discordant maturation of cytoplasm and nucleus that re-
sults directly or indirectly from action of the BCR/ABL 
protein.29 Discordant maturation of cytoplasm and nucleus 
is likely to disrupt regulation of the cell cycle leading to 
nondisjunction and aneuploidy. Evidence that BCR/ABL 
disrupts cell cycle regulation also comes from experiments 
with the (murine) 32D cell line, which, when infected with 
an active BCR/ABL retroviral construct, shows an increase 
in cell size and a striking increase in the percentage of cells 
in the G2/M phase of the cell cycle.30 
Our results suggest that BCR/ABL expression is the 
prime event initiating Ph-positive leukemia and that cytoge-
netic/genetic instability, which sets the stage for additional 
mutations and progression of the leukemia, is either an 
indirect effect of this prime event or a direct effect of 
continued BCR/ABL expression. 
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Abstract 
DNA methylation is recognized as a mechanism by which gene expression can be regulated, directly or indirectly. 
In transgenic organisms, transgene inactivation through methylation has been projected as a host defense mechanism 
against transcription of foreign genes. This results in transgene inactivation, thereby rendering eukaiyotic transgenic 
technology and gene therapy ineffective. We have created transgenic mouse lines for a human BCRJABL oncogene. 
While most lines consistently produced pre-B lymphoid leukemia, animals in some lines failed to develop disease. 
In four of these lines, 626, 629, 787 and 793, a variable penetrance of disease was noted. Southern analysis of the 
5-prime part of the transgene by isoschizomeric restriction analysis with HpaH/MspI showed a close correlation 
between transgene methylation in this region, and lack of transgene expression and absence of malignant disease 
in these animal lines. Attempts to induce leukemia in vivo, among other methods through combined use of mitogens 
and the demethylating agent 5-azacytidine, were not successful, suggesting that transgene silencing was not the direct 
result of de novo methylation. 
Introduction 
Methylation of deoxycytidine in the eukaiyotic 
dinucleotide combination 5'-CG-3' (CpG) can stably 
repress genetic activity of genes and is part of 
normal post-replication regulatory mechanisms 
governing differentiation and development (Bird, 
1992; Tate and Bird, 1993; Eden and Cedar, 1994 
+ references therein). The methylation status of 
CpG islands on genes is also implicated in 
imprinting: differential methylation patterns 
distinguishes alleles of different parental origin 
(Allen et al., 1990; Barlow, 1993; Li et al, 1993; 
Rainier and Feinberg, 1994). Genetical inactivation 
of one of two X chromosomes in somatic cells in 
female mammals results in dosage compensation of 
X-linked genes between XX females and XY males 
(Kay et al., 1993). It is generally accepted that 
methylation of the inactive X chromosome helps to 
maintain its inactive state (Allen et al., 1990). In 
cancer, abnormal methylation patterns have been 
recognized in specific genes and in certain instances 
linked to malignant progression of the disease 
(Feinberg and Vogelstein, 1983a, 1983b; Jones, 
1986; Achten et al, 1991; Felgner et al., 1991; 
Kochanek et al., 1991; Malinen et al., 1991; Nelkin 
et al, 1991; Wahlforss et al., 1992; Razin and 
Cedar, 1994). In prokaryotes DNA methylation is 
part of a defense mechanism against foreign, in 
particular viral, DNA and protects host DNA from 
auto-degradation by its own restriction 
endonucleases (reviewed by Doerfler, 1992). De 
novo methylation of foreign DNA has also been 
postulated to function as a eukaiyotic defense 
against transcription of potentially harmful genes 
(Doerfler, 1992). Gene inactivation in virus-
transformed mammalian cells correlates with 
methylation of specific viral sequences, and can be 
reversed by treatment with 5-azacytidine, a 
demethylating agent (Groudine et al., 1981; Groffen 
et al., 1982; Hoeben et al., 1992). Transgenic 
technology in plants (Weber et al., 1990; Kilby et 
al, 1992; Meyer and Heidmann, 1994) and animals 
(Engler et al., 1991; Lettmann et al., 1991) has 
revealed that transgenes are also subject to 
inactivation; transgene methylation patterns often 
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reflect a species-specific branding (Chaillet, 1994). 
Although currently the mechanisms by which 
(trans)gene inactivation is brought about are poorly 
understood, it is of considerable importance for 
practical reasons: gene technologies such as gene 
therapy depend on stable integration and expression 
of what may be considered, at least in part, foreign 
sequences (Richards and Huber, 1993; Challita and 
Kohn, 1994). 
In Philadelphia (Ph) positive leukemia (Ph+ 
acute lymphoblastic leukemia (ALL) and chronic 
myelogenous leukemia (CML)), the BCR gene on 
chromosome 22 undergoes a reciprocal translocation 
with the ABL proto-oncogene on chromosome 9. 
The resulting fusion gene is transcribed in leukemic 
cells and is responsible for the development of 
leukemia (reviewed by Van Etten, 1993; and 
Heisterkamp et al., 1993a). Depending on the exact 
position of the breakpoint in the BCR locus, 
chimeric BCR/ABL proteins will be 190 kDa 
(ALL) or 210 kDa (ALL and CML) in size 
(reviewed by Heisterkamp and Groffen, 1991). We 
have previously generated mice transgenic for a 
BCR/ABL transgene encoding the P190 
oncoprotein: transgenic BCR/ABL P190 animals 
develop pre-B cell leukemia/lymphoma 
(Heisterkamp et al., 1990; Voncken et al. 1992a; 
Voncken et al, 1992b). Of the in total 14 lines, 1 
line did not develop leukemia at all. Surprisingly, 
four lines displayed a variable penetrance of the 
disease: within these lines some animals did, others 
did not develop disease. The purpose of this study 
was to further characterize the transgenic mice 
carrying the human BCR/ABL PI90 transgene and 
to investigate possible mechanisms that influence 
expression of the transgene in the latter lines. 
Materials and methods 
Transgenic construct 
The P190 producing BCR/ABL construct has 
been studied extensively in our laboratory 
(Heisterkamp et al, 1990; Voncken et al. 1992a; 
Voncken et al, 1992b). Briefly, human BCR exon 
1 and human ABL exon 2 are separated by 
intervening sequences derived from respectively 
BCR intron 1 and ABL intron 1, which provide a 
splice donor and acceptor site. ABL intron 2 is also 
retained in the construct, while ABL exons 3 to 11 
and 3'-untranslated sequences are incorporated as 
cDNA. Intron sequences have been reported to 
enhance transgene expression (Brinster et al., 1988; 
Palmiter et al., 1991). The transgene was placed 
under transcriptional control of a segment of the 
mouse metallothionein-1 (mMT) promoter. The 
MT-BCR/ABL P190 (Fig. 1) construct contains 
only part of the mouse MT promoter, identical to 
that used in earlier studies (Heisterkamp et al. 
1990; Voncken et al., 1992a, Voncken et al., 1992b). 
Transgenic technology 
Mice transgenic for BCR/ABL P190 were 
generated essentially as described (Heisterkamp et 
al., 1990). Transgenic founders were identified by 
Southern analysis. Progeny was obtained through 
breeding to C57BL/CBA Fl, C57BL/6, DBA/2 
(Jackson Laboratories, MA). Fl progeny are 
identified by numbers, of which the first three digits 
identify the founder animal. The transgenic animal 
lines used in these studies have been described in 
detail elsewhere (Voncken et al., 1992a; Voncken 
et al., 1992b). 
Autopsy 
Autopsies on terminally ill or apparently healthy 
animals for methylation studies were carried out as 
described previously (Pattengale et al., 1989). 
Histological examination concentrated on 
hematopoietic tissues (bone marrow, spleen, lymph 
nodes) and served to confirm the health status of 
the animals, whether leukemic or not. 
Transgene methylation 
Genomic DNA was isolated from spleens, 
involved lymph nodes and bone marrow as 
described (Voncken et al., 1992a). DNAs digested 
with Mspl or Hpall were run on 1.2% agarose gels, 
blotted to Nytran (Micron Separations Inc., MA, 
USA) and hybridized to an 0.6 Xhol-Bglll probe 
(Fig. 2). Post hybridization washings were at 0.03x 
standard saline-citrate, 65°C. 
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Analysis of BCR/ABL expression 
At sacrifice, a sample of bone marrow, spleen, 
lymph node or blood was used for RNA isolation. 
Expression in blood and in other tissues was 
evaluated by reverse transcription (RT) followed by 
the polymerase chain reaction (PCR). RNA 
isolation was carried out as described (Voncken et 
al., 1992b). 
In vivo induction trials 
Transgene activation in vivo was attempted with 
heavy metals, a specific B-cell mitogen and 
demethylating agents. 5-Azacytidine (5-Aza) and 5-
Fluorouracil (5-FU) treatment protocols were 
adapted from other studies (Lee et al. 1983; 
Harrison et al. 1990; Naya et al., 1991 and 
Constaninoulakis et al., 1992). In total, 6 different 
induction regimes were tested: I, Animals were 
subjected to 2 intraperitoneal (ip) bolus injections 
with lipopolysaccharide (LPS) (day 0: 10 pg 
LPS/animal (ip), day 33: 20 pg LPS/animal (ip). II, 
Animals were exposed for 60 days to cadmium (100 
pM CdSO^) in drinking water, which was provided 
ad libitum; the experiment was terminated after 180 
days. Ill: Animals were given two bolus injections 
(ip) with 5-Aza, 4 mg/kg body weight (bw) and 12 
mg/kg bw respectively, 12 hours apart. IV: Animals 
received an intravenous (iv) bolus injection of 150 
mg 5-FU/kg bw on day 0, followed by two 5-Aza 
injections (ip) on day 4 (as in III). V: An (iv) 5-FU 
injection on day 0 (as in IV) was followed by 3 
successive (ip) injections with 2.5 mg 5-Aza/kg bw 
on days 3, 6 and 9 respectively. VI: Animals were 
injected (iv) with 150 mg 5-FU/kg bw on day 0, 
followed by 4 injections with 4 mg/kg bw 5-Aza (ip) 
at weekly intervals, starting at day 6. Non-transgenic 
control animals in experiential groups III-VI were 
injected with 5-Aza, control transgenic animals were 
injected with diluent only (5-FU: alkaline PBS (pH 
8.0), 5-Aza: 0.9% saline). WBCs were monitored for 
up to 2-3 months after initiation of the trials; WBC 
measurements were done manually with a 
hemocytometer. Blood samples for RT/PCR analysis 
were taken at regular intervals. When monitoring 
for transgene expression, blood samples from 
leukemic mice of the 623 (Voncken et al. 1992b) 
and non-transgenic controls were taken along as 
respectively positive and negative controls . Animals 
were monitored for development of leukemia, and 
examined for lymphomas or other tumors at 
sacrifice. 
In vitro induction trials 
Healthy transgenic animals were treated with 150 
mg 5-FU/kg bw. One week later bone marrow cells 
or splenocytes were isolated. Bone marrow cells 
were expelled from femur and tibia with a 
syringe/25 G needle, using cold PBS. Single cell 
splenocyte suspensions were obtained by mincing 
the spleen with sterile surgical blades and mashing 
the tissue bits through a 40 micron sterile wire grid. 
The suspensions were allowed to settle for 5 
minutes in a 15 ml conical tube, after which the 
supernatant (i.e. single cell suspension) was 
transferred to a fresh tube. Erythrocytes were lysed 
in hypotonic ammonium chloride/ammonium 
carbonate, after which cells were sedimented and 
washed once in PBS, divided and plated out in 6 
well plates in IMDM medium (Gibco/BRL) 
supplemented with 30% FBS, pénicillium, 
streptomycin, L-glutamine and 100 ^M ß-
mercaptoethanol. Cells were cultured in I: 0, 0.03, 
0.3 or 3.0 /JM 5-Aza for 2x 72 hrs; II, for 7 days in 
medium after which they were exposed to 0.1 pM 
or 1.0 fiM 5-Aza for 24 hours, in the presence or 
absence of a heavy metal cocktail (100 /nM ZnCiyi 
pM CdCl2), after which the cells were washed and 
cultured for an additional 3 days; III: for 9 days in 
medium after which they were exposed to heavy 
metals (100 ^M ZnCl2/l pM CdCl2) in the 
presence or absence of 1.0 pM 5-Aza for 72 hours, 
after which the cells were washed and cultured for 
an additional 2 days. Cultures were then terminated, 
harvested and analyzed for transgene expression 
using RT/PCR; expression analysis was also done at 
the time tissue isolation, prior to culturing (zero-
point controls). 
Results 
Transgenic founders and progeny 
Table I gives an overview of transgenic animal 
lines generated, their offspring and the development 
of disease in these lines. In 50% of the founders 
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Table I. BCR/ABL related disease in transgenic founder animals and offspring 
Founder 
618 
620 
628 
631 
713 
790 
796 
623 
632 
626 
629 
787 
793 
791 
disease" 
LLY 
LLY 
ALL 
LLY 
ALL 
LLY6 
LLY6 
LLY 
ALL/LLY 
no disease 
no disease 
no disease 
no disease 
no disease 
Progeny 
none 
none 
none 
none 
none 
none 
none 
F1-F8 
Fl 
Fl 
Fl 
Fl 
Fl 
F1-F3 
disease0 
_ 
-
-
-
-
-
-
ALL/LLY 
ALL/LLY 
variable penetrance0 
variable penetrance0 
variable penetrance0 
variable penetrance0 
no disease 
a: Abbreviations: ALL: acute lymphoblastic leukemia, LLY: lymphoblastic lymphoma. 
b: Animals were found dead at 31 days (790) and 55 days (796). Although no histological 
analysis was carried out, gross pathological findings were indicative of a leukemic condition. 
f Among siblings in these animal lines, a variable penetrance of disease was noted: some 
animals developed BCR/ABL related disease, others remained disease-free. 
disease developed before offspring was sired. Of 
one founder, 623, an transgenic animal line was 
established successfully; this transgenic mouse line 
has been studied in detail (Voncken et al., 1992a 
and 1992b). Bone marrow of founder animal 713 
was used for bone marrow transplantation 
experiments (Voncken et al., 1992a). Some founders 
did not develop disease, although some of their 
progeny did (626, 629, 787, 793). While only the 
791-line did not develop acute lymphoblastic 
leukemia/lymphoma, four lines, 626, 629, 787 and 
793 showed what appeared as a variable penetrance 
of disease: some progeny did, other did not develop 
leukemia. The estimated transgene copy number of 
the transgenic founder animals in the current study 
varied between 1 and 6, with the exception of 787 
(copy number: >25). A detailed description of 
founder characteristics has been presented 
elsewhere (Voncken et al., 1992b). 
Transgene methylation 
We looked for altered transgenic methylation 
patterns in the 791 and the 626, 629, 787 and 793 
lines. Human BCR exon 1 contains multiple 
Mspl/Hpall restriction sites as indicated in figure 2. 
Because of the human origin of the transgene 
sequences (Fig. 1; Heisterkamp et al., 1990), it was 
possible to discriminate transgene from the 
endogenous mouse bcr gene and thus evaluate the 
methylation status of BCR exon 1. The degree of 
methylation of a DNA sequence can be assessed by 
restriction analysis with the isoschizomers Mspl and 
Hpall: Mspl will digest DNA independent of its 
methylation status, while Hpall will only digest 
DNA if the restriction sites in unmethylated. As is 
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A M T - 1 
exon 1 exon 2 exons 3-11,3'-UT 
Figure 1. The MT-BCRIABL P190 transsene. The transgene 
was constructed from human (BCR/ABL) and front mouse 
sequences (metallothoinein promoter: MT-1). A more 
detailed description of the transgene is presented elsewhere 
(Heisterkamp et al, 1990; Voncken et al, 1995b). The 
human BCR exon 1 is indicated by the open box, human 
ABL exons 2 and 3-11 by dark boxes. The hatched box 
represents the MT-1 promoter. 
human BCR exon 1 
262 bp 
Xhol Bglll 
probe 
Figure 2. Mspl/Hpall restriction sites in human BCR exon 
1; the Mspl/Hpall restriction sites are indicated by vertical 
lines. The dark bar underneath the map represents the 0.6 
kb XhoI-BgUI prob\e used for methylation studies. The 
hybridizing human BCR restriction fragment of 262 base 
pairs is indicated on top; the flanking 3'-restriction 
fragments were too small to detect by Southern analysis. 
indicated in figure 3: hypomethylation of the BCR 
exon 1 region produced indistinguishable 
restriction/hybridization patterns for both 
isoschizomers Hpall and Mspl, while methylation 
allowed for Mspl digestion only. Table II presents 
an overview of the methylation and transcriptional 
status of the transgene in a number of transgenic 
lines and founders. All animals that had an 
unmethylated BCR exon 1, expressed the transgene 
(not shown) and had developed disease at the time 
of sacrifice. Within the 623 line, animals without 
symptoms of leukemia also carried an unmethylated 
transgene in their bone marrow. Three founder 
animals, that revealed a methylated transgene and 
did not develop disease themselves, sired offspring 
that did develop leukemia (Table II). Analysis of 
the methylation status of founder 787 and progeny 
was not possible, due to its high transgene copy 
number. 
Influence of genetic background on transgene 
activity 
Recently, it was proposed that a strain specific 
modifier controls methylation of foreign DNA 
sequences in mice of different genetic background 
(Allan et al., 1990; Engler et al, 1991). We wanted 
to determine whether in-crossing of some of the 
original B6CBA/F1 lines into a 'low' methylating 
mouse strain (DBA/2) or a 'high' methylating 
background (C57BL/6) had an influence on 
transgene activation in the lines with variable 
penetrance of disease (626 and 629). The 623 
mouse line was also bred to both C57BL/6 and 
DBA/2 mice, while line 791, the only line that 
never developed BCR/ABL related disease, was 
bred into DBA background alone. Breeding was 
maintained for at least two generations. Neither the 
C57BL/6 nor the DBA/2 background had little if 
any effect on development of leukemia in the 623 
line (not shown). None of the other lines, 626, 629 
and 791 developed leukemia when bred into the 
DBA/2 background. Transgene activity has remained 
constant for over more than 10 generations in the 
623 line (in a B6CBA/F1 background). 
Induction of transgene activity in vivo 
In transgenic mice, exposure to zinc or cadmium 
causes upregulation of MT promoter activity and 
transgene expression in liver (Dyer and Messing, 
1989; Morahan et al., 1989; Rafferty et al., 1993). 
We do not know whether hepatic BCR/ABL 
transgene expression levels increase after exposure 
to zinc or cadmium, since development of leukemic 
disease was taken as the initial criterium for further 
analysis of an animal. However, no hepatic 
pathology was noted upon sacrifice. 
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Figure 3. Methylation analysis of 
BCR exon 1 sequences in the human 
BCRIABL P190 transgene. Panel 623 
gives an example of an unmethylated 
transgene, the panels 626 and 629 of 
methylated transgenes. The expected 
human BCR fragment size (of 262 
bp) under non-methylated conditions 
(see also: Fig. 2) is marked with an 
arrow; e indicates endogenous mouse 
bcr sequences, line: representative 
animals from different mouse lines 
are indicated by the founder number 
of a line (623, 626 and 629 
respectively); to the far left, non-
transgenic (C) mouse DNA spiked 
(•) with recombinant transgene DNA 
and non-transgenic mouse DNA are 
depicted, tissue: S: spleen, T: tumor, 
M: bone marrow, enzyme: m: Mspl 
digestion, h: Hpall digestion. The 
dots at the left of panel 623 represent 
PhiX(Haelll) marker DNA fragment 
+ . 2 6 2 . £ 
In an attempt to evoke BCRIABL expression 
through de-methylation, we set out to induce 
transcriptional activity using combinations of 
mitogenic and demethylating agents. Mouse lines 
626 and 629 were considered the best candidates 
for experimental induction. Since leukemia can 
evolve in a clonal fashion, Southern analysis for 
altered methylation patterns in treated animals was 
not considered realistic unless the animals 
developed overt leukemia. Therefore, development 
of leukemic disease was taken as an initial criterium 
for further analysis. The effect of the induction 
protocols on appearance of BCRIABL expression 
in circulatory nucleated cells was however closely 
monitored by means of RT/PCR on peripheral 
blood samples. Experimental groups IV, V and VI 
(see 'Materials and Methods') comprised animals of 
both the 626 and 629 lines; Experiments I, II and 
III were done with the 629 line only. Although the 
expected biological responses to the various 
treatments were noted (such as leukopenia [LPS; 5-
FU], loss of coat color [TBI]), none of the 
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Table II. Transgene methylation and disease in founders and offspring. 
founder 
713 
623e 
626 
629 
793 
7 9 / 
disease0; 
(CpG 
ALL; 
LLY; 
-;M 
-;M 
-;M 
-•M 
status0) 
nac 
nd 
progeny 
BMT* 
progeny^ 
626-730 
626-728 
626-729 
626-1354 
629-719 
629-723 
629-741 
629-742 
629-1505 
629-1514 
629-1520 
793-908 
793-1031 
793-1030 
791-894 
791-902 
disease"; 
(CpG status6) 
ALL; U 
ALL/LLY; U 
LLY; U 
-;M 
-;M 
-;M 
LLY; U 
LLY; nac 
ALL; nac 
- ;na c 
-;M 
-;M 
-;M 
LLY; U 
LLY; U 
-;M 
-;M 
-;M 
a: Abbreviations: ALL: acute lymphoblastic leukemia, LLY: lymphoblastic lymphoma 
b: Methylation status of CpG dinucleotides in BCR exon 1: U, unmethylated; M, methylated. 
c: No material was available for Southern analysis from these animals. 
d: Bone marrow of 713 was used for serial transplantation experiments (Voncken et al, 1992a), 
hematopoietic tissues of recipients were analyzed for methylation status and were consistently found 
unmethylated. 
e: Animals of the 623 line developed ALL/LLY with a 100% incidence; this line has been studied 
in detail (Voncken et al., 1992a; Voncken et al, 1992b); the transgene is consistently unmethylated 
in the first BCR exon. 
f: None of the animals of the 791 line developed BCRIABL-related disease: the transgene is 
consistently methylated in its BCR sequence. 
treatment regimes employing 5-FU and/or 5-Aza 
delineated lead to leukemogenesis in transgenic 
mouse lines 626 and 629, although similar protocols 
were successfully applied in other models (Thomas 
and Williams, 1992). In one instance a brief 
BCR/ABL PI90 transgene activation was detectable 
in peripheral blood in two animals when subjected 
to protocol III: BCR/ABL mRNA was detected in 
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one animal between 3 and 5 weeks after the last 5-
Aza induction, while the other animal was positive 
for BCR/ABL expression at only one time point (5 
weeks). The same animals, when treated more than 
6 months later with protocol VI, failed to show 
transgene activation. All animals were kept up to 6-
12 month following treatment, after which they 
were sacrificed, examined for gross pathology and 
some of the animals for transgene expression. None 
of the animals had leukemic symptoms or expressed 
the transgene. All animals were kept up to 6-12 
month following treatment, after which they were 
sacrificed, examined for gross pathology and some 
of the animals for transgene expression. None of 
the animals had leukemic symptoms or expressed 
the transgene. None of the treatment protocols led 
to any other disease in transgenic or control non-
transgenic animals. 
Induction of transgene activity in vitro 
Attempts to induce transgene induction through 
de-methylation in vitro (see Materials and Methods) 
were also to no avail: none of the cultures revealed 
transgene activation under any condition, as 
monitored by RT/PCR. All zero-point controls were 
negative for transgene expression. Since some of the 
animals used for these in vitro studies had been 
pre-treated with 5-FU, we have assumed that 
absence of detectable transgene expression in short 
term bone marrow cultures most likely reflects the 
events that take place in the bone marrow with in 
vivo treatment protocols as well. We tentatively 
concluded from these combined experiments that 
attempts to evoke transgene expression through 
demethylation by administration of 5-azacytidine was 
ineffective in our BCR/ABL PI90 transgenic 
animals. 
Discussion 
The finding that transgene methylation patterns 
in the BCR/ABL mouse lines presented here 
correlate with transcription of the BCR/ABL 
transgene and development of pre-B cell leukemia 
or lymphoma and clearly illustrates that P190 
Bcr/Abl is, directly or indirectly, responsible for 
malignant transformation of immature B-cells in this 
animal model (Heisterkamp et al., 1990; Voncken 
et al., 1992a; Voncken et al., 1992b). 
The BCR/ABL P190 transgene is fairly simple 
in its composition: the promoter is not particularly 
strong and no specific elements, like locus control 
regions (Talbot et al. 1989,; Collis et al., 1990), 
have been included, that would confer position 
independent and copy number dependent expression 
characteristics upon the transgene. Based on 
random integration in the mouse genome, one 
expects to find inactive transgenes more frequently 
(i.e. through integration into heterochromatin). 
However, effectively 1 out of 14 lines was non-
productive. Although incorporation of transgenes 
into transcriptionally active regions in the genome 
might be occur more readily, the findings suggest 
that BCR/ABL P190 transgene expression is 
relatively insensitive to chromosomal positioning. 
Alternatively, this might indicate that the transgene 
harbors regulatory elements that we are currently 
unaware of. We have previously observed that 
BCR/ABL expression patterns in a variety of 
mouse tissues parallels endogenous bcr gene 
expression (Voncken et al., 1992b; Heisterkamp et 
al., 1993b). Expression of Bcr in rodent brain is 
high and found in specific structures (Fioretos et al., 
1995). Interestingly, in the 626, 629 and 787 lines, 
transgene expression was detected by RT/PCR in 
brain and kidney (not shown), while absent in 
hematopoietic tissues (bone marrow and spleen). 
Although to date no cis-activating elements, 
analogous to those described for other genes 
(Stenzel-Poore et al., 1992; Aronow et al., 1992), 
have been described for BCR coding or intervening 
sequences, the above observations would not 
exclude this possibility. 
Expression characteristics of (trans)genes are 
principally directed by upstream regulatory 
sequences. Metallothoinein (MT) genes (Glanville 
et al., 1981) are ubiquitously expressed in animals 
tissues and cell lines (Stuart et al., 1984; and 
references therein). The mouse MT-1 promoter has 
been widely used for control of (trans)gene 
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expression in cells and animals. MT-directed 
transgene expression in animals is generally too low 
for detection by Western analysis, except for 
example in tumor tissue (Iwamoto et al., 1993). We 
have noted similar transgene behavior in several 
MT-BCR/ABL models (Voncken et al, 1995b). 
The detectability of transgene encoded protein in 
terminal cancers is probably the result of 
progressively malignant tumor evolution rather than 
a prerequisite for (clonal) tumorigenesis. BCR/ABL 
P190 transgene expression is detectable by RT/PCR 
in fertilized oocytes (unpublished observations) and 
throughout a variety of tissues during mouse 
development (Voncken et al., 1992b). Transgenic 
animals develop leukemia without prior 
experimental exposure to heavy metals. 
From a mechanistic point of view, the variable 
penetrance of disease in four individual mouse lines 
was of considerable interest to us: controlled 
induction of transgene expression may help unravel 
early events in BCR/ABL mediated neoplastic 
transformation. We therefore attempted to induce 
transgene expression in individual animals lacking 
transgene expression, in lines that displayed a 
variable penetrance of the disease. Unsuccessful 
attempts to induce transgene expression in 
methylated lines included bolus injection with LPS, 
exposure to cadmium and zinc in the drinking water 
or a single dose sublethal (650 rad) total body 
irradiation (TBI). LPS is a known B-cell mitogen 
and an activator of metallothoinein expression (De 
et al., 1990; Leibbrandt and Koropatnick, 1994). 
Repeated LPS administration to transgenic 623-
animals did not change the course of disease, as 
compared to a non-treated transgenic control group, 
either (not shown), indicating that onset and 
development of the disease is relatively insensitive 
to BCR/ABL P190 expression levels, or 
alternatively that the transgene is, because of the 
truncated mMT-I promoter, non-responsive to LPS-
induction. The choice of alternative regimes was 
based on the premise that in order for 5-Aza to 
exert its demethylating effect, active cellular 
replication was necessary. In concordance with this 
idea, high doses of 5-Aza and/or 5-Aza2dC were 
only thyro-carcinogenic in mice in combination with 
a non-genotoxic goitrogen (Thomas and Williams, 
1992). Similar studies in liver have shown that a 
only following a non-genotoxic hepatotrophic 
stimulus and partial hepatectomy, 5-Aza 
administration is capable of initiating tumorigenesis 
(Denda et al., 1985). These results suggested that 
the effect of 5-Aza is best observed when 
administered during active cell growth (division). In 
good agreement with the need for proliferative 
activity, in vitro effects of 5-Aza on cell cultures are 
usually very rapid (Harrison et al., 1983; Lee et al., 
1992). To this end, we first treated our mice with 
5-FU. The cytological and histo-pathological effects 
of 5-FU have been described in detail (Radley and 
Scurfield, 1979; Hoyer and Nielsen, 1992): by 
treating animals with 5-FU, the bone marrow is 
enriched for actively dividing hematopoietic 
progenitors (Shih et al., 1992). Following 5-FU, the 
animals received one or more injections with 5-Aza 
(VI, V, VI). 5-Aza had also been administered 
alone (III). However, none of the animals in any 
protocol developed leukemia, indicating that 
transgene activation through de-methylation is not 
effective in our BCR/ABL transgenic line. 5-FU is 
a known myelo-suppressant, the cytotoxicity of 5-
Aza is not well understood. The possibility exists 
that either one or both agents are selectively 
harmful to cells of the B-lineage. The transient 
transgene expression (protocol III) was not 
sufficient to precipitate leukemogenesis. We and 
others have deduced from earlier studies that 
BCR/ABL expression needs to be sustained in 
order for tumor evolution toward a more malignant 
cancer to occur (Voncken et al. 1992a; Voncken et 
al., 1995b). 
Recently, it was shown that transgene expression 
and imprinting are epigenetically controlled by 
genotype-specific modifier genes: transacting 
modifier gene products were found responsible for 
differences in the ability of various mouse strains to 
methylate foreign DNA, C57BL/6 mice showing the 
highest degree of methylation, DBA/2 the lowest 
(Allen et al, 1990; Engler et al., 1991). We tested 
whether the BCR/ABL transgene activity could be 
altered by back-crossing the founders to either 
C57BL/6 or DBA/2 mice. However, breeding over 
at least two generations into a C57BL/6 or DBA/2 
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background mice, did neither activate transgene 
expression in the inactive 626, 629 and 791 lines 
nor affect mortality rate in the active 623 line (not 
shown). The 623 line has been studied for over 10 
generations in our laboratory and shows no signs of 
diminished transgene activity. Variable penetrance 
in third generation animals (F2) has never been 
observed. This raised the possibility that transgene 
copies separated through germ line transmission. 
However, transgene segregation as a result of 
multiple chromosomal integration was rejected on 
the ground of Southern analysis (i.e. confirmation 
of single integration site and low transgene copy 
number). An alternative, the existence of a 'silencer 
gene' that segregates in the Fl generation, has not 
been explored. 
Although the variable penetrance of disease 
among sibling animals appears to point to a rather 
direct transgene silencing mechanism, the failure to 
induce any expression both in vitro and in vivo 
seems to refute this deduction. Taken together, the 
findings seem to indicate that, although a clear 
marker, transgene methylation is not the sole factor 
determining transgene silencing; indeed epigenetic 
changes to DNA, such as CpG methylation, often 
function to maintain and propagate the newly 
established transcriptional state of a responding 
locus (Bird, 1992; Tate and Bird, 1993 + references 
therein). Mechanisms that regulate de novo 
methylation of foreign DNA sequences in vivo are 
not well understood (Doerfler, 1992). Adenoviral 
sequences, retroviral sequences and transgenes that 
include prokaryotic and viral sequences are subject 
to methylation in transgenic mice and cell lines 
(Lettman et al., 1992; Engler et al., 1992). 
Recognition of species specific sequences (MT-1 
promoter) in our transgene may prevent direct 
inactivation through methylation. Both BCR alleles 
are actively transcribed, both in human (Fioretos et 
al., 1994) and in mouse (Voncken et al., 1995a). It 
would therefore seem unlikely that BCR sequences 
in our transgene would be 'branded' for allelic 
inactivation. Conversely, functional 'counter'-
mechanisms, such as forementioned cis activating 
elements could help explain sustained activity of 
transgenes throughout many generations, despite 
clear harm to the organism. 
In summary, we show that there is a close 
correlation between transgene activity, development 
of disease and transgene methylation in our mouse 
model for Philadelphia positive acute lymphoblastic 
leukemia, as revealed by combined isoschizomeric 
restriction analysis of BCR exon 1 sequences and 
expression studies. Attempts to induce transgene 
expression in mice, which showed BCR/ABL 
transgene methylation, with several protocols 
employing both tissue directed (LPS, 5-FU plus 5-
Aza) and general induction protocols (heavy metals, 
TBI) were unsuccessful: no BCR/ABL related 
hematopoietic disorders were induced. In vivo 
observations also seem to confirm that sustained 
expression of BCR/ABL P190 is required for 
leukemia to develop. Based on failure to detect any 
transgene expression in vitro by means of the very 
sensitive RT/PCR method, we speculate that 
methylation is not the cause for transgene silencing, 
but that CpG methylation in the 5-prime region of 
the transgene possibly serves to preserve an inactive 
transgene and as such provides a marker for 
transcriptional activity. The scientific and clinical 
application of sophisticated genetic technologies, 
such as transgenic technique and gene therapy will 
benefit form further elucidation of mechanisms that 
cause transcriptional silencing of exogenous DNA 
sequences in mammalian cells. 
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A B S T R A C T 
A chimeric BCR/ABL oncogene encoding the p l90 protein has been 
introduced into the mouse germline using microinjection of one-cell 
fertilized eggs. Founder and progeny transgenic animals, when becom-
ing ill, were found to develop lymphoblastic leukemia/lymphoma which 
was transplantable to compatible recipients. Lymphoblasts were ar-
rested at the pre-B stage of development. Expression of BCR/ABL was 
not detected in peripheral blood during the early stages of leukemia but 
became evident as the disease progressed. However, the transgene was 
expressed early in development in bone marrow and was also tran-
scribed in nonhematopoietic tissues although this did not result in tu-
morigenesis. These results strongly suggest that the oncogenicity of 
BCR/ABL is limited to hematopoietic cells, including pre-B cells or 
their progenitors. 
I N T R O D U C T I O N 
T h e P h c h r o m o s o m e , the result o f a reciprocal translocat ion 
between c h r o m o s o m e s 2 2 and 9 ( 1 - 3 ) , i s specifically associated 
with C M L 3 and is a l so found in a percentage o f adult and 
pediatric patients with A L L (4 , 5) . 
D u e to the translocat ion, the ABL p r o t o o n c o g e n e f rom chro-
m o s o m e 9 is fused to the BCR gene o n c h r o m o s o m e 2 2 and 
together they form a chimeric gene . T h e BCR gene contributes 
promoter and 5' e x o n s , and the ABL g e n e contributes i ts 3 ' 
e x o n s . T h e activity o f the A B L gene product, normal ly a ty-
rosine kinase with a low level o f autophosphorylat ion activity, 
is substantially increased in the B C R / A B L protein. Moreover , 
the fusion o f parts o f the BCR gene wi th the ABL combines two 
kinase activities wi th in one protein (6 , 7) . T h e two major forms 
o f B C R / A B L prote ins , p 2 1 0 and p i 9 0 , differ in the a m o u n t o f 
B C R a m i n o acid residues included. O n a g e n o m i c level , p i 9 0 
conta ins only BCR gene e x o n 1, whereas p 2 1 0 conta ins e x o n 1 
as wel l as several other B C R exons . p i 9 0 appears to be associ-
ated main ly wi th Ph-pos i t ive A L L , whereas p 2 1 0 is found both 
in Ph-pos i t ive A L L and in C M L (for reviews see Refs . 8 - 1 0 ) . 
T o investigate the role o f the chimeric gene in leukemia, 
B C R / A B L p 2 1 0 retroviral constructs have been introduced into 
5-fluorouracil-treated m o u s e bone marrow and transplanted 
into lethally irradiated recipients . Different types o f h e m a t o -
poiet ic disease were found. In o n e study 13 o f 3 0 recipients 
(43%) developed either a C M L - l i k e myeloproliferative disease, 
lymphoblast ic leukemia , or macrophage cell type tumors within 
5 m o n t h s (11) . In a different study recipients eventually died o f 
hematopo ie t i c disease involving macrophage , l ymphoid , eryth-
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roid, and mast cell l ineages with the incidence ( 6 9 - 1 0 0 % ) o f the 
exact type o f disease being strain dependent ( 1 2 ) . M y e l o m o n o -
cytic leukemias , granulocytic leukemias , and lymphocyt ic 
l e u k e m i a / l y m p h o m a s were found with p 2 1 0 constructs (13) . 
T h e s e types o f studies have tested on ly the oncogen ic po ten -
tial o f the BCR/ABL gene in ce l ls types l imited to the h e m a t o -
poiet ic sys tem and even there the o u t c o m e could have been 
determined by select ion o f hematopo ie t i c cel ls capable o f being 
infected by these viruses. A different m o d e l sys tem is created 
through the use o f transgenic m i c e because the gene of interest 
will be present in every cell . In a previous study, w e have gen-
erated mice transgenic for a B C R / A B L p i 9 0 construct. O f t e n 
founder mice , e ight died rapidly, within 58 days o f birth, o f 
acute leukemia (the majority lymphoid and poss ibly s o m e my-
e lo id) (14) . T h e t w o remain ing mice were found t o be chimeric 
and did not express the construct in their bone marrow; the 
unexpected early onset o f the disease precluded further studies 
or breeding wi th these m i c e . 
T o e x a m i n e p 190-associated mal ignancies in more detail and 
over a prolonged period o f t ime, we have n o w generated new 
founders and have establ ished a transgenic line from o n e , in 
which the progeny reproducible develop cancer. W e find that 
B C R / A B L express ion is not restricted to bone marrow cel ls . 
Surprisingly, however, the types of mal ignancies found were 
l imited to pre-B leukemias and l y m p h o m a s even in an imals 
with prolonged survival t ime and over 4 generat ions . 
M A T E R I A L S A N D M E T H O D S 
Transgenic Mice. Mice transgenic for the BCR/ABL p 190 construct 
were generated as previously described (14). Founder animals were the 
offspring of matings between CS7BL X CBA Fi animals. Transgenic 
progeny was the result of matings between transgenics and C57BL X 
CBA F] mice. F , progeny are identified by six-digit numbers. The first 
three digits are those of the founder of that specific line. 
Autopsies on terminally ill mice were performed as described previ-
ously (IS). Routine histology examinations included brain, heart, lung, 
liver, kidney, spleen, and thymus. Tissue sections were fixed in 10% 
formalin, 90% B5 (90% B5 = 66 g HgCl2 and 14 g NaAc/liter). Pe-
ripheral blood and bone marrow smears were stained with Wright-
Giemsa and evaluated histologically. WBC were performed manually. 
Mice were diagnosed with lymphoblastic lymphoma/leukemia or ALL 
alone. Of all founder and progeny transgenic mice included in this study 
(n = 100), 50% had died within 70 days of birth and 72% had died 
(range, 31 -199 days) of leukemia/lymphoma at an arbitrarily chosen 
experiment end point. Of the line established from founder 623, ani-
mals died of or were sacrificed with terminal disease on average 68 days 
after birth (range, 41-147 days). 
Southern Blot Analysis. DNAs were isolated from spleens and in-
volved lymph nodes as described (14). DNAs digested with EcoRI were 
run on 0.7% agarose gels, blotted to nitrocellulose, and hybridized to a 
1.2-kilobase Mspl/EcoRl J H probe located immediately 3' to J1-J4. 
Posthybridization washings were at 0.3X standard saline-citrate, 6S*C. 
Analysis of BCR/ABL Expression in Peripheral Blood. WBC and 
BCR/ABL expression assays were performed regularly on peripheral 
blood from transgenic and control mice. Briefly, approximately 10 ul of 
blood were withdrawn from the tail artery using a 25-gauge needle, and 
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3 id heparinized blood were used for RNA isolation. RBC were lysed 
after addition of SO volumes 0.144 M NH4C1-S volumes 0.01 M 
NH4HCO3. WBC were pelleted and lysed in 500 pi "solution D" (16). 
RNA was isolated essentially as described (16). The RNA pellet was 
suspended in 10 til A H 2 0 and RT/PCR were performed on 2 ti\ essen-
tially as described (14) using "ALL E" and "ALL F" oligonucleotides as 
amplimers and "ALL G" as hybridization probe (17). To test the sen-
sitivity of detection under our experimental conditions, a series of di-
lutions of blood from a leukemic mouse (terminal WBC, 85 X lO'/liter) 
with normal blood was performed. These samples were subjected to 
RT/PCR and hybridized to the ALL G probe. A detection level of one 
expressing cell among 10,000 nucleated cells was found. 
To verify that a certain RNA sample was suitable for RT/PCR re-
actions, it was tested for mouse actin expression using as 3' amplimer 
(5'- CGGTTGGCCTTAGGGTTCAGGG-3) and as 5' amplimer (5-
GTGGGCCGCTCTAGGCACCAA-3') (18). In some experiments, an 
oligonucleotide probe (5'-ACTCCTATGTGGGTGACGAGG-3') con-
tained within the amplified region was used for hybridization probe. 
RNA Isolation and Expression in Other Tissues. RNAs were iso-
lated as described (16) using guanidine isothiocyanate. To test for early 
expression, timed matings between transgenic males and nontransgenic 
C57BL x CBA Fi females were set up and embryos were isolated 
between day 14 and day 16 of gestation. Tail DNAs were Southern 
blotted to determine which animals were transgenic. Tissues isolated 
from the embryos were homogenized immediately in solution D and 
stored at —80*C. Preterm and 1 day postpartum bone marrow RNA was 
isolated by homogenizing an entire hind limb. From 2 to 3 ug of total 
RNA were used per RT/PCR reaction. RT/PCR products were sepa-
rated on 1.5% agarose gels, blotted to Nytran (Schleicher and Schuell), 
and hybridized as indicated above. 
RNase Protection Assays. RNase protection assays were performed 
essentially as described (18). To construct a probe for BCR/ABL de-
tection, a 1.4-kilobase segment of the BCR/ABL pi90 mRNA was 
amplified using RT/PCR with amplimers ALL E and CML H. CML H 
is located near the kinase domain of ABL and consists of: 5'— 
CCAAAGCAATACTCCAAATGC-3'. A 450-base pair 5' Taql- 3' 
Kpnl BCR/ABL complementary DNA fragment from this 1.4-kilobase 
amplified product was inserted into pSK digested with ClallKpnl. A 
segment of 3' ABL sequences was removed by Avail digestion. The 
^vall site was blunted by a filling-in reaction; the DNA was digested 
with Hindlll and the insert was ligated into pSK digested with Hindllll 
Hindi. The segment contains 147 base pairs of BCR exon 1 sequences 
and 93 base pairs of ABL exon 2. The construct was linearized with 
BamHl. A 306-base pair probe was synthesized containing the 240 bp 
BCR/ABL fragment plus 66 base pairs of pSK sequence using T7 RNA 
polymerase and [a-32P]UTP. Probes were gel purified prior to hybrid-
ization. Twenty Mg of total RNA were used for BCR/ABL hybridiza-
tions. An approximately 20-fold excess of probe was used. As control, 
mouse actin complementary RNA probes were used and 1 n% of total 
RNA. To quantitate individual signals, cpm were determined using a 
Betascope 603 blot analyzer (Betagen). Relative amounts of actin and 
BCR/ABL mRNA were calculated, after correction for background and 
the actual length of the mRNAs. 
RESULTS 
Pathology of BCR/ABL pl90 Mice. A total of 14 new 
founder mice were generated that were transgenic for the BCR/ 
ABL p i 9 0 construct (14) controlled by the metallothionein 
promoter. Estimated transgene copy numbers varied from less 
than 1 to approximately 26 (Table 1). Two animals died of 
undetermined causes. Four animals were still alive and appar-
ently disease free after 20 months. However, three of these have 
produced progeny which developed malignancies. Eight (57%) 
founders have died with a diagnosable disease; Transgenic prog-
eny was obtained from a number of animals (#632, 623, 626, 
629, 787 ,791 , and 793). The type of disease in the progeny was 
similar to that of the founders, with an average incidence of 
Table 1 Transgenic BCR/ABL f '190 founders 
Animal 
618 
620 
631 
628 
632 
713 
623 
626 
629e 
787 
790 
791 
793 
796 
Transgene 
copy no. 
8 
2 
5 
2 
6 
2 
2 
4 
6 
26 
11 
<1 
1 
16 
Age at 
death (days) 
28 
31 
37 
67 
79 
76 
198 
Alive 
600 
Alive 
31 
Alive 
Alive 
55 
WBC at death 
(xlOMiter) 
20 
ND 
4 
10 
153 
28 
12 
— ND 
— ND 
— 
— 8 
Diagnosis 
LL 
LL 
LL 
ALL* 
LL 
ALL 
LL 
— ND 
— ND 
— 
— LL 
IGH« 
G 
R2 
R2 
R3 
R2 
R3 
R2 
— ND 
— ND 
— 
— R2 
" IGH, immunoglobulin JH rearrangement in splenic DNA; LL, lymphoblastic 
leukemia/lymphoblastic lymphoma; ALL, acute lymphoblastic leukemia; ND, not 
determined; G, germline; Rl, one rearranged band; R2, two rearranged bands. 
* Animal died during routine sedation. Autopsy showed bone marrow packed 
with neoplastic lymphoblasts. 
c
 Animal was found dead with no external signs of tumors. 
67%. Founder animal 623 was used to establish a permanent 
transgenic breeding line. 
Of the eight founders that died, six developed lymphoblastic 
leukemia/lymphoma and two developed lymphoblastic leuke-
mia (Table 1). Fixed and stained tissue sections showed a vary-
ing degree of involvement of lymph nodes with neoplastic lym-
phoblasts in all sick founders and offspring analyzed in detail 
with the exception of animals 713 and 628. None of the animals 
showed involvement of cell types other than lymphoblasts. 
Many animals exhibited pronounced splenomegaly. Gross mor-
phological examination and histological examination of fixed 
and stained tissue sections of samples of brain, liver, kidney, 
lungs, heart, and thymus showed no abnormalities other than 
those associated with the development of lymphomas. 
Cell Type Affected. Southern blot analysis was used to ex-
amine immunoglobulin heavy chain rearrangements in the neo-
plastic lymphoblasts using a mouse J H probe. Splenic DNAs 
from animals such as 713 and 632 showed 3 or 2 rearranged 
bands (Fig. 1, Lanes 7 and 6; Table 1). Other splenic DNAs 
lacked visible IGH rearrangements (618, Table 1; 629-723 and 
632-752, Fig. 1, Lanes 9 and 8). Comparable results were also 
obtained with other DNA samples in that some appeared to 
have an IGH germline configuration, whereas others showed 
few (2-4) prominent rearranged bands indicative of a mono- or 
biclonal population of cells (Fig. 1; Table 1). The immunoglo-
bulin K light chain constant region (Ck) was germline in all 
samples tested (results not shown). 
Peripheral blood from 5 randomly chosen progeny animals 
(626-730,632-749,632-753,632-767,623-881) representing 
three different lines and from transplant recipients of mouse 
713 bone marrow (also see below) were phenotyped in detail 
and were found to uniformly exhibit a pre-B immunopheno-
type: the samples were all positive for the B220/Ly5 (pan-B), 
BP-3 (pan B), and BP-1 (B-cell precursor) markers and were 
negative for the Thy-1 and M1/70 markers which are found on 
cells of T-cell and myeloid lineages, respectively. Surface im-
munoglobulin was absent (results not shown and Ref. 19). The 
genotypic analysis on the other samples using Southern blots of 
immunoglobulin gene segment rearrangements is in agreement 
with this conclusion. 
The leukemia was found to be transplantable. Bone marrow 
from two randomly chosen leukemic mice, 713 and 623-844-
1037 (an F2 descendant of 623) was transferred to sublethally 
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M 1 2 3 4 5 6 7 8 9 10 11 of this set were dead by i93 days (Fig. 2). In a second experi-
ment, ten 19-day-old mice were sacrificed and assayed for BCR/ 
ABL expression both in bone marrow and in blood. Morpho-
logically, bone marrows of these animals appeared normal. 
Control reactions using actin amplimers showed that all sam-
ples were suitable for RT/PCR (Fig. 3). Six of 10 mice lacked 
clear expression in peripheral blood at this detection level (also 
see "Materials and Methods"), but all had a positive bone mar-
row (Fig. 3). Taken together, these results showed that the 
BCR/ABL transgene was not detectably expressed in the pe-
ripheral WBC population of apparently healthy founders, or of 
progeny of 623. However, expression was clearly present in 
bone marrow cells at 19 days after birth. 
To investigate the earliest occurrence of expression in bone 
marrow, samples from 5-6 days of age, day 1, and preterm at 
Fig. 1. Southern blot analysis of IGH rearrangements in involved splenic 
DNAs. DNAs digested with EcoRl include those of founders 618 (Lane I), 620 
(Lane 2), 631 (Lane 3), 631 involved lymph node (Lane 4), 628 (Lane 5), 632 
(Lane 6), 713 (Lane 7). Fl animals include 632-752 (Lane 8) and 629-723 (Lane 
9). Control splenic and tail DNA is shown in Lanes 10 and 11. The position of the 
6.4-, 4.4-, 2.3-, and 2.0-kilobase markers of a \/fflndlll digest is shown to the left 
in Lane M. Arrow, germ line fragment. 
loeo 
1081 
1082 
I08H 
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1087 
1090 
I09M 
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Fig. 2. Expression of BCR/ABL in peripheral blood. Left ordinate, animals; all 
animals are F2 and F3 progeny of 623. ^,-from which age on, in days after birth, 
expression could be detected; • , individual sampling points. Additional sampling 
points (not shown) were taken for most mice subsequent to the detection of 
expression. Blood of mouse 1082 was still negative for BCR/ABl expression at 
the last sample taken (i.e., 30 days). Right ordinate, age of the animals at death or 
sacrifice due to overt disease. 
(500 rads) irradiated syngeneic recipients. After a latency pe-
riod (27-69 days) leukemia developed in some (713) or all (623 
line) of the recipients. Upon secondary and tertiary passage, 
cells from the 713 line became increasingly malignant, with 1 x 
106 cells causing overt leukemia in nonirradiated hosts in as 
little as 14 and 9 days. Analysis of peripheral blood cells from 
three of the secondary transplant recipients showed the same 
phenotype as the leukemic cells of the transgenic mice de-
scribed above (not shown). 
Expression of pl90 in the Development of Leukemia/ 
Lymphoma. These experiments demonstrated the association 
between the presence of the BCR/ABL oncogene and the de-
velopment of a transplantable pre-B leukemia/lymphoma in the 
founder transgenic mice. However, not all animals became leu-
kemic and it is possible that in some the transgene was inte-
grated into a transcriptionally silent region. 
A number of founders were followed prospectively over an 
extended period of time for the possible appearance of BCR/ 
ABL expression in their peripheral blood using RT/PCR. No 
expression could be detected in 626 and 629, although both 
were evaluated up to 3 months of age (not shown). Both animals 
were still alive at 20 months but had sired progeny which ex-
pressed BCR/ABL and developed leukemia/lymphoma. Simi-
larly, 787 and 793 sired expressing progeny. 
Subsequent expression studies were performed with progeny 
of founder 623 (Table 1). The 623 transgenic line has been bred 
for more than 4 generations, and within each generation ani-
mals developed lymphoblastic leukemia/lymphoma. Eight of 
such animals from two randomly chosen nests with transgenic 
mice were assayed at a relatively early age. The first appearance 
of BCR/ABL expression in peripheral blood was at day 20 in 
two animals. At 30 days, 7 of 8 mice were positive and all mice 
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Fig. 3. BCR/ABL expression in the bone marrow and blood of 19-day-old 
mice. Top abscissa, identifying numbers of the individual mice. Animals 111$-
1125 are all F3 descendants of 623. Samples of RNA from blood (BL) or bone 
marrow (BM) were subjected to RT/PCR with the appropriate primers and hy-
bridized to a BCR/ABL or an actin oligonucleotide probe. Exposure time was 21 
h for BCR/ABL and 1 h for actin. 
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between 14 and 16 days of gestation were analyzed. All trans-
genic samples showed clear expression whereas nontransgenic 
siblings were uniformly negative (Table 2). These results sug-
gest a prolonged expression of the BCR/ABL pi90 construct in 
bone marrow. 
Expression of pi 90 mRNA in Other Transgenic Tissues. 
RNA isolated from transgenic brains and livers of the 14-16-
day-old fetuses, 1 day and S-6-day-old mice also showed BCR/ 
ABL expression (Table 2). An examination of different RNAs 
from somewhat older (13-22 days) transgenics from the 623 
line using PCR showed continued expression in brain and liver, 
and also BCR/ABL mRNA in kidney, spleen, and muscle (Ta-
ble 2). 
The RT/PCR method is very sensitive and able to detect 
small amounts of expression. However, since expression of 
BCR/ABL could not be detected in peripheral blood samples 
(not shown) taken simultaneously with those for other RNA 
isolations, it did not seem likely that the signals seen in other 
tissues were from BCR/ABL expressing bone marrow cells 
which had escaped into the circulation. To provide a more 
quantitative measure of the different levels of expression seen 
and to confirm the endogenous tissue-specific BCR/ABL ex-
pression an RNase protection assay (20) was used. 
A protection probe was constructed which spanned the BCR/ 
ABL junction of the pi 90 mRNA and contained both BCR and 
ABL sequences (Fig. 4A). Different lymphoblastic lymphoma 
RNA samples from one founder and progeny of four different 
transgenic lines were examined for BCR/ABL expression (Fig. 
AB). With 20 jug of total lymphoma RNA, BCR/ABL signals 
were generated comparable to those obtained with an actin 
probe in 1 n% total RNA (Fig. 3fi). RNAs from brain, liver, 
kidney, muscle, and spleen of the 13-16-day-old mice (also see 
Table 2) were then examined (Fig. 5). Actin showed a differen-
tial level of expression in different organs. BCR/ABL expres-
sion was relatively low but a consistent level of protection was 
Table 2 Expression of BCR/ABL in different tissues using RT/PCR 
Expression in 
Age of 
animal" 
Bone Animal 
marrow Brain Liver Kidney Muscle Spleen no.* 
14/16 pc. 
14/16 pc. 
14/16 pc. 
Control 
1 d. 
1 d. 
Id. 
Id. 
Control 
5-6 d. 
5-6 d. 
5-6 d. 
5-6 d. 
Control 
13 d. 
13 d. 
16 d. 
16 d. 
19 d. 
19 d. 
22 d. 
22 d. 
+ 
+ 
+ 
-
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
± 
+ 
± 
± 
± 
+ 
+ 
± 
_ 
± 
+ 
± 
+ 
+ 
± 
± 
1132i 
11321 
1132m 
1132k 
1211a 
1211b 
1211c 
1211e 
1211d 
1132b 
1132c 
1132d 
1132e 
1132a 
1262 
1263 
1255 
1260 
1254 
1259 
1256 
1257 
a
 Expressed in days after birth (d) or after conception (pc). 
* Progeny of 1132 and 1211 are F4 and F5 animals. All other mice are F3 
generation of the 623 line. Hybridization signals are designated as readily detectable 
(+), absent at this detection level (—), or very weak (±) as compared to the other 
samples. Indicated control animals are nontransgenic mice. 
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Fig. 4. RNase protection analysis of BCR/ABL expression. A, RNase protec-
tion probe. Upper line, part of the BCR/ABL DNA construct used (14). • , BCR 
coding sequences; ^, ABL coding sequences. Lower line, full-length mRNA pro-
tection probe including plasmid sequences. A', Avail; B, ifamHI; T, Taal. B, 
expression of BCR/ABL in lymphoid tumors. RNAs (1 pg for actin, 20 Mg for 
BCR/ABL) include those isolated from lymphoblastic lymphomas of founder 796 
(Lane I); 629-719 (Lane 2); 632-753 (Lane 3); 787-1018 (Lane 4); 623-880-
1051 (Lane 5). M, QX/Haelll marker. Exposure time was 10 h with intensifying 
screen. 
seen in the tissues examined. The highest levels were found in 
brain, kidney, and spleen (Fig. S). Compared to actin, BCR/ 
ABL expression was approximately 200-fold lower in brain; 
400-600-fold lower in kidney, muscle, and liver; and 1400-fold 
lower in spleen. In brain, protection of the chimeric mRNA was 
detected as early as 14-16 days in utero (not shown). In com-
parison with the (average) expression levels in the lymphomas, 
the (average) relative levels of BCR/ABL expression were cal-
culated as lymphoma:brain:kidney/spleen:liver/muscle as 
100:2:1:0.3. These experiments conclusively demonstrate that 
the BCR/ABL transgene is expressed not only in bone marrow 
but also in nonhematopoietic tissues such as brain, kidney and 
muscle. 
DISCUSSION 
We have examined the development of malignancy in 14 
founder mice and progeny transgenic for a pi90 BCR/ABL 
construct over a prolonged period of time. When any of the 
total of 100 animals developed cancer, it was a lymphoblastic 
leukemia/lymphoma, between 31 and 199 days after birth. In a 
previous study (14) transgenic animals had a somewhat more 
virulent development of overt disease than these animals and 
more significantly, the cause of death in 2 of the 8 previous mice 
was diagnosed as myeloid leukemia. The constructs used in 
both studies were identical, as was the mouse genetic back-
ground (CS7BL x CBA F,) used to generate the transgenic 
founders. The observed differences could be attributed to the 
low numbers of transgenic mice (8 genuinely BCR/ABL trans-
genic mice) analyzed in the first study, environmental factors 
and/or less than optimal pathological diagnosis in the previous 
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Fig. S. BCR/ABL expression in different tissues using an RNase protection assay. Mouse identification numbers are shown above the panels. B, brain; L, liver; K, 
kidney; M, muscle; S, spleen. Marker is $XJHael\l. The size (in nucleotides) of the protected BCR/ABL or actin fragments is as shown. Exposure times were IS h at 
room temperature for actin and 216 h at -80*C with intensifying screen for BCR/ABL. 
study since the two mice diagnosed with myeloid leukemia were 
found dead (14). An advantage of this relative lower initial 
morbidity was that we were able to establish breeding lines and 
characterize the affected cell population in more detail. Pheno-
typic analysis of cell-surface markers on leukemic peripheral 
blood cells of different samples consistently indicated a pre-B 
phenotype (this study and Ref. 19). Thus, a pre-B cell type was 
affected both in these animals as well as was suggested in the 
animals of the previous study (14) and parallels the dominant 
cell type observed in Ph-positive lymphoblastic leukemia in 
humans. These data differ considerably from those published by 
others (21) who, among other differences, found that the ma-
jority of mice developed T-cell lymphomas. However, consid-
erable variation in the constructs used are obvious. Most im-
portantly, in the study of Hariharan et al., a bcr/v-abl construct 
was used for injection. In comparison with mouse abl, v-abl has 
undergone multiple deletions and amino acid substitutions 
which are thought to enhance tumorigenicity (22). Our exper-
iments to examine possible BCR/ABL expression in peripheral 
blood of founders yielded a somewhat surprising result in that 
expression was not found in the circulating WBC of early leu-
kemic mice. One of many possible explanations for this re-
stricted expression is that the BCR/ABL construct is turned on 
only in immature (precursor) cells and is silenced when the cells 
mature. However, the metallothionein promoter used to con-
trol expression of the construct is active in many tissues and is 
not known to be regulated in such a way in hematopoietic cells. 
It would therefore seem more likely that some sequence belong-
ing to the BCR or ABL part of the transgene is responsible for 
this regulation. 
A different explanation is that the continued BCR/ABL ex-
pression in bone marrow directly or indirectly causes matura-
tion arrest or causes the cells to die. Because maturation/ 
viability and BCR/ABL expression would be mutually 
exclusive, only cells not expressing the transgene would be able 
to mature and be subsequently found in peripheral blood. The 
BCR/ABL-expressmg cells, because of their immaturity, would 
remain within the bone marrow until either crowding and/or 
mutations leading to termination of stromal dependence cause 
migration into the peripheral blood. Such mutations for cells of 
the B-cell lineage which render the cells, e.g., interleukin 7 
and/or stromal cell-independent have been demonstrated in in 
vitro lines derived from the blood of these transgenic mice (19). 
Previously, it has been shown that BCR/ABL (p210) can 
transform rat fibroblasts (23) but not NIH 3T3 cells (24) sug-
gesting that BCR/ABL might also cause the development of 
solid tumors. We have observed morphological changes in both 
NIH 3T3 and Rat-2 cells upon transfection of BCR/ABL p210 
and/or pl90.4 These changes were quite subtle in comparison 
with those caused by other transforming oncogenes and we were 
unable to unambiguously determine if BCR/ABL causes trans-
formation of cultured fibroblasts. However, in vivo, in a mouse 
model, the consequences of BCR/ABL expression with respect 
to tumorigenesis in other cell types should be more significant 
than in immortal and in vitro cultured fibroblasts. 
Since in our mice the transgene is transcribed in tissues other 
than bone marrow, why do no malignancies develop there? 
There are at least two possible explanations for these findings. 
Since the absolute level of BCR/ABL expression found in brain 
is on the average approximately 50-fold lower (range, 25-500-
fold) than that found in lymphomas it is possible that a certain 
threshold level is required for the generation of tumors. How-
ever, the lymphomas consist predominantly of a single type of 
cell, represent terminal stage disease tissues, and may contain 
malignant cells which were selected for high BCR/ABL expres-
sion after leaving the bone marrow. The brain sample will con-
tain a heterogenous collection of cell types with a possible very 
high level of expression in some cell types and none in others. 
It is therefore difficult to prove that an overall 50-fold differ-
ence in expression levels is realistic from the viewpoint of a 
single cell. 
A second possibility is that only the bone marrow precursor 
cells expressing BCR/ABL contain those effector molecules 
that are necessary for mediating the oncogenic effect of the 
BCR/ABL protein. This view is consistent with the demon-
strated critical role of the normal ABL protooncogene in a 
restricted population of cells of the immune system (25, 26). 
The normal BCR gene product has sequence similarity with a 
GTPase activator protein for p2r h o , and was shown to have 
GTPase activator protein activity for p21 r ac l (27). p21rac is a 
member of the GTP-binding protein superfamily of signal-
transducing proteins, is ubiquitously expressed, and is involved 
in secretory processes in myeloid cells (28, 29). 
The restricted oncogenicity of BCR/ABL for a certain type of 
hematopoietic progenitor cells may thus be a reflection of cell-
ular functions of the BCR and/or ABL genes in signal transduc-
tion pathways found only in those types of cells. This would 
further explain why the Ph chromosome, which one would 
expect to arise by chance in many proliferating tissues, is found 
only in blood cell cancers. 
* Unpublished data. 
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Abstract 
DNA constructs encoding BCRIABL P210 have been introduced into the mouse germ line using microinjection 
of one-cell fertilized eggs. Kinetics of BCRIABL P210 expression in transgenic mice were very similar to those of 
BCRIABL P190 constructs in transgenic mice: mRNA transcripts were detectable early in embryonic development 
and also in hematopoietic tissue of adult animals. Expression of BCRIABL in peripheral blood preceded development 
of overt disease. P210 founder and progeny transgenic animals, when becoming ill, developed leukemia of both B 
and T cell origin after a relatively long latency period. In contrast, P190 transgenic mice exclusively developed 
leukemia of B-cell origin with a relatively short period of latency. The delayed progression of BCRIABL P210 
associated disease in the transgenic mice is consistent with the apparent indolence of human CML during the 
chronic phase. We conclude that in transgenic models, comparable expression of BCRIABL P210 and BCRIABL P190 
results in clinically distinct conditions. The observed dissimilarities are most likely due to intrinsically different 
properties of the P190 and P210 oncoproteins and may also involve sequences that control transgene expression. 
Introduction 
A reciprocal translocation between chromosomes 
9 and 22 results in the formation of the 
Philadelphia (Ph) chromosome (Nowell and 
Hungerford, 1960; de Klein et al., 1982; Rowley, 
1973). Although invariably associated with chronic 
myeloid leukemia (CML), the /%-chromosome also 
occurs in a percentage of adult and childhood acute 
lymphoblastic leukemias (ALL) (Sandberg et al, 
1980; Priest et al., 1980) and in acute non-
lymphocytic leukemia (ANLL) . The 
[t(9;22)(q34;qll)] translocation fuses BCR to the 
ABL proto-oncogene. Activation of the Abl tyrosine 
kinase in hybrid Bcr/Abl oncoproteins is considered 
essential for the development of leukemia (reviewed 
in Van Etten, 1993). The two major forms of 
Bcr/Abl proteins, P190 and P210, differ only in the 
amount of Bcr amino acid residues included. P190 
contains only residues encoded by BCR gene exon 
1, whereas P210 contains residues encoded by BCR 
exons 1 to 13 or 14, depending on the exact 
location of the breakpoint on chromosome 22. PI90 
appears to be associated mainly with Ph-positive 
ALL, whereas P210 is found both in Ph-positive 
ALL and in CML (for reviews see Kurzrock, 
Gutterman and Talpaz, 1988; Sawyers, Denny and 
Witte, 1991; Heisterkamp and Groffen, 1991). 
The 160 kDa BCR gene product contains several 
distinct domains. The segment encoded by exon 1 
harbors a serine/threonine kinase activity in vitro 
and is held responsible for activating ABL in the 
chimeric BCRIABL gene product (Mam et al., 
1991; McWhirter and Wang, 1991; Muller et al., 
1991). BCR exons 3-10, which are only present in 
BCRIABL P210 but not in BCRIABL P190, share 
sequence homology with a guanine nucleotide-
exchange factor for human CDC42: the DBL 
proto-oncogene (Eva and Aaronson, 1985; Hart et 
al., 1991). The C-terminal end of pl60S c r has 
GTPase activating protein (GAP) activity toward 
the small GTP-binding proteins Racl/2 and CDC42 
in vitro (Diekmann et al., 1991; Hart et al., 1992). 
Examination of bcr null mutant mice recently 
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connected plóO5"" GAP in vivo to regulation of 
superoxide production by the NADPH-oxidase 
system in myeloid and B lymphoid cells (Voncken 
et al., 1995). 
The non-receptor tyrosine kinase ç\4?Abl 
negatively regulates cell growth when overexpressed 
in fibroblasts (Sawyers et al., 1994), a function 
which contrasts with that of abl fusion oncogenes 
such as v-abl and BCR/ABL. ABL null mutant 
mice are runted and die within 2 weeks after birth. 
In addition, many show B and T cell lymphopenia, 
the cause of which remains unknown (Tybulewic et 
al, 1991; Schwartzberg et al., 1991). 
To investigate the role of the chimeric BCR/ABL 
gene in leukemia, BCR/ABL P210 encoding 
retroviral constructs have been introduced into 
mouse bone marrow and transplanted into lethally 
irradiated recipients. Different types of 
hematopoietic disease were found. In one study, 
43% of the recipients developed either a CML-like 
myeloproliferative disease, lymphoblastic leukemia, 
or macrophage cell type tumors within 5 months 
(Daley et al., 1990). Other investigators reported 
BCR/ABL mediated hematopoietic disease involving 
macrophage, lymphoid, erythroid and mast cell 
lineages. The incidence (69-100%) of the exact type 
of disease was strain-dependent (Elefanty et al., 
1990). Myelomonocytic leukemias, granulocytic 
leukemias and lymphocytic leukemia/lymphomas 
were found both with P210 and P190 (Kelliher et 
al., 1990; Kelliher et al., 1991). It appears that the 
kinetics and the nature of the induced disease in 
this experimental setting, besides on choice of 
internal promoter, depend on culturing conditions, 
infection procedure and genetic background of the 
grafted mice (Elefanty et al., 1992; Kelliher et al., 
1993). It was further concluded that retroviral 
regulatory sequences may have influenced the 
outcome of the experiments. A major obstacle in 
retroviral technology is targeting the infection to 
stem cells. This is essential since CML is thought to 
be a clonal disease originating in the hematopoietic 
stem cell (Fialkow et al., 1977). 
A different model system is created through the 
use of transgenic mice as the gene of interest will 
be present in every cell. In a previous study, we 
have generated mice transgenic for a BCR/ABL 
P190 construct under the transcriptional regulation 
of a mouse metallothionein (MT-1) promoter; most 
transgenic founder animals and progeny died rapidly 
of an acute leukemia, which was clinically classified 
as ALL (Heisterkamp et al., 1990; Voncken et al., 
1992a, Voncken et al., 1992b). Initial attempts to 
generate a transgenic mouse model for human CML 
with a BCR/ABL P210 transgene controlled by the 
human BCR promoter failed, due to deleterious 
effects of the construct on embryogenesis 
(Heisterkamp et al. 1993). Here we present the 
generation of mouse lines transgenic for MT-
BCR/ABL P210 constructs, and describe the 
development of hematopoietic neoplasia caused by 
the P210 transgenes. 
Materials and Methods 
Transgenes and mice 
The sMT-BCR/ABL P210 (see Fig. 1) construct 
contains only part of the mouse MT promoter, 
identical to that used before to generate óMT-
BCR/ABL PI90 transgenic animals (Heisterkamp 
et al., 1990). The sMT-BCR/ABL construct was 
generated by ligating a 5' Clal-Sall fragment 
containing the truncated MT-1 promoter (a 200 bp 
Sstl-Bglll fragment; Stuart et al., 1984) and BCR 
gene exon 1 till the Sail site to a large Sall-Clal 
fragment encompassing the remainder of 
BCR/ABL. The latter fragment was from the 
previously described cosmid cl(8)der, a BCR/ABL 
DNA construct containing the human BCR gene 
promoter (Heisterkamp et al., 1993). The Sall-Clal 
fragments were ligated into vector pHEP and 
packaged in vitro. The 32.5 kb cosmid insert was 
separated from the vector by pulsed field gel 
electrophoresis. In this construct the entire BCR 
coding region up to Mbcr exon 3 (BCR exon 14) 
and ABL exons 2-8 are contained within one large 
cDNA fragment. The rest oiABL includes introns 
and is a genomic sequence. The MT-BCR/ABL 
P210 was constructed from three segments: (a) the 
complete murine MT-1 promoter fused to BCR 
exon 1 plus a segment of 3' intron (b) the intron 
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immediately preceding BCR gene exon 2, additional 
BCR gene exons up to and including Mbcr exon 2 
and Mbcr exon 3 with flanking introns (c) ABL 
exon 2 with 5' and 3' introns, and ABL exon 3-11 
as cDNA. 
Transgenic &MT-BCR/ABL P190 animals have 
been described in detail elsewhere (Heisterkamp 
et al, 1990; Voncken et al. 1992a; Voncken et al., 
1992b). Mice transgenic for the MT-BCR/ABL 
P210 constructs were generated as described 
(Heisterkamp et al., 1990). Founder animals were 
the offspring of matings between C57BL/CBA F^ 
animals. Transgenic progeny was the result of 
matings between transgenics and C57BLxCBA F^ 
mice, bcr null mutant (Voncken et al., 1995) or 
P53 null mutant mice (Donehower et al, 1992). 
Progeny are identified by eight-digit numbers; the 
first four digits are those of the founder of that 
specific line. 
AMT-BCR/ABL P190 
MT-BCR/ABL P210 
AMT-BCR/ABL P210 
4+ 
Figure 1. Human BCRIABL transgenic constructs. 
Expression of the MT-BCR/ABL P210 transgene (middle 
line) is regulated by the complete mouse metallothionein 
(MT-1) gene promoter, whereas the SMT-BCR/ABL P210 
transgene (lower line) is controlled by a part of the MT 
promoter. Promoter sequences in the sMT-BCR/ABL P190 
construct (upper line) are identical to those of the sMT-
BCRIABL P210 construct. Thin lines indicate intron 
sequences. Hatched boxes represent BCR gene exons, and 
black boxes ABL gene exons; the small black boxes 5' to 
BCR exon 1 represent murine MT-1 promoter sequences. 
Histology 
Pathologic analysis was performed as described 
previously (Pattengale et al., 1989), on autopsy 
material obtained at sacrifice from mice which were 
generally terminally ill. Routine histology 
examinations included bone marrow, lymph nodes, 
liver, kidney, spleen and thymus. Tissue sections 
were fixed in 10% formalin, 90% B5. All MT-
BCR/ABL P210 males displayed fertility problems: 
severely reduced testis size and aspermia were 
frequently encountered. For this reason only a 
limited amount of offspring was obtained from MT-
BCR/ABL founders. The sMT-BCR/ABL P210 
and P190 animals apparently had normal fertility. 
Periodic monitoring of peripheral blood for signs 
of disease 
WBC counts and BCRIABL expression assays 
were performed regularly on peripheral blood from 
transgenic and control mice. Briefly, approximately 
70 pi of blood was obtained via retro-orbital sinus 
bleeding. White blood cell (WBC) counts were 
performed manually, as were differential white blood 
cell counts. Peripheral blood films were stained with 
Wright-Giemsa and evaluated histologically. 
Evidence of myeloid involvement (differential 
counts) in the period that preceded the 
development of overt leukemia in BCRIABL P210 
transgenic animals was not found. 50 pi heparinized 
blood was used for RNA isolation. Red cells were 
lysed in two successive treatments with 20 volumes 
0.144 M NH4CI, 5 volumes 0.01 M NH4HC05 , 
interchanged with washes in normal PBS. White 
cells were pelleted and lysed in 500 pi "solution D"; 
RNA was isolated essentially as described 
(Chomcyznski and Sacchi, 1987). The RNA pellet 
was suspended in 40 pi d ^ O and reverse transcrip-
tase/polymerase chain reactions (RT/PCR) were 
performed on 8 pi essentially as described (Voncken 
et al, 1992b) using "CML A" and "CML H" 
oligonucleotides as amplimers and "CML B" as 
hybridization probe (Kawasaki et al., 1988); in every 
experiment RNA from the human CML cell line 
K562 was used as a positive methodological control. 
In previous experiments, the level of sensitivity of 
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Figure 2. Flow cytometric analysis of BCR/ABL positive tumors: Panel a shows a pre-B cell leukemia lymphoma of a 
SMT-BCR/ABL P190 mouse, a B lymphocytic leukemia/fymphoma of a sMT-BCR/ABL P210 mouse (2762) and a small 
T lymphocytic leukemia of a sMT-BCR/ABL P210 animal (2720). Panel b shows two examples of granulocytic 
involvement in P210 related leukemia (see 'Results'): animal 2685 B-lymphocytic leukemia with cells staining double 
positive for B220 and GR-1; mouse 2663 revealed acute myeloblastic leukemia. All flowcytometric analyses were performed 
on peripheral blood samples. The animal identification numbers are printed in the top right comer of the respective graphs. 
the RT/PCR method for BCR/ABL expression was 
established at one in 100,000 nucleated cells. To 
verify, that a certain RNA sample was suitable 
forRT/PCR reactions, it was tested for mouse actin 
expression using as 3' amplimer (5'-CGGTTGGC-
CTTAGGGTTCAGGG-3,) and as 5' amplimer (5'-
GTGGGCCGCTCTAGGCACCAA-3') (Alonso et 
al., 1986). In some experiments, an oligonucleotide 
probe ( 5'-ACTCCTATGTGGGTGACGAGG-3') 
contained within the amplified region was used for 
hybridization probe. 
Composition of hematopoietic tumors and 
peripheral blood samples 
Composition of hematopoietic tissues was 
determined by double-color flow cytometry on a 
FACScan (Beckton-Dickinson, NJ). Briefly, tissues 
were disaggregated and washed twice in cold PBS. 
Approximately lxlO6 white cells were stained with 
phycoerythrin (PE) and/or fluorescein-isothiocyanate 
(FITC)-conjugated antibodies for 20 to 30 minutes 
in 50-100 pi RPMI containing 3% fetal bovine 
serum and 0.1% sodium azide on ice in the dark. 
Cells were then washed in PBS fixed in 1% 
paraformaldehyde and analyzed. Monoclonal 
antibodies used include: anti-CD45R (RA3-6B2), 
anti-CD45 (30F11.1), anti-CD36 (145-2C11), anti 
Thyl.2 (53-2.1), anti-GR-1 (RB6-8C5) (PharMingen, 
CA) and anti-CDllb (Ml/70.15) (Caltag, 
California). 
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RNA isolation and expression in other tissues 
RNAs were isolated as described (Chomcyznski 
and Sacchi, 1987) using guanidine-isothiocyanate. 
To test for early expression, timed matings between 
transgenic males and non-transgenic C57BlxCBA Fl 
females were set up and embryos isolated between 
day 13 and 15 of gestation. Three fetuses were 
pooled and homogenized immediately in solution D 
and stored at -80 °C. Bone marrow, spleen or tumor 
RNA was isolated after homogenizing part of the 
tissue in slnD. 1-3 /jg of total RNA was used per 
RT/PCR reaction. RT/PCR products were separated 
on 1% agarose gels, blotted to Nytran (Schleicher 
and Schuell) and hybridized as indicated above. 
Immunoblotting 
Tissues were minced and homogenized in a Potter 
homogenizer in 2x SDS sample buffer and analyzed 
by Western blotting as described (Harlow and Lane, 
1988). The chimeric Bcr/Abl P190 and P210 
oncoproteins were detected with the mouse 
monoclonal antibody Ab-3 (anti-c-Abl; Oncogene 
Science, Inc., Uniondale N.Y.) 
Results 
Transgenes and transgenic animals 
To circumvent the problem of embryonic lethality 
observed with the human BCR promoter 
(Heisterkamp et al., 1993b), the mouse 
métallothionein-1 promoter was chosen as an 
alternative regulatory sequence for BCR/ABL P210 
transgenes. Analysis of a mouse model for human 
ALL in which this MT promoter was utilized to 
control P190 expression (the sMT-BCR/ABL P190 
construct (also see Fig. 1); Heisterkamp et al. 1990; 
Voncken et al. 1992a) revealed that transgenic 
animals developed pre-B cell leukemia without prior 
exposure to heavy metals. BCR/ABL mRNA could 
be detected, by RT/PCR, as early as the 1 cell stage 
embryo and was found in all tissues examined at 
later stages (Voncken et al. 1992b). This low level 
of transgene expression is apparently enough to 
predispose for cancer development. 
Subsequently, two BCR/ABL P210 DNA 
constructs were made (Fig. 1), both controlled by 
the murine MT-1 promoter. They differ in the 
length of the MT promoter segment included and 
in their intron/exon structure (see Fig. 1). The 
sMT-BCR/ABL P210 and 5MT-BCR/ABL P190 
constructs share identical MT promoter sequences; 
MT-BCR/ABL P210 and sMT-BCR/ABL P190 
harbour identical BCR exon 1/intron 1 and ABL 
sequences (Fig. 1). 
Transgenic founder and progeny animals were 
generated with both BCR/ABL P210 constructs 
(Table I) and hematological tumors were obtained. 
Animals containing a "double" sMT-BCR/ABL 
P210 transgene were also generated by breeding 
(i.e. P210/P210). However, the transgene copy 
number had no influence on the kinetics and/or 
type of disease that developed (not shown). In 
addition, the sMT-BCR/ABL transgene was 
introduced into a bcr(+/-) and a P53(+l-) genetic 
background. The lack of one copy of the 
endogenous bcr or P53 gene had no apparent 
influence on the type of disease which developed 
or its latency period (Table I). 
Disease 
Unlike mice transgenic for BCR/ABL P190, 
which developed pre-B cell acute lymphoblastic 
leukemia, BCR/ABL P210 animals developed B as 
well as T cell leukemias with approximately the 
same frequency; no difference was found in type of 
disease between the two BCR/ABL P210 constructs 
(Table I). Tumor phenotypes were confirmed by 
flowcytometric analysis (Fig. 2). Incidence of 
hematologic disease in sMT-BCR/ABL P210 mice 
was 58% and in MT-BCR/ABL P210 53%; by 
comparison, sMT-BCR/ABL P190 had a disease 
incidence of nearly 100% (Fig. 3; also see Groffen 
et al., 1993). 
In contrast to studies by others which reported 
the development of T cell neoplasias upon injection 
of either BCR/ABL P190 or P210 retroviral vectors 
directly into the thymus (Clark et al., 1993), we 
found no evidence that T lymphoid cells are targets 
for BCR/ABL P190: to date, among more than 20 
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Mortality (%) 
Age (weeks) 
Filtre 3. Mortality curve of BCRIABL P190 versus 
BCRIABL P210 transgenic mice. Both SMT-BCRIABL 
P210 and MT-BCRIABL P210 groups included FQ 
(founder) and F1 and F2 progeny animals (open triangles; 
n=36). A comparable selection of animals (including F„ 
F. and F , animals of both sexes) is represented in the 
sMT-BCRIABL P190 graph (open circles; n=42). 
different founders and their transgenic offspring, 
none have shown any leukemia other than of the 
B-lineage. 
Neoplasias in BCRIABL P210 animals were of 
both B and T cell type. B lymphoid leukemias or 
lymphomas were invariably accompanied by 
splenomegaly, involvement of lymph nodes, but 
never of the thymus. Most T-cell lymphoid leukemia 
involved the thymus, frequently lymph nodes and 
spleen; white blood cell counts were often extremely 
high. Mature lymphocytic leukemia (B or T) was 
further characterized by absence of mitotic figures 
in the peripheral blood. In both B and T-lymphoid 
tumors, a coexisting but separate and presumably 
non-neoplastic prominent hematopoiesis 
(erythropoiesis and megakaryocytosis) was frequently 
observed in the spleen (not shown). Since clonality 
studies (immunoglobulin heavy or light chain and/or 
T-cell receptor rearrangements) and/or Bcr/Abl 
protein levels were not evaluated in isolated 
megakaryocyte population, we can not exclude the 
possibility that these phenomena related to direct 
oncogenic action olBCRIABL. Macrophage tumors 
were not found in either BCRIABL P190 or 
BCR/ABL P210 animals and primary granulocytic 
disease was rarely found. All leukemias were rapid 
in onset; no evidence for chronic disease was found 
in the peripheral blood. 
At some terminal stages of disease, myeloid 
involvement was found: circulating mature 
neutrophil counts were elevated in one case 
(1994/2663), and a relatively high percentage of 
cells in the bone marrow compartment of another 
terminally sick animal (1994/2685) stained positive 
for both B220 and GR-1 (Fig. 2b). Myeloblasts 
leukemia with a sarcomatous component in animal 
2663 involved the red pulp in the spleen, lymph 
nodes, liver and kidney (Table 1). Since mouse 2685 
revealed a lymphoid proliferative disorder at an 
earlier stage, this myeloid involvement could be 
secondary to lymphoid tumorigenesis (i.e. a 
deregulated cytokine production) as has been 
suggested before (Elefanty et al. 1990; Elefanty et 
al. 1992). Alternatively, BCRIABL P210 expression 
could disturb differentiation or proliferation of 
relatively rare myeloid-lymphoid precursors. Such 
rare stem cell origins in Ph-positive leukemia are 
occasionally encountered (Akashi et al., 1993a and 
1993b); also switching within myeloid and pre-B 
lymphoid tumor lineages has been reported before 
(Martin et al., 1993), demonstrating a close 
developmental link between these hematopoietic 
lineages. 
Taken together, we conclude from our data that 
P190 and P210 cause clinically distinct disorders in 
a transgenic setting. 
Kinetics of transgene expression 
To investigate whether differences in type of 
disease could be associated with different levels of 
BCRIABL expression, total protein was isolated 
from different end-stage tumors. However, tumors 
of all three transgenic animal lines expressed 
comparably high levels of the chimeric Bcr/Abl 
oncoproteins (Fig. 4). 
We also examined transgene expression on an 
RNA level using RT/PCR early in development and 
in bone marrow. Both P210 transgenes were actively 
expressed early in utero (not shown) and in bone 
marrow of different transgenic animal lines (see: 
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Table I. Tumorigenesis in BCR/ABL P210 transgenic animals. 
Animal Age^ Tissue involvement2 
(wks) BM SPL THY LN 
WBC* Diagnosis4 
(xl06/ml) 
MT-BCR/ABL P210 
1063 
1063-1164 
1102-1684 
1102-1691 
2160-2302 
2179 
11 
13 
17 
15 
20 
15 
6MT-BCR/ABL P210 
1994-2725 
1994-2762 
1994-2777 
1994-2781 
1994-2784 
bcr(+/-)' 
1994/2683 
1994/2685 
1994/2720 
1994/2744 
1994/2748 
P53(+/-Y 
1994/2619 
1994/2661 
1994/2663 
1994/2710 
11 
12 
9 
28 
28 
22 
21 
19 
18 
25 
18 
44 
54 
14 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
_ 
-
+ 
+ 
_ 
+ 
+ 
-
+ 
-
+ 
-
-
+ 
+ 
-
+ 
+ 
-
-
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
110 
53 
376 
219 
nd 
nd 
84 
29 
56 
196 
nd 
1 
1 
128 
nd 
19 
nd 
126 
98 
2 
pre-B lymphoblastic leukemia 
small B-lymphocytic leukemia 
small T lymphocytic leukemia 
small T lymphocytic leukemia 
B lymphoblastic leukemia/lymphoma 
small T lymphocytic leukemia 
T lymphoblastic leukemia 
small B lymphocytic leukemia/lymphoma 
T lymphocytic leukemia 
pre-B lymphoblastic leukemia 
T lymphoblastic lymphoma 
pre-B lymphoblastic lymphoma 
B lymphocytic leukemia/lymphoma* 
small T lymphoblastic leukemia 
T lymphocytic leukemia 
T lymphoblastic leukemia 
T lymphoblastic leukemia 
T cell lymphoma leukemia 
myeloblastic leukemia* 
lymphoblastic lymphoma (B or T) 
1: Age at death; autopsies were performed on terminally ill animals or animals were followed until they perished 
2: Tissue involvement was established by gross pathological and histological examination. 
3: White blood cell count was either determined at or a few days before death. 
4: Phenotype of lymphoid tumors was assessed by flowcytometry (see: 'Materials and Methods'). §: These animals 
displayed granulocytic involvement in the peripheral blood at terminal stages of disease. *: diagnosis of myeloblastic 
leukemia in animal 2663 was based on pattern, general morphology and anatomic sites involved (see also: 'Results'). 
•: (+/-) indicates that animals were heterozygous for either the bçr or the P53 eene. 
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Table II. Transgene expression in bone marrow of different BCR/ABL P210 lines 
6MT-BCR/ABL P210 
animal 
of line' 
168 
170 
171 
1989 
1994 
2039 
2043 
TG2 
xpr 
nd 
+ 
nd 
+ 
+ 
_ 
+ 
disease in 
founder oi 
no 
+ 
no 
nd 
+ 
_ 
-
mouse line: 
offspring 
MT-BCR/ABL P210 
animal 
of line' 
1063 
1102 
1105 
2148 
2160 
2179 
TO2 
xpr 
+ 
+ 
nd 
+ 
+ 
+ 
disease in mouse line: 
founder or offspring 
+ 
+ 
no 
-
+ 
+ 
1: Animal lines are represented by founder identification numbers. 2: Transgene expression in bone marrow was 
evaluated in at least one transgenic animal per line by RT/PCR. nd: not determined, no: no offspring sired by 
this founder. 
Table II), without prior exposure to zinc or 
cadmium. As was the case in the 6MT-
BCR/ABL P190 animal model, appearance of 
BCR/ABL P210 expressing cells in the 
peripheral blood preceded the development of 
overt leukemia (Voncken et al., 1992b). 
However, not all transgenic animal lines that 
expressed the transgene in the bone marrow 
developed peripheral expression (Table II). 
Moreover, appearance of transgene expression 
in circulating blood cells did not necessarily 
herald subsequent development of disease: 
some animals, of which transgene expression 
in circulating nucleated cells had been 
confirmed between 10 and 16 weeks of age, 
remained disease free, some past 16 months 
of age. These observations were valid for both 
BCR/ABL P210 constructs. In P190 animals, 
a close correlation exists between transgene 
expression and development of disease 
(Voncken et al., unpublished observations). 
The differences between P190 and P210 
transgenic lines is also quite apparent in the 
mortality curves (Fig. 3). The large differences 
between transgenic animals as far as latency 
time is concerned indicates that BCR/ABL 
P210 expression is not the sole cause of 
leukemia, but rather predisposes for the 
cancer. In agreement with current concepts, 
additional (epi)genetic mutations, directly or 
indirectly resulting IxoraBCR/ABL expression, 
most likely contribute to malignant tumor 
evolution. 
Discussion 
Transgenic mouse models allow direct 
comparison of P210 and P190 associated 
disease 
In recent years, attempts to generate a 
reliable animal model for the study of CML 
have been thwarted by lack of reliabilty and 
reproducibility (Daley, 1993). The outcome of 
bone marrow transplantation experiments 
employing retroviral BCR/ABL constructs was 
shown to depend largely on infection 
conditions, retroviral and internal regulatory 
sequences used and also on genetic 
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«P210 
«P190 
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Figure 4. Bcr/Abl expression in primary tumors of 
transgenic animals. A high molecular weight protein 
marker of 200 IcDa is indicated to the left (square). 
Lane 1 and 2: P190 expression in lymphomas of two 
different sMT-BCRIABL P190 animals. Lane 3: 
P210 expression in a T cell lymphoma (thymoma) 
in a SMT-BCRIABL P210 mouse of the 1994-line 
and Lane 4: transgene expression in a B-cell 
lymphoma of an MT-BCRIABL P210 animal 
background of the irradiated recipient mice; 
in essence, the outcome of the disease 
depends on which hematopoietic progenitor 
cell was targeted by retroviral vectors 
(Elefanty et al. 1992; Kelliher et al., 1993). 
Myelo-proliferative disorders could be 
obtained by manipulating these experimental 
conditions. In this fashion, BCR/ABL P190 
and P210 were shown to cause similar disease 
(Kelliher et al, 1991). Even with \-abl, which 
under natural conditions exclusively induces 
pre-B cell leukemia in mice, myeloproliferative 
illness could be produced (Kelliher et al., 
1990). 
In transgenic animals, every cell including 
hematopoietic stem cells will contain a 
BCR/ABL transgene. The disease which 
develops is independent of influences of 
retroviral sequences or other experimental 
factors, such as infection and bone marrow 
culture conditions. Hence, a transgenic mouse 
model solely reflects the tumorigenetic 
properties of BCR/ABL oncoproteins. The 
present study shows that, although the 
transgenic constructs are very similar in 
composition, BCR/ABL P190 and P210 tumor 
biology clearly differ. The longer latency time 
of P210 associated tumorigenesis, independent 
of whether a B or T lineage tumor develops, 
would seem to indicate intrinsic variation in 
biochemical properties between the two 
distinct oncoproteins. 
Influence of Bcr protein moiety and Bcr 
gene promoter on leukemogenesis 
It has been reported that P190 Bcr/Abl has 
a higher auto-phosphorylation activity than 
P210 in vitro, a property which correlated 
with its higher transforming ability in cultured 
fibroblast cell lines (Lugo et al., 1990). Such 
differences in tyrosine kinase activity might for 
example have a differential effect on the 
differentiation of certain hematopoietic 
lineages and may help explain the altered 
disease-spectrum associated with P210 as 
compared to P190. 
The combined findings in our transgenic 
mice demonstrate that, as in human leukemia, 
the additional Bcr domains included in the 
P210 oncoprotein modulate the outcome of 
the disease. The mechanisms which govern 
these distinct neoplastic processes are however 
not understood. As indicated above, the Bcr 
domains modify the tyrosine kinase activity of 
the Abl moiety (reviewed in Van Etten, 1993) 
and also F-actin binding activities of c-Abl 
(McWhirter and Wang, 1991). In addition, the 
Dbl-homology (Eva and Aaronson, 1985) and 
pleckstrin-homology domains (Mayer et al., 
1993) only present in P210 may allow protein-
protein interactions with other cellular factors, 
which can not occur with PI90. 
Apart from its structural role in the Bcr/Abl 
oncoprotein, there appears to be a second 
discrete mechanism through which BCR may 
contribute to leukemogenesis. We have 
recently shown that the effect of bcr gene 
ablation specifically affects hematopoietic cells 
in mice affected by BCR/ABL in man and 
mouse (Voncken et al., 1995). It seems 
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reasonable to conclude from our data that a 
correlation exists between the cell type 
affected in Ph-positive leukemia and Bcr 
function. The BCR promoter controls 
expression of both the remaining non-
rearranged BCR allele and the BCR/ABL 
oncogene in human leukemia. It is very well 
possible that regulatory sequences that 
normally govern BCR expression have 
substantial influence in directing BCR/ABL 
mediated tumorigenesis. The prominent 
myeloid development in BCR/ABL P210 
mediated human CML may be related to the 
presence of factors in myeloid lineages that 
regulate BCR expression through specific 
elements in the BCR promoter. These factors 
may be less prevalent in human T and B cell 
lineages and preferentially direct BCR 
promoted tumorigenesis in granulocytes. 
All experimentally derived BCR/ABL 
lymphoid tumors were generated with 
regulatory sequences other than the BCR 
promoter. To date, all animals models for 
human Ph-positive leukemia, whether 
generated through retroviral (Elefanty et al., 
1990; Daley et al. 1990; Kelliher et al., 1991; 
Gishizky et al., 1993) or transgenic 
technologies (Hariharan et al, 1989; 
Heisterkamp et al, 1990; this study), develop 
predominantly lymphoid malignancy of B and 
T type. Although hematologic tumors in Ph-
positive ALL are principally of the pre-B 
phenotype, B lymphoid involvement occurs 
only in about 25% of cases of human CML 
in blast crisis and T cell involvement is rarely 
seen in human. We suggest that regulatory 
sequences within the BCR gene are important 
for the type of disease found in human and 
mouse. This concept contrasts with the 
postulate that neither BCR sequences nor 
myeloid cell promoter elements are essential 
for myeloid tumorigenic transformation 
(Kelliher et al, 1990) and that the BCR 
sequences that distinguish BCR/ABL P190 
and BCR/ABL P210 do not control the 
selection of particular types of hematopoietic 
cells (Kelliher et al., 1991). 
Myeloid expansion in BCR/ABL P210 
transgenic mice does not result in 
transformation 
BCR/ABL expression in CML results in 
myeloid expansion. It was suggested, that this 
is the consequence of a reduced programmed 
cell death (Carlesso et al., 1994; Laneuville et 
al., 1994; Kabarowski et al., 1994 and 
references therein), which plays an important 
part in normal hematopoietic homeostasis. 
Preliminary experiments performed in our 
laboratory, with isolated bone marrow cells in 
semi-solid medium from P210 and P190 
animals seem to indicate an absolute increase 
in primitive myeloid progenitor cells (CFU-
GM) and total number of myeloid colonies in 
our P210 mouse model at the 50% mortality 
time-point, while a decrease in myeloid colony 
formation is observed in the P190 bone 
marrow at a comparable time-point. These two 
opposing effects of P190 and P210 again seem 
to reflect a biological difference between the 
two oncoproteins. 
The expansion of the myeloid cell pool in 
human CML is believed to effectively increase 
their susceptibility to additional mutagenic 
events, which ultimately accompany malignant 
transition from chronic phase to fatal blast 
crisis. The idea that BCR/ABL expression 
causes genomic instability was corroborated by 
the appearance of karyotypic abnormalities at 
relatively early stages of disease and their 
nearly invariable presence in malignant 
terminal tumors in our BCR/ABL P190 
transgenic mouse model (Voncken et al., 
1992a). The absence of a chronic phase in the 
present study (e.g. by elevated peripheral 
granulocyte count), despite an elevated 
primitive myeloid progenitor pool in the bone 
marrow, could be a direct result of the 
restricted size of the cell population subject to 
secondary mutational events in a small animal 
like the mouse. A similar scenario was 
suggested to explain the absence of 
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retinoblastoma in heterozygote retino-blastoma 
susceptibility gene (Rb)-mutant animals (Jacks 
et al., 1992). 
In human, about 50% of cases of Ph-
positive ALL carry the BCR/ABL P190 
translocation, the other 50% the P210. 
Consequently, the issue whether Ph+ ALL is 
actually CML in blastic phase has been 
controversial for some time. Recently, 
however, clinical and molecular studies have 
established that indeed Ph+ ALL and acute 
phase CML are two distinct diseases 
(reviewed by Berger, 1993). All results of the 
present study support this concept. In 
transgenic mice, BCR/ABL P210 clearly 
causes a distinct disease from BCR/ABL 
P190. This is caused by inherently distinct 
properties of P190 and P210, possibly 
including the intrinsically different kinase 
activities of the ABL moiety in the hybrid 
oncoproteins and/or cellular interactions of the 
Dbl and pleckstrin homology domains or as of 
yet to be identified domains in Bcr. In 
addition, regulatory sequences upstream from 
or within the BCR gene are likely to 
contribute to the occurrence of myeloid 
leukemia in human and presumably in the 
mouse. These ideas will be the subject of 
future investigations in our laboratory. 
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Abstract. Interferon-alfa (IFN-a) is one of the most effective 
drugs in the treatment of chronic myeloid leukemia (CML). 
Recently, IFN-a has also been tried in the treatment of Ph-
positive acute lymphoid leukemia (ALL), a disease in part 
sharing the same molecular genetic lesion as CML, namely a 
BCR/ABL fusion gene. In the present study we analyzed the 
effect of IFN-a (rHuIFN-aA/D) on a mouse model for Ph-
positive ALL - mice transgenic for the P190 BCR/ABL fusion 
gene. IFN-a treatment was started in the early leukemic 
phase and continued throughout the course of the disease in 
eight transgenic animals. No prolonged survival or altered 
disease pattern with regard to the development of leukemia 
and/or lymphoma was observed. We conclude that IFN-a, at 
least in a transgenic setting, does not interfere with the 
leukemogenic process induced by the PI90 BCR/ABL fusion 
gene. 
Introduction 
Interferon-alfa (IFN-a) is currently one of the most potent 
drugs in the treatment of chronic myeloid leukemia (CML), 
and recent studies have shown that IFN-a is capable of 
inducing partial or total cytogenetic remission in 40-60% of 
CML patients (1). A series of studies have recently given 
new insights into the pathway by which IFN-a signals 
through its receptor to the nucleus (2-4). The mechanism of 
action and the reason for the high response rate in CML 
however remains largely unknown. 
CML and a subgroup of acute lymphoid leukemia (ALL) 
patients (approximately 20% of adult patients) share a 
common cytogenetical marker, namely the Philadelphia 
chromosome (Ph). The Ph chromosome is the result of a 
reciprocal translocation, t(9;22)(q34;qll), which brings the 
ABL oncogene on chromosome 9 into the BCR gene on 
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Diagnosis, Department of Pathology, Childrens Hospital of Los 
Angeles, 4650 Sunset Boulevard, Los Angeles, CA 90027, USA 
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chromosome 22. This results in the synthesis of a BCR/ABL 
fusion protein, P210 (for review see refs. 5-7). 
Approximately half of the adult patients with Ph-positive 
ALL also have a break in the same region of the BCR gene 
(M-bcr) as CML patients. The remainder have a break further 
upstream in the BCR gene (m-bcr), resulting in a fusion 
protein of 190 kDa. Both P210 and P190 show a deregulated 
tyrosine kinase activity, believed to be of importance in the 
leukemogenic process (5-7). 
Given the similarity between CML and Ph-positive ALL 
in terms of the presence of a BCR/ABL fusion protein, IFN-a 
treatment has lately been tried in Ph-positive ALL patients. 
The number of patients studied to date is limited, but some 
beneficial effect has been reported in ALL patients with an 
M-bcr rearrangement (8,9). 
Recently we have established an 'ALL-type' P190 
BCR/ABL transgenic mouse model (10-13) in which founder 
animals develop acute leukemia/lymphoma within 10-58 
days after birth. In the present study we analyzed the effect 
of IFN-a treatment on the disease evolution in a line of these 
transgenic animals. 
Materials and methods 
Mice. A total of 12 mice were included in this study. All 
mice were heterozygous carriers of a P190 type BCR/ABL 
transgene (10) and were from a single line of mice, #623, 
which has been characterized extensively (11-13). 
Lymphoblastic leukemia/lymphoma invariably develops in 
this line, with death following around 68 days on an average 
(13). The average age at death has slightly increased in 
successive generations of this line (unpublished observations). 
Mice initially have no detectable BCR/ABL expressing cells 
in their peripheral blood (PB). As they grow older, such cells 
can be detected in the peripheral blood and this heralds the 
onset of overt disease (12). 
Mice were genotyped at 10 days of age, and control and 
treatment group mice were housed in the same cage and were 
of comparable age at the start of the experiment. A blood 
sample of 5-10 (J.1 was withdrawn from the tail artery of each 
mouse every 10 days. At the first detection of BCR/ABL 
expression in PB, mice were randomly assigned to a control 
or treatment group. 
The animals were monitored by peripheral white blood 
cell (WBC) count twice a month and for signs of lymphoma 
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Table I. Disease characteristics of control and IFN-a treated mice. 
Animal no. BCR/ABL expression IFN-a (units) Terminal WBC Lymphoma Spleen Survival 
detected at day (xl09/l)a burdenb weight (g)a (days)c 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
51 
59 
36 
51 
51 
36 
30 
61 
70 
78 
102 
99 
none 
none 
none 
none 
104 
104 
104 
104 
104 
104 
5X104 
5x10" 
70 
51 
3 
12 
11 
24 
ND 
28 
63 
26 
60 
28 
+ 
-
++ 
-
+++ 
-
-
+++ 
+++ 
-
++ 
-
0.30 
0.60 
0.15 
0.13 
0.48 
0.20 
ND 
1.00 
0.36 
0.22 
0.62 
0.33 
103 
129 
225 
241 
89 
124 
90 
98 
92 
165 
169 
222 
"Normal mean values in mice: WBC, 8xl09/l; spleen weight, O.lg; ND, not determined; b(-) no, (+) low, (++) medium, (+++) high; 'Animal 
no. 7 was found dead at the age of 90 days. No autopsy was performed. 
daily. Animals were sacrificed when terminally ill. Autopsy 
was performed and the degree of splenomegaly and 
lymphoma recorded. 
Injection of mice with interferon. Control group mice (4 total) 
received an intraperitoneal injection of 100 \l\ 0.15 M NaCl 
five times per week. Six mice received 100 [d injections of 
104 units rHuIFN-aA/D in 0.15 M NaCl five times per week, 
whereas two animals received 5xl04 units. rHuIFN-aA/D 
was a generous gift from Hoffmann-La Roche Inc., Nutley, 
NJ. This hybrid protein is active on mouse cells in vivo and 
in vitro (14). To verify its biological activity, a control mouse 
was injected with 104 units of rHuIFN-aA/D, and RNA was 
subsequently isolated using the acid guanidinium 
thiocyanate-phenol-chloroform method (15). Total RNA (10 
Jig) was run on formaldehyde/formamide gels, blotted as 
described (16), and subsequently hybridized to the IFN 
inducible probe #204, kindly provided by Dr P. Lengyel, 
Yale University (17). This gene was induced 2-3 fold as 
compared to a non-treated control. 
Expression of BCR/ABL. To detect BCR/ABL expression in 
PB, RT/PCR was performed as described (10) on a small 
sample of PB withdrawn from the tail artery. All samples 
were tested for suitability in the RT/PCR reaction using actin 
amplimers. Samples were run on agarose gels, and 
hybridized to an oligonucleotide specific for the PI90 
BCR/ABL translocation junction as described (10). In 
addition, the presence of the BCR/ABL PI90 protein was 
confirmed using Western blot analysis on splenic samples 
taken at sacrifice from animal 6, 10, and 11 (Table I). 
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Results 
As determined by RT/PCR, all animals started to express the 
BCR/ABL fusion messenger in the range between 30-102 
days (Table I). At this stage all animals had normal WBC 
counts and no signs of lymphoma. IFN-a treatment was well 
tolerated based on the observation that no difference in 
behavior between control and treated mice was apparent. All 
control animals (n=4) developed leukemia and/or lymphoma; 
the average lifespan was 174 days (range 103-241 days). The 
average time from first detection of BCR/ABL expression to 
death in this group was 125 days (range 50-190 days). 
Leukemia and/or lymphoma also developed in the group of 
mice treated with 104 (n=6) and 5x10* (n=2) units of IFN-a. 
The average lifespan in this group was 131 days (range 89-
222 days) (Table I). The average time from first detection of 
BCR/ABL expression to death was 65 days (range 22-123 
days). Thus, in summary, no prolonged lifespan or altered 
disease pattern was observed in the IFN-a treated group 
when compared with untreated animals. 
Discussion 
CML and Ph-positive ALL are in part characterized by the 
same molecular genetic lesion, a BCR/ABL fusion gene, 
believed to be of major importance in the initiation of the 
leukemogenic process. IFN-a has been shown to induce 
partial or total cytogenetic response in a large fraction of 
patients with CML (1). The detailed mechanism of how IFN-a 
induces hematologic and cytogenetic remission in CML is 
however unclear, and it remains controversial whether the 
suppression of the leukemic cells through IFN-a is a result of 
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a direct effect on the leukemic cells or an indirect effect 
mediated through the normal host cells (18-20). 
Transgenic animal models offer a unique possibility to 
study the influence of various treatment regimens on specific 
diseases. Disease course and treatment protocols can be 
monitored strictly, and drugs can be administered in the very 
early disease phase, before secondary genetic changes have 
accumulated. A potential disadvantage, however, is that cure, 
in a strict sense, might not be achieved, since all cells in 
these animals carry the transgene. Also, transgenic constructs 
are usually regulated by an artificial promoter not present in 
the normal gene. This could result in a lack of effect if the 
drug were to interfere with the regulation of the natural 
promoter. Nevertheless, if a drug would interfere with the 
signal transduction pathway used by, e.g., BCR/ABL to 
induce leukemia, prolonged survival and/or altered disease 
pattern could be expected. In this study we investigated 
whether IFN-a, instituted in the very early leukemic phase, is 
c a p a b l e of p r o l o n g i n g the l i f e span , or c h a n g e the 
characteristic disease pattern in P190 BCR/ABL transgenic 
animals. The average lifespan in eight transgenic animals 
treated with IFN-a was 131 days, compared to 174 days in 
four control animals. Moreover, the disease pattern with 
regard to development of lymphoblastic leukemia and/or 
l y m p h o m a was s imi lar in the two groups . Desp i t e the 
relatively small number of animals investigated, we find it 
reasonable to assume that IFN-a is not capable of prolonging 
the lifespan in these animals, and thus does not interfere with 
the leukemogenic process induced by the P190 BCR/ABL 
fusion gene in this transgenic mouse model. 
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Summary 
Philadelphia (Ph)-positive leukemias Invariably con-
tain a chromosomal translocation fusing BCR to ABL. 
The BCR-ABL protein is responsible for leukemogene-
sis. Here we show that exposure of bcr-null mutant 
mice to gram-negative endotoxin led to severe septic 
shock and increased tissue injury by neutrophils. Neu-
trophils of bcr (-/-) mice showed a pronounced in-
crease in reactive oxygen metabolite production upon 
activation and were more sensitive to priming stimuli. 
Activated (-/-) neutrophils displayed a 3-fold increased 
p21',c2 membrane translocation compared with (+/+) 
neutrophils. These results connect Bcr In vivo with the 
regulation of Rac-mediated superoxide production by 
the N ADPH-oxidase system of leukocytes and suggest 
a link between Bcr function and the cell type affected 
in Ph-posltlve leukemia. 
Introduction 
Chronic myelogenous leukemia (CML) is characterized cy-
togenetically by the presence of the Philadelphia chromo-
some and clinically by a clonal expansion of neutrophils 
and their myeloid precursors. Philadelphia chromosome 
(Ph)-positive leukemias have a specific reciprocal translo-
cation, [t(9;22)(q34;q11)j, which fuses the ABL proto-
oncogene to BCR (Heisterkamp et al., 1983; Groffen et al., 
1985). BCR-ABL transgenic mice and retroviruses have 
been used to show that the resulting fusion protein, BCR-
ABL, is directly responsible for the generation of leukemia 
(reviewed by Van Etten, 1993; Heisterkamp et al., 1993a). 
The product of the ABL gene is a ubiquitously expressed 
tyrosine kinase, and its activation in BCR-ABL by the BCR 
moiety is essential for the development of leukemia (re-
viewed by Van Etten, 1993). The normal function of ABL 
in vivo is unclear. ab/-null mutant mice are runted and die 
1-2 weeks after birth. In addition, many show B and T 
cell lymphopenia, the cause of which remains unknown 
(Tybulewic et al., 1991; Schwartzberg et al., 1991). 
The 160 kDa product of the BCR gene has several dis-
tBoth authors made an equal contribution. 
tinct domains. The segment encoded by exon 1 has serine/ 
threonine kinase activity in vitro and is responsible for acti-
vating ABL in the chimeric BCR-ABL gene product (Maru 
and Witte, 1991; McWhirter and Wang, 1991; Muller et 
al., 1991). BCR exons 3-10 have sequence homology to 
the DBL proto-oncogene, a guanine nucleotide exchange 
factor for human CDC42 (Eva and Aaronson, 1985; Hart 
et al., 1991), suggesting a similar catalytic activity for Bcr. 
In vitro, the C-terminal end of p160,)c' has GTPase-
activating protein (GAP) activity toward the small GTP-
binding proteins Rad and Rac2, and CDC42 (Diekmann 
et al., 1991; Hart et al., 1992). Rad and Rac2 belong to 
the Rho family of small p21'"-like GTPases, members of 
which are involved in cytoskeletal organization. Rac1 is 
required for growth factor-induced membrane ruffling of 
Swiss 3T3 fibroblasts. Bcr can regulate this Rad-induced 
ruffling in vitro, since microinjection df the purified Bcr 
GAP domain abolishes this process (Ridley et al., 1993). 
A number of other proteins are also GAPs toward Rac1 or 
Rac2 in vitro, including rhoGAP, ß-chimaerin, n-chimaerin, 
ABR, and p190 (Diekmann et al., 1991 ; Leung et al., 1994; 
Ahmed et al., 1994; Heisterkamp et al., 1993b; Ridley et 
al., 1993). Because of the multitude of proteins implicated 
in the in vitro regulation of Rac, the in vivo importance of 
the Bcr GAP activity toward Rac is unclear. 
On the basis of the data described above, Bcr seems 
likely to play a role in signal transduction. However, no 
naturally occurring mutants have been identified, nor has 
Bcr directly been shown to participate in signal transduc-
tion in vivo. Therefore, we have generated bcr-null mutant 
mice to examine the function of Bcr in normal and leukemic 
cells within the context of a whole organism. Our results 
connect Bcr for the first time with the regulatory control 
of Rac in vivo during neutrophil priming and activation 
and suggest a correlation with the cell types involved in 
Ph-positive leukemia. 
Results 
bcr Gene Targeting 
A segment of the genomic murine bcr gene containing 
exons 2, 3, and 4 was isolated from a B„CBA/F1 mouse 
genomic library (Figure 1 b). A targeting vector, containing 
a large 15.5 kb genomic segment, was constructed in 
which exon 2 was partially replaced by insertion of the 
positive neomycin resistance selection marker (Figure 1 a). 
The construct was electroporated into embryonic stem 
(ES)-D3 cells, and correct targeting, as confirmed by 
Southern blot analysis, was obtained. 
Clone p11.2, which contained a correctly targeted bcr 
gene, was injected into recipient C57BL/6 blastocysts and 
chimeric and bcr (+/-) animals obtained. The line was 
test-bred to C57BL/6, CF-1, and B„CBA/F1 females. 
Mutant bcr (+/-) animals appeared phenotypically nor-
mal, and matings between heterozygous animals yielded 
the expected Mendelian ratio of wild-type, heterozygote, 
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Figure 1. Targeted Disruption of the Mouse bcr Gene 
(a) The positive/negative selection targeting vector pBEKO-2. 
(b) Part of the wild-type bcr locus. 
(c) Structure of the interrupted bcr gene following homologous recom-
bination, bcr exons 2 and 3 are shown as closed boxes, the PGK-neo 
gene as a hatched box. B, BamHI; C, Clal; H, Hindlll; Xb, Xbal; X, 
Xhol. Individual ES cell clones were screened for homologous recombi-
nation with external probes (a and b in [c]) and internal probe (c 
in [b]). 
and homozygote offspring. Fertility of null mutant males 
and females was normal. 
Northern blot analysis with a bcr exon 1 -specific probe 
did not reveal any stable messenger RNA(s) in (-/-) 
mouse brain (data not shown), which has the highest level 
of bcr expression in wild type (Heisterkamp et al., 1993b). 
To confirm that no bcr gene products were being synthe-
sized in the mutants, Western blot analysis was per-
formed. bcr(+l-) animals expressed levels of bcr approxi-
mately half of that of wild type (Figure 2; compare lanes 
1 and 2), whereas the bcr (-/-) mice produced no pISO"" 
(Figure 2, lanes 3 and 4). Together, these results demon-
strate that the mutant (-/-) mice indeed produce no Bcr. 
Hematopoietic Development and Lymphoid 
Function Are Intact in bcr (- /-) Mice 
Because of the involvement of BCR in leukemia and its 
suggested role in myeloid development (Bedi et al., 1993; 
Wetzler et al., 1993), composition, and functionality of mu-
tant hematopoietic compartments were examined in de-
tail. In wild-type animals, different hematopoietic tissues 
and cells, including splenocytes, thymocytes, total bone 
marrow, and neutrophils, express significant amounts of 
p160°" (data not shown). However, mutant and wild-type 
hemograms were alike. Size, cellularity, histology, and 
composition of spleen, thymus, and bone marrow were 
similar in (-/-) and wild-type tissues (data not shown). 
Isolated (-/-) splenocytes responded normally to T and 
B cell mitogen stimulation in vitro as determined by 
[3H]thymidine incorporation (data not shown). Functional 
adequacy of the humoral immune response was confirmed 
in vivo by challenge with sheep erythrocytes (SRBC): anti-
SRBC antibody titers in bcr(-l-) and bcr(+l+) serum were 
+/+ +/. -/. -/. 
Figure 2. Western Blot Analysis of bcr Expression Levels in Wild-Type 
(+/+), Heterozygote (+/-), and Homozygote (-/-) Brain Extracts 
In mice, brain has the highest level of bcr expression. The location 
of p160ftcr is as indicated to the left. Lanes 1-3 were loaded with 40 
ug of protein extract; lane 4 contains 100 ug of brain extract. 
similar (data not shown). Amounts of myeloid differentia-
tion antigen-positive (GR-1+) cells in hematopoietic tis-
sues (bone marrow, spleen, and thymus) were comparable 
for wild-type and mutant animals, and peripheral neutro-
phil counts yielded similar numbers for (+/+) and (-/-) ani-
mals (respectively, 19.5% ± 9.3%, n = 17, and 19.4% ± 
5.7%, n = 22). This shows that Bcr plays no clear role in 
these aspects of hematopoietic regulation and function. 
Microfilament Reorganization In bcr (-/-) Cells 
Because of the GAP activity of Bcr toward members of 
the Rho family in vitro, we examined microfilament reorga-
nization in bcr (-/-) cells. Three independent primary skin 
fibroblast cultures were established from both (+/+) and 
(-/-) genotypes. In vitro growth characteristics of bcr(-l~) 
fibroblasts were similar to those of (+/+) fibroblasts. Cells 
were stimulated with recombinant human platelet-derived 
growth factor (PDGF). No apparent effect of the bcr-null 
mutation was found on the appearance and degree of 
PDGF-induced membrane ruffling in primary fibroblast 
cultures (data not shown). 
Neutrophils undergo extensive morphological changes 
when activated. Two key functions of neutrophils, Chemo-
taxis and phagocytosis, involve microfilament reorganiza-
tion, and we compared these activities in bcri-l-) and bcr 
(+/+) polymorphonuclear neutrophils (PMNs). Phagocytic 
ingestion of latex beads by isolated (-/-) PMNs in vitro 
was not impaired; the percentage of cells involved in 
phagocytosis and the number of microspheres ingested 
by neutrophils of both genotypes were comparable (data 
not shown). In vivo chemotactic ability of bcr (-/-) neutro-
phils was confirmed by their presence in peritoneal exu-
dates: (+/+) and (-/-) lavage yielded equal amounts of 
PMNs. Wild-type and mutant PMNs spread equally well 
on fibronectin-coated slides, and F-actin distribution was 
comparable for wild-type and mutant neutrophils (data not 
shown), demonstrating lack of gross abnormalities in cy-
toskeletal reorganization in (-/-) cells. 
Experimental Endotoxemia Causes Septic Shock 
and Severe Tissue Damage in bcr (- /-) Mice 
To test for possible abnormalities of bcr (-/-) neutrophils 
in inflammatory processes in vivo, experimental endotoxe-
mia was induced with a sublethal dose of bacterial endo-
toxin (lipopolysaccharide [LPS]) in bcr(-l-) and bcr{+l+) 
animals. Under these conditions, wild-type mice devel-
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Figure 3. Aggravated Tissue Damage in b-,r-Null Animals in Experimental Endotoxemia 
(a) Body weight loss and regain of wild-type (WT) and mutant (MUT) animals after experimental induction of endotoxemia. Data are expressed 
as percentage of control (n = 5 animals for each genotype; from t = 4 on, n = 4). Asterisk, P < 0.05 versus the wild-type group at the same 
time point. 
(b) Degenerative changes in the small bowel of ( - / - ) animals at 24 hr after injection of endotoxin. Left, (+/+); right, ( - / - ) . 
oped mild symptoms that disappeared within 12-24 hr. In 
sharp contrast, (-/-) mice gave clear evidence of serious 
distress within hours of endotoxin injection. The clinical 
condition of the mutant mice deteriorated rapidly and de-
veloped into septic shock, which was characterized by 
decreased spontaneous movements in the cage, in-
creased respiratory rates, piloerection, shivering, and diar-
rhea; this condition persisted in (-/-) mice for at least 4 
days. Null mutant animals displayed a sustained loss of 
body weight and delayed recovery from endotoxemia as 
compared with wild-type mice (Figure 3a). The pathologi-
cal condition of (-/-) animals was accompanied by in-
creased intestinal edema (n = 4): wet weight/dry weight 
ratios were notably increased in null mutant mice (data 
not shown). 
Animals were also sacrificed at 2, 6, 24, 48, and 72 hr 
after endotoxin injection. Histological analysis of wild-type 
and bcr-null mutant tissues revealed extensive damage 
to multiple organs only in the bcr (-/-) mice. Degenerative 
changes in the small bowel of (-/-) animals were obvious 
95 
at 24 hr after LPS injection. While the ileum of a (+/+) 
animal at 24 hr revealed normal histology (Figure 3b, left), 
the presence of cellular debris and mucus plugs in the 
intestinal lumen and in between microvilli of a (-/-) animal 
indicated marked necrosis of mucosal epithelial cells (Fig-
ure 3b, right). Extensive vacuolization in proximal convo-
luted tubules and cortical necrosis was obvious in the kid-
ney of (-/-) animals from 24 hr to 72 hr (data not shown); 
collapse of glomeruli (diffusely cellular, undistended capil-
laries) was apparent as early as 6 hr in (-/-) kidneys, at 
which time leukocytosis was most prominent. Liver sec-
tions of (-/-) mice at 6 hr also showed marked leukocyto-
sis: margination in portal veins clearly involved neutro-
phils, and presence of PMNs in hepatic sinuses indicated 
an active neutrophil recruitment; (-/-) liver parenchyma 
displayed distinct fatty vacuolization at 72 hr (data not 
shown). At this time, hematopoiesis in (-/-) bone marrow 
presented a distinct shift toward granulopoiesis as com-
pared with (+/+) bone marrow (data not shown). 
In other experiments, changes in total numbers of circu-
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lating leukocytes and specifically neutrophils were moni-
tored during the course of LPS-induced endotoxemia. 
Both (+/+) and (-/-) animals responded to LPS injection 
with decreased leukocyte counts and a relative neutro-
philia that developed within 6 hr, 55.1% ± 12.6% (+/+) 
and 85.0% ± 11.1% (-/-), respectively (percentage ratio 
of PMNs to leukocytes). While the total number of circulat-
ing neutrophils in wild-type animals did not change notably 
within the first 24 hr, the total number of circulating neutro-
phils had increased 2- to 3-fold in (-/-) animals within 6 
hr (data not shown). Neutrophilia was more pronounced 
and sustained in null mutants; the percentage of neutro-
phils was still markedly elevated over wild-type levels at 
48 hr, 26.6% ± 13.0% (+/+) and 56.4% ± 1.0% (-/-) 
(percentage ratio of PMNs to leukocytes). Neutrophilia 
was confirmed by flow cytometric analysis of whole blood 
samples and coincided with an altered body weight loss-
regain curve (data not shown). 
Histological time course analysis of the experimental 
endotoxemia showed that at 6 hr, neutrophil margination 
and infiltration were significantly more prominent in (-/-) 
tissues than in (+/+) counterparts (data not shown). This 
distinct granulocytosis was not as obvious at early stages 
(1-2 hr) in either wild-type or mutant tissues, suggesting 
that neutrophil infiltration per se was not elevated in null 
mutant animals at initiation of the inflammatory response. 
Tissue Damage in Endotoxemic bcr (-/-) Mice 
Is Mediated by Neutrophils 
The experiments above showed that (-/-) mice developed 
septic shock and significantly more pronounced inflamma-
tory tissue injury than (+/+) animals and suggested that 
this was caused by neutrophils. However, although the 
induction of experimental endotoxemia with LPS rapidly 
results in the recruitment of massive amounts of neutro-
phils, this process is mediated by the concerted effort of, 
among others, macrophages, endothelial cells, and neu-
trophils, as well as multiple cytokines (Edwards, 1994). 
Therefore, the possibility existed that lack of bcr aug-
mented the inflammatory response through mechanisms 
unrelated to neutrophils. 
We tested this by inducing neutropenia, as described 
by others in experiments linking multiple system organ 
failure to neutrophils (Hewett et al., 1992; Simpson et al., 
1993; Wakiyama et al., 1993). Wild-type and mutant mice 
were first rendered neutropenic by cyclophosphamide 
(CTX) treatment. The animals were then injected with LPS 
to induce endotoxemia. Of the four experimental groups, 
only the control null mutant animals (LPS alone) displayed 
the earlier-described clinical manifestations associated 
with severe septic shock. Neutropenic animals ([+/+] and 
[-/-]) recovered as fast as wild-type control animals (LPS 
alone) from experimental endotoxemia, which was also 
reflected by the progression of body weight loss and regain 
(data not shown). 
Generalized and specific tissue damage was assessed 
by plasma lactate dehydrogenase (LDH) and plasma 
aspartate and alanine aminotransferase (AST and ALT), 
plasma creatinine, and blood urea nitrogen (BUN) level 
measurements at 24 or 48 hr after LPS or CTX plus LPS 
LPS CTX + LPS 
Figure 4. Neutropenia Abolishes LPS-induced Tissue Damage in bcr 
(-/-) Mice 
Plasma LDH and AST levels 48 hr after injection of LPS or LPS plus 
CTX. Hatched bars indicate bcr (-/-) values, open bars wild-type val-
ues. Three animals of each genotype were used. Data are shown as 
± SEM. 
injection. In concordance with histological findings, null 
mutant mice injected with LPS only had considerably 
higher levels of plasma LDH and AST (Figures 4a and 4b) 
and ALT, BUN, and creatinine (data not shown) than the 
wild-type animals, indicative of considerable damage to 
the hepatic and renal organ systems, among others. The 
combined treatment with CTX and LPS was somewhat 
more damaging than injection with LPS alone (in wild-type 
animals), but no significant differences were measured be-
tween neutropenic animals of either genetic constitution. 
At 48 hr, the degenerative histological characteristics 
associated with renal system organ failure in (-/-) kidney 
were absent from (-/-) mice treated with LPS plus CTX, 
and no differences were noted between ileum and liver of 
either wild-type (LPS), wild-type (LPS plus CTX) or mutant 
(LPS plus CTX) mice (data not shown). Thus, the biochemi-
cal and clinical differences between neutropenic and nor-
mal (-/-) animals were unambiguous: preestablished 
neutropenia prevented the distress caused by the experi-
mental septic condition. Taken together, these results 
demonstrate that neutrophils are responsible for the se-
verely aggravated pathological condition observed in bcr 
(-/-) mice. 
Superoxide Production by bcr (-/-) Neutrophils 
Is Elevated 
During the respiratory burst, neutrophils generate reactive 
oxygen metabolites via the nicotinamide adenine dinucle-
otide phosphate (NADPH)-oxidase system. These metab-
olites are the major mechanism for killing microorganisms. 
Bone marrow (BM) neutrophils, circulating neutrophils, 
and elicited (e.g., through peritoneal injection of casein) 
peritoneal exudate (PE) neutrophils can all perform the 
respiratory burst if appropriately activated, although they 
differ in their degree of biological maturation. 
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Figure 5. The Production of Reactive Oxygen Metabolites Is Elevated 
in bcr (-/-) Neutrophils 
(a)02 production by BM-PMNsand by PE-PMNs.Thedata are normal-
ized for wild-type values. Combined data are displayed for two female 
and three mate mice per histogram in three independent experiments. 
Open bars, (+/+) mice; hatched bars, (-/-) mice. BM-PMNs were stim-
ulated with PMA, PE-PMNs with fMLP. 
(b) Cytochrome C reduction by (-/-) mutant (circles) and wild-type 
(triangles) PE-PMNs after activation with fMLP. 
(c) Priming of BM-PMNs with a low concentration of the phorbol ester 
PMA enhances the superoxide production by (-/-) PMNs. Data from 
two independent experiments are combined. Open bars, (+/+) mice; 
closed bars, (+/-) mice; hatched bars, (-/-) mice. V™,, values are 
expressed as percentage of wild-type activity at t = 0. 
BM granulocytes of (-/-) and (+/+) mice were purified 
through density gradient centrifugation. Upon activation 
with phorbol myristate acetate (PMA), bcr (-/-) neutro-
phils showed an almost 100% increased respiratory burst 
compared with that of wild-type neutrophils (Figure 5a). 
Consistent with this result, the respiratory burst evoked in 
vitro by both non-receptor- and receptor-mediated stimuli 
(PMA and N-formyl-Met-Leu-Phe [fMLP], respectively) in 
(-/-) PE neutrophils was also higher than that of corre-
sponding wild-type cells (Figure 5a). Since the duration 
of respiratory burst was similar for both (+/+) and (-/-) 
neutrophils, the increased production rate resulted in a 
correspondingly 2-fold higher endpoint Of production by 
(-/-) neutrophils under in vitro conditions (Figure 5b). 
bcr (-/-) Neutrophils Are More Easily Primed 
and Activated 
Priming of neutrophils by very low concentrations of ago-
nists (which, by themselves, do not activate the neutrophil) 
causes an up-regulation of their function upon subsequent 
activation. This includes the oxidative burst (Edwards, 
1994). We used BM-PMNs to investigate whether bcr (-/-) 
neutrophils were more readily primed than wild type. BM-
PMNs were left undisturbed or were treated with concen-
trations of PMA (as described by Shaafi et ai., 1988; Lof-
gren et al., 1993) that were too low to cause priming of 
(+/+) neutrophils. Interestingly, this same concentration 
of PMA did prime (-/-) PMNs, resulting in superoxide pro-
duction that was 260% of that of (+/+) PMNs (Figure 5c), 
relative fluorescence intensity 
relative fluorescence intensity 
Figure 6. Oxidative Burst Activity in (-/-) Circulating Neutrophils 
Oxidation of the nonfluorescent intracellular DCFH to the highly fluo-
rescent DCF was examined by flow cytometry; cell populations were 
gated for granulocytes. Peripheral blood neutrophils from wild-type 
(broken line) and bcr (-/-) (solid line) mice are compared. 
(a) Animals were treated with <2 mg LPS/kg of body weight (intraperito-
neally) 1 hr before isolation of blood. 
(b) Animals had received 20-22 mg LPS/kg of body weight 48 hr before 
a blood sample was obtained. 
while resting levels of superoxide production of primed 
(-/-) and of (+/+) neutrophils were negligible (data not 
shown). This suggested that bcr(-l-) BM-PMNs were also 
more sensitive to priming stimuli than wild-type PMNs. 
Heterozygous (+/-) and wild-type responses were alike 
(Figure 5c). 
We determined whether (-/-) neutrophils in circulation 
also had an increased sensitivity to stimuli, or showed 
elevated superoxide production in vivo, or both. Peripheral 
blood neutrophils were allowed to take up 2T-dichloro-
dihydrofluorescein diacetate (DCFH-DA), and intracellular 
oxidation of DCFH to fluorescent dichlorofluorescein (DCF) 
by reactive oxygen metabolites was measured. Resting 
neutrophils in whole peripheral blood samples of (+/+) and 
(-/-) mice showed a similar baseline fluorescence (data 
not shown). Circulating neutrophils were then harvested 
from mice after a brief (60 min) exposure to a low (<2 
mg/kg body weight) dose of LPS. This dose is more than 
10-fold lower than that used to induce experimental endo-
toxemia. Without additional (in vitro) activation, over 50% 
of the bcr (-/-) neutrophils showed a high level of sponta-
neous cytoplasmic fluorescence, as compared with an 
identically treated wild-type control (Figure 6a). 
The circulating neutrophils of bcr{-l-) animals in severe 
septic shock and from similarly treated control (+/+) mice 
were also examined 48 hr after LPS injection. Neutrophils 
isolated from (-/-) mice showed extensive spontaneous 
(i.e., no additional activator was added in vitro) respiratory 
burst, while the neutrophils of similarly treated wild-type 
mice again showed only baseline fluorescence (Figure 
6b). This demonstrated that the severe septic shock exhib-
ited by the bcr (-/-) mice was accompanied by a massive 
production of reactive oxygen metabolites by activated 
PMNs. 
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Figure 7. Western Blot Analysis of Rac2 in bcr ( - / - ) and Wild-Type 
Neutrophil Membrane Fraction 
Lanes were loaded with 40 tig of protein. Lanes 1 and 2, wild-type 
membrane fraction; lanes 3 and 4, bcr ( - / - ) membrane fraction. Neu-
trophils in lanes 2 and 4 were additionally activated in vitro by treatment 
with 10 ng/ml PMA for 8 min. 
Increased Membrane Translocation of p21'"2 
in (-/-) Neutrophils 
Apart from the more generalized function for Rad in mem-
brane ruffling, Rac1 and Rac2 also play an important spe-
cialized role in the NADPH-oxidase system of phagocytic 
cells (Knaus et al., 1991 ; Dorseuil et al., 1992; Abo et al., 
1991; Heyworth et al., 1993). Since Bcr is a GTPase-
activating protein for Rac in vitro, we asked whether the 
deregulated production of oxygen radicals in bcr(-l-) neu-
trophils was related to Rac. 
PE neutroph ils were isolated from bcr (-/-) and bcr (+/+) 
mice. These neutrophils had been activated in vivo. One 
portion was left without further treatment, the other addi-
tionally activated in vitro. Membrane and cytoplasmic frac-
tions were assayed quantitatively for Rac2 by Western 
blotting and densitometry. The total amount of Rac2 recov-
ered (membrane plus cytoplasmic fractions) was approxi-
mately equal for bcr (-/-) and bcr (+/+) neutrophils. In 
wild-type mice, the amount of Rac2 present in the mem-
brane fraction after in vivo activation was initially low (Fig-
ure 7, lane 1), but increased nearly 2-fold upon further 
(in vitro) activation (lane 2). Similar data were previously 
obtained by Quinn et al. (1993) with human neutrophils. 
In bcr (-/-) mice, a substantially higher amount of Rac2 
was associated with the membrane (Figure 7, lane 3): a 
3-fold increase was measured in comparison with wild-
type cells (lane 1). In vitro stimulation of the bcr {-I-) neu-
trophils did not further increase the level of membrane-
associated Rac2 (Figure 7, lane 4). 
Discussion 
Lack of Correlation between bcr Expression 
and Mutant Phenotype 
The bcr gene is expressed in many different types of tis-
sues in the mouse. During development, it is detectable 
from the zygote stage on, and expression continues 
throughout embryogenesis (unpublished data). The ab-
sence of a functional mouse bcr gene, however, has no 
apparent effect on fertility or development. A role of BCR 
in myeloid development (Bedi et al., 1993; Wetzler et al., 
1993) has also been suggested. Although bcr is expressed 
in all mature hematopoietic cell types tested, size, cellu-
larity, histology, and composition of the major hematopoi-
etic organs (bone marrow, spleen, thymus, and blood) 
were similar in wild-type and Dcr-null mutant mice. We 
conclude that lack of Bcr alone is not sufficient to perturb 
myeloid and lymphoid development or T and B lymphoid 
function in vitro and in vivo. However, it is possible that dis-
turbances, if any, will become apparent with advanced age. 
To explain the preferential involvement of the maternal 
allele of BCR in the Philadelphia translocation, it has been 
suggested that the SCR gene may be imprinted (Haas et 
al., 1992). In our bcr mutant mice, the remaining bcr allele 
is actively expressed in heterozygote brain (Figure 2) and 
in blood cells of heterozygotes (+/-), regardless of whether 
the allele is from paternal ([+/-] male x [-/-] female) or 
maternal origin ([+/-) female x [-/-] male) (our unpub-
lished data). This is in agreement with experiments per-
formed with human peripheral blood (Fioretos et al., 1994). 
In all experiments in which neutrophil function was tested, 
bcr heterozygote (+/-) responses were found to be compa-
rable to those in wild type, which would seem to eliminate 
the possibility of a gene dosage effect of monoallelic loss 
of bcr. 
Activities of Bcr In Vitro and In Vivo 
Similar to several other proteins, Bcr has GAP activity to-
ward P21™"1«02 and CDC42Hs, members of the Rho family 
of small GTP-binding signal transduction molecules. One 
function identified for p21™e' is that it mediates mitogen-
induced membrane ruffling in fibroblasts (Ridley et al., 
1992). When Swiss 3T3 mouse fibroblasts are microin-
jected with the GAP domain of Bcr, PDGF-induced mem-
brane ruffling is abolished (Ridley et al., 1993). Mouse bcr 
was abundantly expressed in our wild-type skin fibroblast 
cultures and in neutrophils (unpublished data). We exam-
ined both membrane ruffling and cytoskeletal reorganiza-
tion in isolated bcr (-/-) cells but were unable to find any 
differences between (-/-) and (+/+) cells. We conclude 
that there must be a functionally redundant mechanism 
that compensates for the lack of Bcr, such as one involving 
the Bcr-homologous protein p93*" (Heisterkamp et al., 
1993b), in membrane ruffling. Alternatively, Bcr does not 
interact with the Rac that is involved in this process. Adhe-
sion and cell spreading of neutrophils did not appear af-
fected by lack of p160°", in agreement with earlier observa-
tions (Ridley et al., 1992) that demonstrated that Bcr does 
not stimulate GTP hydrolysis by p21*°, a regulator of focal 
adhesion and stress fiber formation, in vitro (Ridley and 
Hall, 1992). 
Bcr Regulates Oxygen Radical Production 
in Neutrophils 
Neutrophils are key mediators in the defense against in-
vading micro-organisms, and inherited or acquired impair-
ment of the production of reactive oxygen metabolites by 
neutrophils can lead to life-threatening infections. Al-
though the primary function of neutrophil- and macro-
phage-produced oxidants is microbicidal, paradoxically, 
the reactive oxygen metabolites they produce can also 
cause extensive injury to surrounding tissue. This is of 
great clinical importance; generalized inflammation in 
gram-negative sepsis is perpetuated by phagocytic super-
oxide release and may evolve into septic shock and multi-
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pie organ system failure (Shasby et al., 1982; Demling, 
1990; Shiratori et al., 1990; Yoshikawa et al., 1994). There-
fore, the production of toxic oxygen radicals must be tightly 
regulated: biologically appropriate amounts must be pro-
duced only at the site of inflammation, and only after 
proper activation. 
Our experiments show that bcr is important for at least 
two potentially overlapping aspects of this regulation. 
First, activated neutrophils isolated from bcr (-/-) bone 
marrow showed up to 100% increased production of reac-
tive oxidants in vitro as compared with wild-type neutro-
phils. Similarly, ocr(-/-) exudative neutrophils showed an 
elevated superoxide production. Circulating neutrophils 
isolated from severely endotoxemic bcr (-/-) animals pro-
duced reactive oxygen metabolites without further addi-
tional in vitro activation. Thus, the regulation of absolute 
amounts of superoxide production is impaired in bcr (-/-) 
neutrophils. 
Second, (-/-) neutrophils are more sensitive toward 
priming stimuli. After activation, primed (-/-) neutrophils 
from the bone marrow produced an even larger excess 
of superoxide than similarly treated (+/+) neutrophils. Cir-
culating neutrophils of bcr (-/-) mice injected with a low 
dose of LPS showed a significant increase in DCF fluores-
cence after uptake of DCFH-DA in comparison with identi-
cally treated control animals. This is indicative of the intra-
cellular production of reactive oxygen metabolites. We 
conclude that bcr (-/-) neutrophils are more readily 
primed in comparison with wild-type neutrophils. 
Circulating neutrophils are expected to be exposed to 
priming substances in vivo. Regulation of neutrophil activ-
ity at this level appears biologically quite important in vivo, 
as is dramatically illustrated by the severe pathological 
reaction of bcr(-l-) mice to experimentally induced endo-
toxemia. Experimental endotoxemia led to extensive tis-
sue damage in bcr(-l-) animals, as measured by clinical, 
biochemical, and histological parameters; (-/-) mice be-
came lethargic and overtly sick and in some instances 
even died. 
In conclusion, Bcr normally has a function in the nega-
tive regulation of the oxidative burst in neutrophils. This 
is consistent with the negative regulatory effect of Rac 
GAPs in in vitro experiments (Heyworth et al., 1993). In 
particular, our data point to a specialized role of Bcr in the 
protection of the organism against premature activation of 
the oxidative burst. 
Regulation of Rac2 Is Affected by Lack of Bcr 
P21"c ' *"2 is an essential part of the activated respiratory 
burst (NADPH)-oxidase present in neutrophils, macro-
phages, and B cells (Abo et al., 1991; Quinn et al., 1993; 
Knaus et al., 1991; Bokoch and Knaus, 1994; Benna et 
al., 1994). Activation of the NADPH-oxidase in a cell-free 
assay is completely dependent upon the presence of GTP, 
and nonhydrolyzable GTP analogs potentiate Of produc-
tion (Bokoch and Knaus, 1994, and references therein). 
Inhibition of Rac function blocks superoxide (Of) produc-
tion (Knauset al., 1991; Dorseuiletal., 1992). Upon neutro-
phil activation, Rac undergoes a GDP-GTP exchange and 
translocates from the cytosol to the plasma membrane 
(Bokoch et al., 1994). This translocation correlates with 
oxidase activation and the generation of reactive oxygen 
metabolites (Quinn et al., 1993). Several proteins exhibit 
regulatory activity as a GAP toward Rad and Rac2 in vitro 
(Diekmannet al., 1991; Heisterkampetal., 1993b; Ridley 
et al. ,1993; Ahmed et al. ,1994; Leung et al. ,1994), includ-
ing Bcr. We therefore examined Rac translocation in bcr 
(-/-) neutrophils. 
Although the total amount of Rac2 was similar in bcr 
(-/-) and (+/+) neutrophils, its subcellular distribution in 
PE neutrophils, which were activated in vivo, was different. 
Purified membrane fractions of elicited PE bcr (-/-) neu-
trophils showed a significantly increased translocation of 
p21"K:Z to the membrane, providing evidence for a direct 
link between Bcr and Rac2 in the biochemical processes 
that lead to superoxide production. It is of interest that 
further in vitro activation of bcr (-/-) neutrophils had no 
effect on the level of Rac2 translocation. This suggests 
that there is a maximum to the amount of Rac2 that can 
be membrane associated. In vitro, the GAP function of 
Bcr stimulates GTP hydrolysis by Rac (Diekmann et al., 
1991), thereby rendering Rac inactive. Because of this, it 
is tempting to speculate that relatively more p21"c is pres-
ent in a GTP-bound state in primed or activated neutrophils 
that lack cellular Bcr, and that this causes an increase in 
membrane association. Since the process of GTP loading 
by itself is sufficient to cause Rac to translocate to the 
membrane (Philips et al., 1993; Bokoch et al., 1994), the 
increased membrane association of Rac2 in the bcr (-/-) 
neutrophils would correspond with the presence of in-
creased levels of Rac-GTP in the cell. 
BCR in Disease 
These studies were initiated to explore the normal cellular 
function of a gene that is involved in Ph-positive leukemia 
in humans. In the leukemic cells of such patients, only 
one intact BCR allele remains; the other is rearranged as 
a result of fusion to ABL. The BCR-ABL fusion protein 
consists cf BCR exon 1-encoded sequences and often 
also includes the DBL homology domain. The carboxy-
terminal end of BCR-ABL contains almost all of the ABL 
protein. The BCR GAP domain is translocated to chromo-
some 9 (reviewed by Van Etten, 1993; Heisterkamp et ai., 
1993a) and may be transcribed as a chimeric mRNA from 
the ABL promoter (Melo et al., 1993). 
Our data define BCR as a protein that functions as a 
regulator of the respiratory burst in certain hematopoietic 
cells; phagocytes (neutrophils, macrophages) and B cells 
are all specialized hematopoietic cells with an active 
NAOPH-associated oxidative burst complex (Edwards, 
1994). It is unlikely to be a coincidence that these cell 
types are also involved in Ph-positive leukemia. 
There appear to be a number of discrete mechanisms 
through which BCR contributes to leukemogenesis. One 
is at the level of transcription: the BCR promoter controls 
expression of both the remaining nonrearranged BCR al-
lele and the BCR-ABL oncogene in human leukemia. 
Apart from the structural influence on ABL in BCR-ABL 
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(Maru and Witte, 1991; McWhirter and Wang, 1991; Muller 
et al., 1991), BCR may contribute to leukemia on another 
level: the presence of a functional plôO"" was proposed 
as a requirement for malignant transformation by BCR-
ABL (Liu et al., 1993; Lu et al., 1993). We are now able to 
test this hypothesis in BCfl-ABL-transgenic ocr (-/-) mice. 
Independent of the exact mechanism, it seems reason-
able to conclude from our data that there is a correlation 
between the cell type affected in Ph-positive leukemia and 
Bcr function. In addition, the findings presented here con-
nect p160*" with the regulatory control of the cellular Rac-
GTP/Rac-GDP pool in vivo during neutrophil priming and 
activation. Although its exact function remains to be estab-
lished, it is clear that Bcr has a previously unsuspected 
role as a regulator of the oxidative burst. Because of the 
clinical importance of neutrophils in, among others, adult 
respiratory distress syndrome, bacterial septicemia, and 
rheumatoid arthritis, it will be of interest to examine Bcr 
regulation and activity in these clinical conditions as well 
as in normal cells. 
Experimental Procedures 
Construction of bcr Targeting Vector and Generation 
of Null Mutant Mice 
The mouse bcr locus was cloned from a partial Mbol BeCBA/F1 geno-
mic library. Targeting vector pBEKO-2 was constructed by replacing 
a 500 bp Xhol-Clal fragment, spanning part of bcr intron 1 and exon 
2, with a 1.7 kb Xhol-Clal fragment that contained a PGK-neo-poly(A) 
cassette. Negative selection was with a herpes simplex virus thymidine 
kinase gene. pBEKO-2 DNA (25 (ig) was linearized with Notl and used 
to electroporate 2.5 x 10" ES-D3 cells. ES cultures were maintained 
on STO feeder layers in medium supplemented with 70% buffalo rat 
liver cell-conditioned medium. DNA from individual colonies was di-
gested with Clal-Xbal or Hindlll-Xhol (Figure 1) and hybridized to 
external probes. Of 35 doubly resistant clones screened, 10 had under-
gone homologous recombination. Injected blastocysts were cultured 
overnight and then reimplanted into 2.5 days pseudopregnant fe-
males. 
Western Blot Analysis 
Tissues and organs were homogenized and analyzed by immunoblot-
ting procedures essentially as described (Harlow and Lane, 1988). The 
bcr (AB-2) anti-human BCR monoclonal antibody (Oncogene Science, 
Incorporated) is directed against an epitope in exon 8. Rac2 antiserum 
was as described (Quinn et al., 1993). 
Membrane Ruffling 
Primary skin fibroblast cultures were established from term embryos 
or newborn pups. Membrane ruffling was studied in chamber slides 
(Nunc, Incorporated). Confluent wild-type and mutant fibroblast cul-
tures were stimulated with 6 ng/ml PDGF-BB (human recombinant; 
GIBCO BRL) in serum-free medium at 37°C, 100% humidity, 5% car-
bon dioxide as described (Ridley et al., 1992). Durations of stimulation 
were 0,2, 5,10, and 30 min. Cells were fixed in 7.4% formaldehyde 
and stained with a NBD-phallacidin solution (Molecular Probes, Incor-
porated) containing lysophosphatidylcholine (Sigma) to permeabilize 
the cells. Ruffle formation was studied by using Nomarsky and fluores-
cent microscopy. The extent of ruffling by wild-type and mutant fibro-
blasts in response to PDGF was assessed by blinded analysis. 
Neutrophil Spreading 
Neutrophils were allowed to attach to fibronectin-coated slides for up 
to 45 min at 37°C, 5% carbon dioxide, and 100% humidity. Cells were 
fixed with 7.4% formaldehyde in PBS and permeabiiized and stained 
for F-actin with a lysophosphatidylcholine, NBD-phallacidin solution 
(Molecular Probes, Incorporated). Comparison of cell spreading, focal 
adhesion, and lamellipod formation of wild-type and mutant neutro-
phils was done by blinded analysis. 
Phagocytosis Assay 
Exudative neutrophils and BM neutrophils were incubated at a density 
of1 x 10scells/mlinKRPGbufferinsiliconizedtubes.A50-foldexcess 
of fluorescent latex beads was added (Fluoresbrite; Polysciences, In-
corporated). In some experiments, neutrophils were stimulated with 
100 ng/ml PMA. Incubations were carried out at 37°C with gentle 
agitation and stopped at 30 min, 60 min, 90 min, or 120 min by addition 
of ice-cold PBS. Phagocytic ingestion was assessed by flow cytometric 
analysis. The amount of cells participating in phagocytosis and the 
amount of fluorescent microspheres ingested were evaluated. 
Induction of Endotoxemla In Vivo 
Age- and sex-matched animals of 23-25 g body weight were anesthe-
tized with metofane (methoxyflurane; Pitman-Moore) and injected in-
traperitoneally with 20-22 mg LPS/kg body weight unless differently 
stated. Changes in body weight were monitored at 24 hr intervals; 
the general clinical condition of the animals was monitored at regular 
intervals during the days following induction of experimental endotox-
emia. To assess acute edematous bowel injury, animals were sacri-
ficed 2 hr after administration of LPS. Wet tissue weight was deter-
mined immediately; dry tissue weight was determined after overnight 
incubation at 80°C. The ratio of net wet weight to net dry weight was 
calculated. As reported previously (DeForge et al., 1994), no measur-
able edema formation was found in lung tissue at 1 or 2 hr after LPS 
injection. 
Induction of Neutropenia 
Animals were anesthetized and injected intraperitoneal^/ with 150 or 
200 mg of CTX (Cytoxan; MeadJohnson)/kg of body weight. Neutro-
penia was confirmed 72 hr later by manual peripheral leukocyte and 
differential count. Animals were then injected with 20-22 mg LPS/kg 
of body weight. Body weight loss and regain was monitored for two 
(LPS only) or four to five animals (Cytoxan plus LPS) for each genotype. 
Three experiments were done. Heparinized blood was centrifugea, 
and plasma was collected and frozen at -80°C until analysis. BUN, 
serum creatinine, ALT, AST, and LDH were determined at the clinical 
laboratories of Childrens Hospital, Los Angeles. 
Isolation of Neutrophils from Bone Marrow and Peritoneum 
Bone marrow was used as a source of unelicited PMNs (Jutila et al., 
1991; Levinovitz et al., 1993). BM-PMNs were obtained by density 
gradient centrifugation (Watt et al., 1979). PE-PMNs were isolated by 
peritoneal lavage, 4 hr after injection of 2 ml of 0.05% sodium casein-
ate. Lavage was performed by washing the peritoneal cavity twice 
with, respectively, 6 and 8 ml of ice-cold Hanks' balanced salt solution 
(HBSS) buffer (GIBCO BRL) supplemented with 2 U/ml heparin. Care 
was taken not to cause internal bleeding while collecting exudative 
neutrophils. Washed neutrophils were suspended in cold Krebbs-
Ringer phosphate buffer containing 1 mg/ml glucose (KRPG buffer). 
Mature BM-PMN phenotype was confirmed by microscopic analysis. 
Purity of the BM-PMN and PE-PMN populations was assessed by flow 
cytometry: a consistent purity of 85%-95% and 90% or higher for 
GR-1+ cells was found for BM-PMNs and PE-PMNs, respectively. 
Equal levels of PE-PMN activation were measured by staining with 
anti-CD11b (M1/70.15) monoclonal antibodies (Caltag). 
In Vitro Superoxide Production Assay 
Respiratory burst was induced by stimulation of 5 x 10s mouse PMNs/ 
250 ul with 100 ng/ml PMA (BM-PMNs and PE-PMNs) or 1 x 10"5 M 
fMLP (PE-PMNs), in standard KRPG buffer. Ol production was fol-
lowed for 5-10 min in a kinetic microplate reader by inhibitable fer-
ricytochrome C reduction (Mayb and Curnutte, 1990). The rates of 
fMLP- and PMA-induced superoxide production were consistent with 
previous observations. The range of superoxide production by PMA-
stimulated wild-type BM-PMNs was 10-15 nmolOj/min/107 cells; wild-
type PE-PMN Vm„ values ranged from 35 to 45 nmol 0;/min/107 cells. 
Preincubation was accomplished for varying amounts of time (90-120 
min) at 37°C with low (0.1-1.0 ng/ml) PMA concentrations that did 
not evoke measurable superoxide production in either (-/-) or (+/+) 
PMNs. Following preincubation, the cells were stimulated with 100 
ng/ml PMA. The maximal rate of cytochrome C reduction was calcu-
lated by using the extinction coefficient 21.1 mM~1 cm 1. All PMN exper-
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iments were carried out within 2 hr of isolation. Animals used in each 
individual experiment were always age- and sex-matched. 
Priming and Activation of Circulatory Neutrophils In Vivo 
Animals were injected with lipopolysaccharide. At the indicated time 
points, animals were anesthetized with metofane, and 50-100 \x\ blood 
samples were taken by retro-orbital sinus bleeding. Erythrocytes were 
lysed, and leukocytes were washed with PBS and suspended in 500-
1000 \i\ of PBS containing 40 jiM DCFH-DA. Cell suspensions were 
incubated in siliconized 5 ml polypropylene tubes for 30-45 min at 
37°C under reduced light, while gently agitated. Cells were then fixed 
by addition of 1 vol of ice-cold 2% paraformaldehyde and immediately 
analyzed by flow cytometry essentially as described (Himmelfarb et 
a l , 1992). 
Translocation of Rac2 to the Membrane 
Exudative neutrophils were isolated and prepared as described above. 
Cells from 15 mice were pooled and divided into two equal portions, 
one for each experimental point. PMNs were treated with diisopropyl 
fluorophosphate (DFP) prior to activation with 10 ng/mi PMA. Stimula-
tion occurred at 37°C in siliconized tubes, in the presence of superox-
ide dismutase, catalase, and 0.1 % bovine serum albumin. Incubations 
were terminated after 7-8 min by addition of ice-cold reaction buffer. 
Cells were disrupted by nitrogen cavitation as described elsewhere 
(Quinn et al., 1993). Membrane fractions were obtained by centrifuga-
tion over a discontinuous sucrose gradient and examined by Western 
blot analysis as described (Quinn et al., 1993). Relative amounts of 
Rac2 were determ ined by video densitometry using an image analysis 
system. 
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Abstract 
The BCR gene is implicated in the development of Ph-positive leukemia through its fusion with the non-receptor 
tyrosine kinase gene A8L. The normal 160 kDa Bcr protein has several functional domains and recently one specific 
role for Bcr was established in the regulation of respiratory burst activity in white blood cells. Bcr expression levels 
are relatively constant throughout mouse development until adulthood in brain and in hematopoietic tissues, a 
pattern which is distinctly different from that of the functionally related n-chimerin gene. In the present study RNA 
in situ hybridization was used to explore the normal cellular function of Bcr in rodent brain and hematopoietic 
organs. The data pinpoint the high bcr expression in brain to the hippocampal pyramidal cell layer and the dentate 
gyrus, and to the piriform cortex and the olfactory nuclei, reflecting a potentially interesting function for Bcr in these 
highly specialized brain regions. 
Introduction 
The human BCR locus was first identified in a 
breakpoint cluster region on chromosome 22 in 
Philadelphia positive leukemia (Groffen et al., 1985; 
Heisterkamp et al., 1983): through a 
t(9;22)(q34;qll) translocation, the BCR gene 
becomes fused with the ABL gene, a non-receptor 
tyrosine kinase normally located on chromosome 9 
(Heisterkamp and Groffen, 1991; Rowley et al., 
1990) The leukemogenic role of BCR/ABL has 
been demonstrated experimentally in transgenic 
mice carrying a BCR/ABL fusion-transgenes and by 
retroviral transduction experiments in which mice 
receive BCR/ABL-positive bone marrow transplants 
(Daley et al., 1990; Elefanty et al., 1990; 
Heisterkamp et al., 1990; Voncken et al., 1992). 
The BCR gene encodes a 160 kDa cytoplasmic 
protein with several functional domains and is a 
protein likely to participate in signal transduction. 
Its N-terminal domain encoded by exon 1 has a 
serine/threonine kinase activity, can oligomerize, and 
is capable of binding other protein factors, among 
which pUS401 (McWirther et al., 1993; Sawyers et 
al., 1991). The central part of Bcr has homology to 
the G-nucleotide exchange factor (GEF) Dbl and 
the carboxy terminal part is homologous to the n-
chimerin protein, which is selectively expressed in 
neuronal tissue (Diekman et al., 1991; Ron et al., 
1991). As is the case for n-chimerin, this domain of 
Bcr has GTP-ase activating protein (GAP) activity 
toward a subfamily of p21iSw-related small GTP-
binding proteins,
 p21Rho/Rac (Diekman et al., 1991). 
Recently, we have established at least one function 
for Bcr as a regulator of NADPH-oxidase mediated 
superoxide production in neutrophils (Voncken et 
al., 1995). 
In the mouse, bcr expression is detectable as 
early as at the zygote stage, continues throughout 
embryogenesis (unpublished observations) and is 
found in most adult tissues examined (Heisterkamp 
et al, 1993). In man, BCR has also been shown to 
be ubiquitously expressed. Notwithstanding its role 
in normal and leukemic blood cells (Campbell et al., 
1991; Collins et al., 1987; Voncken et al., 1995), the 
Bcr protein is found in high levels in brain. This 
observation has intrigued us as it suggests a possible 
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different function for pl60^cr. This notion is 
corroborated by the seemingly highly significant 
function of G-proteins in brain (Hopkin, 1994). In 
an attempt to further delineate a putative cellular 
function of Bcr in the brain we have studied the 
regional expression of bcr in rodent brain by means 
of RNA in situ hybridization. We also report data 
on the expression kinetics of bcr during mouse 
development in hematopoietic organs and in brain. 
Materials and methods 
Tissue preparation 
Paraffin embedded adult mouse brain sections 
were obtained from Novagen Inc. (Madison, WI). 
Adult Sprague-Dawley rats were decapitated rapidly 
and brains were removed onto dry ice and stored 
at -80°C. Coronal sections (20 pm) were mounted 
on gelatine-coated slides and stored at -80°C. 
Probes 
A 400 bp fragment of mouse bcr was amplified 
by RT/PCR with the primers ALLE (Kawasaki et 
al., 1988) and BEX3 (5' AACCCACTTTCTCATCT-
CCAG 3') as previously described (Heisterkamp et 
al., 1990). The RT/PCR product was gel purified 
and digested with EcoRI and Clal yielding a 251 bp 
fragment which was subcloned directionally into 
pSK (Stratagene). The identity of the cloned 
fragment was confirmed by sequencing both strands 
using the Sequenase 2.0 system (USB). To obtain 
antisense and sense RNA probes, the construct was 
linearized with BamHI (antisense) or Xhol (sense) 
and transcribed in vitro with a- S-UTP using T7 
and T3 RNA polymerase respectively, essentially as 
described by the manufacturer (Novagen Inc., 
Madison WI). A second bcr antisense RNA probe 
was produced by digesting a 1.8kb Hindlll/EcoRI 
genomic fragment (Zhu et al., 1990) cloned in pSK 
with Narl and transcription with T7 RNA 
polymerase. Probes were labeled to high specific 
activity, typically 2.0 x 10° cpm/pg. The 
o l i g o n u c l e o t i d e p r o b e B E X 2 ( 5 ' 
GAGGAAGAAGGTGAATCATCG 3') was labeled 
on the 3' end with -"S-dAIT using terminal deoxy-
nucleotidyl transferase (Bethesda Research Lab.). 
An oligonucleotide probe for an unrelated gene, 
CRH, was similarly generated and labeled as 
specificity control (Baram and Schultz, 1991; Yi et 
al., 1993). 
In situ hybridization procedures 
In situ hybridization on paraffin embedded mouse 
tissues was performed using the SureSitell System 
from Novagen. Briefly, paraffin was removed by 
three washes in xylene and rehydrated through a 
graded ethanol series. Tissue pretreatment consisted 
of ribosome disruption in 0.2 N HCl for 5 minutes, 
deproteinization in 1 pg/ml proteinase K for 5 
minutes, followed by acetylation in 0.1 M 
triethanolamine-HCl, pH 8.0, containing 0.25% (v/v) 
acetic anhydride for 5 minutes. Prehybridization, 
hybridization with antisense and sense probes on 
parallel sections, and subsequent washings were 
performed according to the manufacturers 
instructions. Slides were apposed to XAR2 films for 
1-2 days, then dipped into Kodak NTB-2 emulsion, 
exposed in a sealed container for 2-3 weeks at 
+4°C, and finally developed and fixed using Kodak 
developer D-19 and Kodak fixer respectively. Slides 
were stained in 5% aqueous Giemsa, examined and 
photographed with bright and darkfield optics using 
an Olympus BH-2 microscope equipped with an 
Olympus C-35AD-2 camera. In situ hybridization on 
rat brain sections using the oligonucleotide probes 
described above was performed essentially as 
previously described (Baram and Schultz, 1991; 
Baram and Schultz, 1992; Yi et al., 1993). After 
prehybridization for 1 hr and hybridization for 20 
hr at 40°C in a humidity chamber, serial washes 
were performed (4 washes at 2xSSC for 15 min at 
40°C, followed by one wash in lxSSC and one in 
lxSSC at room temperature), followed by 
dehydration through ethanol-0.3M NH^Ac and 
apposition to X-ray film (Hyperfilm B-max, 
Amersham) for 24-48 hrs. 
Northern blot analysis 
Tissues from C57B1/6 x B6CBA Fl mice were 
minced in a polytron and total RNA was extracted 
using the acid guanidinium thiocyanate phenol-
chloroform method (Chomczynski and Sacchi, 1987). 
At embryonic day E15, E17, and E20 the head 
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region was separated from the remainder of the 
embryo. At parturition (PO) and postnatal day 1, 5, 
10, 15, 20, 25, 30, and 35, the entire brain including 
cerebellum was dissected. In order to compare the 
developmental expression of bcr in brain with bcr 
expression in hematopoietic tissue, RNA was 
prepared from liver at E15, E17, E20, at 
parturition, and from spleen at postnatal day 1, 5, 
10, 15, 20, 25, 30, and 35. Samples (10 fig) were 
run on formaldehyde/formamide gels, blotted as 
described (Sambrook et al., 1989) and subsequently 
hybridized to the 1.8kb Hindlll/EcoRI probe 
containing coding sequences from mouse bcr exon 
1. Filters were washed at low stringency (2.5xSSC, 
65°C for 20 min). At this stringency the probe also 
cross hybridizes to the 28S and 18S ribosomal bands 
making it possible to check for equal loading of the 
lanes. Densitometrie scanning was performed using 
an in-house manufactured densitometric device. 
Results 
In situ hybridization patterns 
Coronal sections of adult mouse brain revealed 
specific hybridization mainly localized to cells of 
neuronal morphology when hybridized with either 
of the two (non-overlapping) antisense bcr probes 
described above. The sense probe did not produce 
any specific signal in any of the experiments 
performed. High concentration of bcr mRNA was 
present in hippocampus, and to a somewhat lower 
degree in the cerebral cortex. In hippocampus and 
dentate gyrus, region CA1-CA3, the pyramidal cell 
and granular cell layers were strongly labeled (Figs, 
la and lb). In cortex, neurons in layers II-VI were 
moderately labeled, whereas a stronger labelling was 
noted in the piriform cortex. Some thalamic nuclei 
showed a weak hybridization. Neurons in amygdala 
and hypothalamus were not labeled above 
background hybridization. The hybridization pattern 
in cerebellum was not investigated. In rat, in situ 
hybridization with the labeled oligonucleotide 
revealed similar expression patterns: dentate gyrus 
granular cells, hippocampal pyramidal layer and 
piriform cortex clearly displayed a specific 
hybridization pattern, diminishing in intensity, in the 
order indicated above (Fig 2.). The anterior 
olfactory nucleus also displayed a specific 
hybridization pattern (not shown). 
Figure la. Darkfield photograph of a coronal section of a 
mouse brain showing strong hybridization to the 
hippocampus (large arrow-heads) and dentate gyrus (small 
arrow-heads) when hybridized with the antisense bcr probe. 
Figure lb. A parallel section of the section presented in 
figure la showing only weak background hybridization to 
the hippocampus (large arrow-heads) and no hybridization 
signal to the dentate gyrus when hybridized with the sense 
bcr probe. 
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Figure 2. Coronal section of rat brain showing strong 
hybridization to hippocampus (large arrow-heads) and 
dentate gyrus (small arrow-heads) when hybridized to the 
bcr oligonucleotide (see: Material and Methods). 
Gene expression throughout development 
Northern blot analysis of bcr expression in 
mouse brain showed a transcript of approximately 
7 kb which was present at E15 and remained 
constant throughout the embryonal period of 
development, as well as through postnatal days 1-
35 (Fig. 3). Densitometrie scanning revealed no 
clear changes in bcr expression level over time, 
when corrected for unequal loading on the basis of 
background hybridization to 18 and 28S ribosomal 
RNA The role of Bcr in blood cells has recently 
been validated (Voncken et al, 1995). Northern 
blot analysis of liver and spleen samples, both 
organs, that have a distinct hematopoietic function 
during embryogenesis and for some period after 
birth, showed a lower level of bcr expression 
throughout the same developmental stages, but 
similar to bcr expression in brain, the level 
remained constant throughout pre- and postnatal 
development (data not shown). 
(Heisterkamp and Groffen, 1991; Van Etten, 1993). 
Although we have recently established a function 
for Bcr in neutrophils, the reason why bcr is highly 
expressed in brain remains elusive. We have used 
in situ hybridization to study bcr expression patterns 
in rodent brain. Our data show that bcr is highly 
expressed in the hippocampus and dentate gyrus, 
and to a lower level in the piriform cortex and 
anterior olfactory nuclei. 
Granule cells of the dentate gyrus are primarily 
generated postnatally. In the mouse and the rat, a 
small percentage of these cells is constantly 
generated in the adult (Gage, 1994; Gould et al., 
1994; and references therein). Since bcr expression 
appears highest in these structures, we cannot 
entirely exclude the possibility that Bcr is directly or 
indirectly associated with cell proliferation. 
Regulatory molecules for small GTP-binding 
proteins have been increasingly implicated in cell 
growth and division over the recent years. The 
DBL gene, a G-nucleotide exchange factor, is an 
oncogene (Eva et al, 1985), and tissue directed 
expression of DBL-transgenes in animals causes 
specific metaplasias (Eva et al., 1991). BCR is 
implicated in human myeloid and lymphoid 
leukemias and a region on chromosome band 17p 
15 17 20 0 1 5 10 15 20 25 30 35 
^ß ^ff ^^..'^P-q^ ^ P/ ^ ff ^Q BCR 
t # * * 
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Discussion 
The Bcr protein is a multidomain protein and is 
involved in Ph-positive leukemogenesis through its 
fusion to the non-receptor tyrosine kinase Abl 
Figue 3. Autoradiogram showing a constant expression of 
brain bcr from embryonal day 15 (E15) to postnatal day 
35 (P35). The bcr transcript of approximately 7 kb and the 
28 and 18S ribosomal bands are indicated 
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which contains the ßCÄ-related ABR gene, appears 
to be deleted in particular cancers (Isomura et al, 
1994; Morris et al., 1995; Saxena et al, 1992). 
Recently, a novel etiological mechanism was 
described for the development of malignant 
Schwannomas in von Recklinghausen 
neurofibromatosis: not p21 itself, of which 
mutated forms are frequently implicated in human 
neoplasias, but one of its regulators, neurofibromin, 
a GTP-ase activating protein (GAP) for RAS, 
appeared deactivated through loss of both 
functional neurofibromin alleles (Basu et al., 1992; 
Bollag and McCormick, 1992; DeClue et al., 1992). 
Loss of neurofibromin also contributes to the 
formation of malignant myeloid diseases in children 
(Shannon et al., 1992). The resulting constitutive 
activation of p21 in neurofibromatosis illustrates 
an obvious role for small GTP-binding proteins as 
well as their regulatory molecules (i.e. GAPs and 
GEFs) in processes that control cellular growth in 
the brain. 
The C-terminal part of Bcr has a high degree of 
homology with that of n-chimerin, which, like Bcr, 
possesses GTP-ase activity toward p21 r ac , a member 
of the RAS superfamily. The regional expression 
pattern of bcr in brain overlaps in part that of n-
chimerin. N-chimerin expression is restricted to 
neurons, with the highest levels of expression in 
hippocampal pyramidal cells, granulae cells of the 
dentate gyrus, in cortical neurons, and in the 
Purkinje cells of the cerebellum (Lim et al., 1992). 
The developmental expression of bcr, however, 
displays different dynamics than that of n-chimerin: 
whereas n-chimerin expression rises sharply after 
birth to maximal levels at 20 days postpartum (Lim 
et al., 1992), a period coinciding with cellular 
differentiation and synaptogenesis, bcr expression 
remained constant from E15 through day 35 after 
birth. Northern blot analysis of hematopoietic 
organs (liver and spleen) also revealed a constant 
level of bcr expression from embryonal stage E15 
throughout development until adulthood. 
It is difficult to assess the significance of the 
relatively high level of bcr expression in the 
hippocampal region of the brain. Recently, n-
chimerin expression in the canary forebrain was 
connected with seasonal changes in song learning 
and behavior; the conserved structure and pattern 
of n-chimerin expression in the song circuit 
suggested a fundamental function for this gene in 
the vertebrate forebrain, and a role in the 
regulation of neural plasticity (George and Clayton, 
1992). In the young mouse brain, the developmental 
expression pattern of n-chimerin seems to disclose 
a potential role in development of particular 
cognitive functions (Lim et al., 1992). The finding 
that bcr expression is more or less constant 
throughout brain maturation would seem to point 
to a regulatory role of a more fundamental 
character in cellular processes. 
In rodent brain, bcr mRNA in hippocampus is 
most abundant in dentate gyrus cells, lower in CA3 
and lowest in CA1. The functional organization of 
hippocampus is such that input through the 
perforant path reaches granule cell layers. The 
granular cells, through axons (mossy fibers) synapse 
on CA3 neurons, which then impinge on CA1. The 
gradient of bcr expression levels along this 
functional neuronal path may reflect a potentially 
interesting, yet presently poorly understood function 
of Bcr in these highly specialized structures. 
A growing number of GTPases and GAPs has 
been implicated in brain biology over the most 
recent years. Often these proteins (i.e. n-chimerin, 
a2-chimerin, Bcr, Abr) display a brain specific 
expression pattern (Hall et al., 1993; Leung et al., 
1994; Lim et al., 1992;; Tan et al., 1993), or are, as 
described above, implicated in brain physiology (n-
chimerin) or neoplasia (neurofibromin). Members 
of the extended family of GTPases have also been 
implicated in synaptic vesicle transport in nerve 
terminals (Liu et al., 1994; Von Gersdorff and 
Matthews, 1994), furthermore indicating the 
importance of such protein factors in fundamental 
brain related processes. Future investigations will 
undoubtedly identify additional regulatory molecules 
for G-proteins (i.e. GAPs and GEFs) that play 
key roles in brain biology. 
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'Two mice and a mouse'. By Nora and John (30-something) 
CHAPTER 9 
Discussion 
• Discussion 
In 1990, the group of Groffen and Heisterkamp reported on a transgenic mouse model for 
Philadelphia-positive acute lymphoblastic leukemia (ALL). The disease that developed in the BCRJABL 
P190 transgenic mice resembled the human disease closely: most founder animals died of acute pre-B 
lymphoblastic leukemia. 
In subsequent studies, the transgenic animal model for Ph + ALL was characterized in detail and used 
to examine processes that accompany tumor onset and progression (reviewed by: Groffen et al., 1992; 
Groffen et al., 1993). 
Analysis for BCR/ABL expression in other tissues, than those of hematopoietic origin, demonstrated 
that the transgene was expressed in all tissues examined (Chapter 4). This observation is important in view 
of tumor etiology: since BCR/ABL expression affects bone marrow cells, it would seem, that in these cells, 
the appropriate factors (effector molecules, affector molecules) are present for mediating the effects of 
the Bcr/Abl protein. This view is consistent with the demonstrated critical role for the normal c-abl proto-
oncogene in a restricted population of cells in the immune system (Tybulewic et al., 1991; Schwartzberg 
et al., 1991). Also, bcr gene ablation in mice affects cells of myeloid and lymphoid origin (Chapter 7). The 
combined results indicate that cellular factors and/or signal transduction pathways in cells of hematopoietic 
origin, that involve the parental molecules (Bcr and Abl), are quite possibly implemented in Bcr/Abl 
mediated leukemogenesis as well. Not only would this explain the restricted oncogenicity of Bcr/Abl, the 
observations would also explain why the iVi-chromosome, which one would expect to arise by chance in 
many proliferating tissues, has so far been found in blood cancers only. 
Such a scenario would, however, question the relevance of in vitro experimentation for example in 
rodent fibroblasts or kidney cells. How can transformation by BCR/ABL occur in cell lines, which bear 
no apparent biological relevance to disease in human or mouse? A possible answer is found in studies, 
that scrutinized the establishment of BCR/ABL mediated growth factor independence in myeloid cells 
in vitro. It was speculated that, because additional mutations are required to BCR/ABL expression for 
abrogation of growth factor dependence in vivo, such cell lines may harbour co-operating mutations (such 
as for example the co-operation of BCR/ABL with myc in transformation of Rat-1 cells; Lugo and Witte, 
1990) already (Karabinowski et al., 1994). Alternatively, overexpression of an activated kinase in Bcr/Abl 
could cause immediate (reversible) epigenetic alterations in these assay systems. Neither human 
Philadelphia-positive hematopoietic progenitors nor chronic phase CML cells loose their growth factor 
requirement and normal proliferative responses to growth factors (Moore et al., 1973; Goldman et al, 
1974; Metcalf et al., 1974; Lansdorp et al., 1985). Also, analysis of our mouse model suggests, that over-
expression of the BCR/ABL transgene is not a prerequisite for leukemic transformation (Chapters 3 and 
2), indicating that the chosen in vitro assay conditions are not necessarily relevant to human leukemia. 
Karyotypic analysis of leukemic bone marrow of a significant number of BCR/ABL P190 transgenic 
mice demonstrated that leukemic cells undergo a clonal development and karyotype evolution toward a 
more aggressive tumor: a high frequency of aneuploidy was found in advanced leukemia, as occurs in 
human leukemia (Sandberg, 1990; Williams et al., 1990), with a preference for gain of chromosomes 10, 
12, 14 and 17 (Chapter 2). Tumor advancement toward a more aggressive genotype, through accumulation 
of multiple genetic mutations, was illustrated by serial leukemic bone marrow transplants, that revealed a 
gain of clinical malignancy of the cancer in irradiated recipient mice (Chapter 2). 
It has been argued, that the initial development of /%-positive leukemia in man is unrelated to the 
presence of the PA-chromosome (i.e. BCR/ABL): primary PA-negative clone(s) would have an increased 
susceptibility, of unknown nature, to acquire chromosomal abnormalities (Fialkow et al., 1967; Fialkow, 
1977). The data obtained by analysis of karyotypic abnormalities and clonal evolution, as it develops in 
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leukemie clones in our BCR/ABL P190 transgenic mice, seem to argue against such scenario (Chapter 
2). The expression of BCR/ABL, the consequence of the Ph-translocation, appears to be correlated with 
an increased risk of developing chromosomal abnormalities. Although it can be argued that this 
phenomenon is simply the consequence of expanded pool of B-cell precursors and would therefore be 
unrelated to BCR/ABL expression, this explanation could not readily account for the random extra 
chromosomes seen in some of the early leukemic mice which did not clearly exhibit a packed bone marrow. 
It was concluded, that in the BCR/ABL P190 transgenic mice, the presence of the BCR/ABL gene 
product is directly or indirectly responsible for the development of chromosomal abnormalities (Chapter 
2)-
This does, however, not imply that BCR/ABL on its own, without the contribution of any other gene 
is sufficient to cause leukemia. It is possible that BCR/ABL expression predisposes the cells to secondary 
events (e.g. additional gene mutations and/or chromosomal translocations). An ever increasing number of 
genes is being implicated in cancer, including, among other broad categories, tumor suppressor genes, 
genes for growth factors and their receptors, for intracellular signal transducing proteins, transcription 
factors, and for proteins affecting programmed cell death and cell cycle control. Any of these categories 
is likely to be affected by mutation which will allow the leukemia to gain in malignancy. In human CML, 
the t(9;22) somehow predisposes to further malignant progression of the leukemia in almost all patients. 
A large number of additional chromosomal abnormalities have been observed as CML progresses from the 
chronic phase to an accelerated or blastic phase (Sandberg, 1990). Karyotypically, additional non-random 
changes are found in some CML patients, but not in all. This could yield clues as to which additional genes 
are involved. Rearrangements of the p53 gene have been noted frequently during transition to blast crisis, 
as have been mutations in RAS or deletions of interferon genes (Ahuja et al, 1990; Marshal et al., 1990; 
Liu et al., 1988; Neubauer, 1990). 
In view of the above, it is unlikely that the expression of the BCR/ABL oncogene is the only factor 
necessary to realize malignant leukemogenesis. Based on the analysis of our P190 transgenic mice, we 
hypothesize that BCR/ABL expression is the prime event initiating P/î-positive leukemia. Prolonged 
exposure to the biological action of Bcr/Abl deregulates the normal process of signal transduction and 
cell division. The resulting genetic instability sets the stage for accumulation of mutations, and malignant 
progression of the leukemia, would either be an indirect effect of this prime event, or the direct result 
of continued BCR/ABL expression (Chapter 2). Indeed, it has been postulated, that discordant maturation 
of cytoplasma and nucleus explains disruption of cell cycle regulation in P/z-positive CML (Clarkson and 
Strife, 1991): non-disjunction and aneuploidy would be a direct or indirect effect of BCR/ABL expression. 
Evidence that BCR/ABL upsets regulation of the cell cycle also comes from in vitro observations: 
BCR/ABL expression in (murine) myeloid cell line leads to an increase in the percentage of cells in the 
G2/M phase of the cell cycle (Laneuville, 1991). 
In human P190 appears to be associated mainly with /%-positive ALL, whereas P210 is found both 
in iVz-positive ALL and in CML (reviewed by: Kurzrock et al., 1988; Sawyers et al, 1991; Heisterkamp 
and Groffen, 1991). The longer latency time of P210 associated tumorigenesis, would seem to indicate 
an intrinsic variation in biochemical properties between the two distinct oncoproteins. This notion was 
corroborated by in vitro experiments with retroviral BCR/ABL P190 and P210 constructs: the transforming 
potential of BCR/ABL PI90 was higher, a property which correlated with an intrinsically higher auto-
phosphorylation activities in cultured fibroblast cell lines (Lugo et al., 1990). In transgenic mice, the P190 
and P210 forms were found to cause clinically distinct conditions (Chapter 4). In human, about 50% of 
7%-positive ALL cases carry the BCR/ABL P190 translocation, the other 50% the P210. Consequently, 
the issue whether Ph+ ALL is actually CML in blastic phase has been controversial for some time. 
Recently, however, clinical and molecular studies have established that indeed Ph+ ALL and acute phase 
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CML are two distinct diseases (reviewed by Berger, 1993). The finding, that BCR/ABL P190 and P210 
cause distinct disease in the transgenic setting, supports this idea. 
To date, all animals models for human /Vi-positive leukemia, whether generated through retroviral 
(Elefanty et al., 1990; Daley et al. 1990; Kelliher et al., 1991) or transgenic technologies (Hariharan et 
al., 1989; Heisterkamp et al., 1990; Chapter 5), develop predominantly lymphoid malignancy of B and T 
type. All experimentally derived BCR/ABL lymphoid tumors were generated with regulatory sequences 
other than the BCR promoter. Although hematologic tumors in /%-positive ALL are principally of the 
pre-B phenotype, B lymphoid involvement occurs only in about 25% of cases of human CML in blast 
crisis and T cell involvement is rarely seen in human. One explanation for this discrepancy could be that 
regulatory sequences within the BCR gene are important for the type of disease found in human and 
mouse. This concept contrasts with the postulate, that neither BCR sequences nor myeloid cell promoter 
elements are essential for myeloid tumorigenic transformation (Kelliher et al., 1990) and, that the BCR 
sequences that distinguish BCR/ABL P190 and BCR/ABL P210 do not control the selection of particular 
types of hematopoietic cells (Kelliher et al, 1991). Recently, the Bcr function was connected with the 
regulation of superoxide production by the NADPH-oxidase system of leukocytes in vivo (Chapter 7). 
Interestingly, bcr gene ablation affects specifically those cell types in mice affected by BCR/ABL in man 
and mouse. It seems reasonable to conclude from our data that a correlation exists between the cell type 
affected in /Vi-positive leukemia and Bcr function. 
Although data concerning the normal cellular function of Bcr are accumulating, the precise role(s) 
of this gene in normal cell physiology remains unclear. In the mouse, bcr expression is detectable as early 
as at the zygote stage, continues throughout embryogenesis (unpublished observations) and is found in 
most adult tissues examined. In man, BCR has also been shown to be ubiquitously expressed (Heisterkamp 
et al., 1993b). Notwithstanding its function in hematopoietic cells, the Bcr protein is found in high levels 
in brain. This observation has intrigued us as it suggests a possible different function for pl60^cr. This 
notion is corroborated by the significant function of G-proteins in brain (Liu et al., 1994; Von Gersdorff 
and Matthews, 1994). 
In the mouse and the rat, a small percentage of granule cells of the dentate gyrus is constantly 
generated in the adult animal (Gould et al., 1994; Gage et al, 1994 and references therein). Since bcr 
expression appears highest in these structures, the possibility that Bcr is directly or indirectly associated 
with cell proliferation cannot entirely be excluded. The involvement oiDBL gene, a G-nucleotide exchange 
factor (GEF), in oncogenesis (Eva et al., 1985), and the implication of RAS and neurofibromin, a GTPase 
activating protein (GAP) for RAS, in malignant neurofibromatosis (Bollag and McCormick, 1992; DeClue 
et al., 1992; Basu et al., 1992) and myeloid disease in children (Shannon et al., 1992) illustrate a role for 
small GTP-binding proteins, as well as their regulatory molecules (i.e. GAPs and GEFs) in processes that 
control cellular growth, among other tissues, in the brain. 
In mouse brain, the expression pattern of bcr shows some overlap with that of the biochemically 
related n-chimerin gene (Chapter 8). The kinetics of bcr expression are, however, different from n-
chimerin, of which expression peaks at around 2 weeks of age; bcr mRNA levels are constant throughout 
late development and the first weeks after birth. N-chimerin may be involved in development of particular 
cognitive functions in the young mouse brain (Lim et al., 1992). Bcr is highly expressed in the hippocampal 
pyramidal cell layer and the dentate gyrus, and at a lower level in the piriform cortex and the anterior 
olfactory nuclei. The gradual change in expression levels along these structures, may reflect a potentially 
interesting function for Bcr in these highly specialized areas of the brain (Chapter 8). 
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• Future directions 
The study of Philadelphia-positive leukemia is ultimately aimed at formulating successful treatment 
protocols to fight the disease. The availability of a mouse model for Ph + ALL will have a positive impact 
on the accuracy and the pace at which new anti-cancer drugs can be tested. Studies in this direction have 
been undertaken already: we have tested the effectiveness of interferon-a (IFN-a) in the transgenic setting 
(Chapter 6), unfortunately without promising results. IFN-a was shown an effective drug in the treatment 
of human CML (Kantarjian et al., 1993); recently a similar strategy was tried in /%-positive ALL patients 
(Haas et al., 1988; Ohyashiki et al., 1991) some promising results were obtained in ALL patients with an 
M-bcr breakpoint. Treatment of BCR/ABL P190 bone marrow recipient mice with dihydroepiandosteron 
(DHEA) was shown to have a adverse effect on tumor progression and prolong animal survival (Catalina 
et al., 1995). DHEA is an adrenal steroid hormone, which, among other preventative actions, inhibits 
development of cancer, atherosclerosis, autoimmune disease and viral infections. Future investigations will, 
besides an evaluation of (yet to be discovered) anti-cancer drugs in their effectiveness against leukemia, 
center around the development of drugs specifically designed to inhibit BCR/ABL expression (e.g. 
hammerhead ribozymes, antisense constructs) or prevent biological functioning of the oncogene product 
(e.g. synthetically designed zincfinger proteins; öïms-inhibitory factors). Collaborations in this area are well 
underway at this time. 
At a more fundamental level, it has now become possible to investigate the nature of cytoplasmic and 
nuclear factors, and signal transduction pathways, that contribute to the development and malignant 
progression of P h + leukemia in our transgenic mice. The etiological significance of cellular factors in 
leukemogenesis, that interact with either the BCR/ABL oncoproteins and/or with either one of both 
parental proteins, can now be analyzed. A transgenic setting is particularly well suited for the in vivo 
evaluation of mechanistic hypotheses which were based on in vitro observations. For example, mechanistic 
models that involve interaction with critical amino acid residues in Bcr/Abl oncoproteins, can be evaluated 
in vivo by using mutated Bcr/Abl genes in a transgenic setting. 
Although animal models have provided strong evidence linking the development of leukemia specifically 
to the presence of a chimaeric BCR/ABL gene, attempts to generate a dependable experimental in vivo 
model system to study human CML have been largely unsuccessful to date. The need for a reliable animal 
model to study CML is still clear. Future research will focus on using endogenous bcr regulatory sequences 
in combination with BCR/ABL transgenes in mice. The design of BCR/ABL P210 transgenes will include 
repressible or inducible regulatory elements. Future experimental strategies may combine transgenic and 
embryonic stem cell technology. 
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CHAPTER 10 
Summary 
Summary 
Human Philadelphia-positive leukemia results from a balanced chromosomal translocation, which fuses 
the BCR gene on chromosome 22 to the ABL proto-oncogene on chromosome 9. The understanding of 
/Vi-positive leukemogenesis has advanced enormously over the last few decades. Although in vitro assay 
systems currently used, are not always relevant to human tumor biology, much can and has been learned 
from studies, employing cell cultures and overexpression of BCR/ABL oncogenes. 
Another restriction in leukemia research is the availability of primary human tumor material for study. 
Moreover, such tissues often represent terminally advanced stages of tumorigenesis. Therefore, the 
importance of in vivo models to study Philadelphia-positive leukemia is manifold. A well defined transgenic 
mouse model allows for tumorigenesis to be studied from its earliest stages onward and factors and 
mechanisms that eventually contribute to malignant progression of the leukemic cells can be uncovered. 
Besides an 'unlimited' provision of tumor material for analysis, more importantly, the availability of a trans-
genic mouse model provides a means by which cancer treatment regimes can be tested. In addition, 
identification of cellular components and/or pathways that contribute to the onset or progression of 
leukemia may eventually lead to the discovery and development of new drugs. 
In 1990, Heisterkamp and co-workers reported on a transgenic mouse model for Philadelphia-positive 
acute lymphoblastic leukemia (ALL). Since most of the transgenic animals of an earlier study had 
succumbed to leukemia, part of the aim of this thesis was to generate BCR/ABL PI90 transgenic founder 
animals de novo and to derive a transgenic animal line(s) which was to be used for future studies. In 
order to better understand the animal model, leukemogenesis was studied in great detail in transgenic 
founder animals and their progeny. In the second chapter a cytogenetic study of the mouse model for 
acute lymphoblastic leukemia is presented. Karyotypic analysis of leukemic bone marrow of a significant 
number of mice shows, that leukemic cells undergo a clonal development and karyotype evolution toward 
a more aggressive tumor: a high frequency of aneuploidy is found in advanced leukemia, as occurs in 
human leukemia, with a preference for gain of chromosomes 10, 12, 14 and 17. These findings are 
corroborated by experiments that reveal a gain of malignancy of the cancer upon serial transplantation 
of leukemic bone marrow to irradiated recipient mice and by molecular analysis of lymphomas using 
immunoglobulin rearrangement as an indicator for tumor clonality. The results suggest that BCR/ABL 
has a destabilizing effect on the regulation of the proces of mitosis. 
In the third chapter, a correlation is described between the transcriptional status of the BCR/ABL 
P190 transgene and the development of leukemia: methylation of particular sequences in BCR exon-1 in 
the transgene is closely coupled to transgene inactivation, providing additional evidence for a direct role 
of BCR/ABL in leukemogenesis. A biological dissection of the oncogenic specificity of BCR/ABL is 
presented in the fourth chapter. Using sensitive molecular biological techniques, it is shown that, although 
expression of the BCR/ABL transgene is detectable in every tissue, from very early on in mouse develop-
ment, no other neoplasias than of hematopoietic origin are found. The results strongly suggest that the 
oncogenicity of BCR/ABL is restricted to nucleated blood cells, which is very likely a reflection of cellular 
functions of the BCR and or ABL gene in signal transduction specific to hematopoietic lineages. The 
observations would also explain why the Ph -chromosome, which one would expect to arise by chance in 
many proliferating tissues, is found only in blood cancers. 
An analysis of transgenic mouse models for chronic myelogenous leukemia, using BCR/ABL P210 
transgenes is presented in the fifth chapter. The clinical disease spectrum includes differentiated and 
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undifferentiated T and B cell leukemias. The myeloid compartment is implicated only sporadically and 
rather late in the disease process. In some instances, the observed myelo-proliferation is a sequel to 
deregulation of cytokine production at advanced stages of leukemia. The course of P210 induced leukemia 
was acute rather than chronic, be it with an on average longer latency period than typical for ALL in 
BCR/ABL P190 mice. From these studies is was concluded that in the mouse, BCR/ABL P210 evokes 
a clinically different disease than BCR/ABL P190. Although no evidence for a chronic myeloproliferative 
disorder in the peripheral blood was found, an imbalance in myelopoiesis in the bone marrow suggests an 
effect of BCR/ABL P210 on primitive myeloid progenitors. 
The sixth chapter summarizes an analysis of interferon-a (IFN-a) treatment of the BCR/ABL P190 
transgenic mice. IFN-a is currently one of the most effective drugs in the treatment of CML. Recently, 
IFN-a was tried in the treatment of ALL. No effect of IFN-a on animal survival or disease pattern were 
noted when administered to the BCR/ABL P190 mice. The conclusion was reached that, at least in a 
transgenic setting, IFN-a does not interfere with BCR/ABL P190 mediated leukemia. 
In order to study the normal cellular function of the BCR gene and to eventually assess its role in 
leukemogenesis, studies focussing on the mouse bcr gene function are presented in chapters 7 and 8. The 
seventh chapter describes the ablation of a functional mouse bcr gene by means of recently developed 
gene targeting techniques. One of two mouse bcr alleles was inactivated in a mouse embryonic stem cell 
line through gene interruption by insertional replacement vectors. This genetically altered cell line was 
then injected into developing mouse embryos. Through germline transmission of the mutated allele and 
subsequent breeding both bcr alleles were inactivated. Although bcr-mx\\ mutants are phenotypically 
normal, their neutrophils display impaired regulation of respiratory burst, which becomes apparent when 
these cells are activated in vivo: an overproduction of superoxide leads to significantly more oxidative 
tissue damage during experimental endotoxemia. The results connect Bcr in vivo with the regulation of 
superoxide production by the NADPH-oxidase system of leukocytes and suggest a link between the cell 
types affected by loss of Bcr function and the those involved in Ph -positive leukemia. 
Additional information on biological processes that Bcr participates in, are described, in the eighths 
chapter. Notwithstanding its function in hematopoietic cells, the Bcr protein is normally found in high levels 
in brain. The expression pattern of bcr in rodent brain was examined by means of in situ hybridization and 
Northern analysis. Although not directly connected with leukemogenesis, a potentially interesting role for 
pl60" c r in the brain is discussed as its expression pattern appears to coincide with the functional 
organization of particularly highly specialized structures in the brain. 
With the availability of well defined transgenic mouse models for BCR/ABL positive leukemia, an 
opportunity is created to study the nature of cellular interactions and processes that contribute to the 
onset and development of iVi-positive leukemia. Ultimately, such investigations are aimed at designing 
and testing effective therapeutic drugs to fight the disease. 
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Samenvatting 
Philadelphia-positieve leukemie in de mens ontstaat als gevolg van een translocatie tussen de 
chromosomen 22 en 9, waarbij het BCR gen en het ABL proto-oncogen gefuseerd worden. De kennis 
omtrent de etiologie van deze leukemie is de laatste jaren sterk toegenomen, mede door de informatie 
die uit in vitro experimenten met cellijnen en gezuiverde eiwitten is verkregen. Resultaten uit deze 
experimenten mogen echter niet zonder meer naar de in vivo situatie worden geëxtrapoleerd. 
Een andere duidelijke belemmering bij het bestuderen van leukemie is de beschikbaarheid van 
patientenmateriaal: indien al beschikbaar, representeert dergelijk primair tumorweefsel vaak een terminaal 
stadium van de kanker. Het belang van betrouwbare diermodellen voor de studie van Philadelphia-positieve 
leukemie is daarom meervoudig. Zo wordt met een goed gedefinieerd transgeen muizemodel voorzien in 
een bron van studiemateriaal voor het bestuderen van tumorigenese vanaf de beginstadia en de ontrafeling 
van processen, die uiteindelijk aan kwaadaardige progressie van leukemie bijdragen. Naast een 
ongelimiteerde voorraad aan tumormateriaal voor analyse, biedt een muizemodel bovendien de mogelijkheid 
om kankertherapieën te testen. Daarbij kan de identificatie van cellulaire factoren en processen, die een 
rol spelen bij onstaan en progressie van leukemie, leiden tot de ontdekking en ontwikkeling van nieuwe 
medicijnen. 
In 1990 werd door Heisterkamp en medewerkers gerapporteerd over een transgeen muizemodel voor 
Philadelphia-positive acute lymfoblastisch leukemie (ALL). Omdat de meeste transgene dieren in deze 
studie waren gestorven aan leukemie, was een gedeelte van het in dit proefschrift beschreven onderzoek 
gewijd aan het maken van nieuwe transgene muizen en het opzetten van muizelijnen voor verdere studie. 
Om een beter begrip te krijgen van de diermodellen is het proces van ontwikkeling van leukemie in de 
transgene muizen uitgebreid bestudeerd. In het tweede hoofdstuk wordt een cytogenetische studie van 
het diermodel voor acute lymfoblastische leukemie (ALL) gepresenteerd. Karyotypische analyse van 
leukemisch beenmerg van een groot aantal muizen laat zien, dat de leukemie een proces van klonale 
ontwikkeling en karyotypische evolutie doorloopt naar een meer agressieve kanker: een hoge mate van 
aneuploïdie kan aangetoond worden in ver gevorderde stadia, met, net als in de mens, een voorkeur voor 
verdubbeling van bepaalde chromosomen. Zowel een toename in kwaadaardigheid van de kanker na 
seriële transplantatie naar bestraalde muizen, als een tumor-klonaliteitsanalyse onderstrepen deze 
waarneming. De resultaten laten zien, dat het Bcr/Abl eiwit destabiliserend werkt op de normale cel- en 
kerndeling. 
In het derde hoofdstuk wordt een verband tussen de transcriptionele status van het BCR/ABL PI90 
transgen en de ontwikkeling van leukemie in een aantal verschillende muizelijnen gelegd: methylering van 
sequenties in BCR exon 1 in het transgen is gekoppeld aan transgen-inactivatie. Deze waarneming 
benadrukt nogmaals de directe rol van BCR/ABL in het ontstaan van leukemie. 
Een biologische ontrafeling van de oncogene specificiteit van BCR/ABL wordt gepresenteerd in 
hoofdstuk drie. Gebruikmakend van gevoelige moleculair biologische technieken wordt aangetoond, dat 
geen andere kanker dan bloedkanker gevonden wordt, ofschoon het transgen in elk weefsel tot expressie 
komt vanaf vroeg in de embryonale ontwikkeling van de muis. De resultaten geven aan, dat oncogeniciteit 
van BCR/ABL beperkt is tot witte bloedcellen, hetgeen zeer waarschijnlijk de cellulaire functie(s) van 
het Bcr en/of Abl eiwit in signaaloverdrachts processen, die specifiek zijn voor hematopoietische cellen, 
weerspiegelt. Deze waarneming biedt mogelijkerwijs ook een verklaring voor het uitsluitend aantreffen 
van het Philadelphia chromosoom in bloedkanker, terwijl verwacht mag worden, dat het bij toeval ook 
in andere weefsels zou kunnen ontstaan. 
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Een studie aan een transgeen muismodel voor chronische myelogene leukemie (CML), dat gebruik 
maakt van BCR/ABL P210 transgenen, wordt gepresenteerd in hoofdstuk vijf. In de muizen worden 
vooral lymfoide bloedkankers van gedifferentieerde en ongedifferentieerde T en B-origine gevonden. 
Daarentegen wordt een bijdrage van myelogene cellijnen aan deze kankers slechts sporadisch aangetroffen 
en dan bovendien vrij laat in het ziekteproces. In bepaalde gevallen kan de myelogene celexpansie 
verklaard worden door een ontregelde cytokine-productie in het zieke dier. Het verloop van het 
ziektebeeld in BCR/ABL P210 muizen is acuut, zij het met een langere latentietijd dan voor ALL in 
BCR/ABL P190 muizen. Vergelijking van BCR/ABL P190 and BCR/ABL P210 muizemodellen leert, 
dat leukemie in deze muizen via klinisch verschillende patronen verloopt. Ofschoon geen chronisch 
ziektebeeld in het bloed aangetoond kan worden, suggereren voorlopige resultaten wel een effect van 
BCR/ABL P210 op primitieve myeloide precursor cellen in het beenmerg-compartiment van transgene 
muizen. 
Het zesde hoofdstuk is gewijd aan de effectiviteit van interferon-a (IFN-a) behandeling van BCR/ABL 
P190 transgene muizen. IFN-a is momenteel een van de meest effectieve medicijnen in de behandeling 
van CML. Recentelijk heeft men IFN-a ook toegepast in de bestrijding van ALL. In BCR/ABL P190 
muizen werd geen effect op overleving en/of verloop van het ziektebeeld waargenomen na IFN-a 
behandeling. Hieruit is afgeleid dat, althans in het transgene muizemodel, IFN-a geen effect heeft op 
BCR/ABL gerelateerde leukemie. 
Om de normale cellulaire functie van het BCR gen en de rol, die het speelt in leukemie, beter te 
kunnen begrijpen, worden in hoofdstuk zeven en acht een aantal studies beschreven, die specifiek het 
muize-bcr gen betreffen. Hoofdstuk zeven beschrijft de functionele uitschakeling van dit gen door middel 
van gen-onderbreking in embryonale stamcellen. Deze genetisch gemanipuleerde cellen zijn vervolgens 
geïnjekteerd in zich ontwikkelende muize-embryo's. Door middel van onderlinge kruising van heterozygote 
muizen zijn vervolgens beide bcr allelen uitgeschakeld. Hoewel deze bcr nulmutanten fenotypisch normaal 
zijn, vertonen hun neutrofiele granulocyten een verhoogde superoxide productie. Dit is gemeten na in 
vivo activering van deze cellen: onder experimenteel septische condities wordt significant meer oxidatieve 
weefselschade in bcr nulmutanten gevondem De resultaten wijzen op een regulerende functie voor het 
Bcr eiwit in de superoxideproductie door het NADPH-oxidase systeem in leukocyten. De celtypen, waarvan 
de functie verandert door verlies van Bcr, zijn dezelfde celtypen, die betrokken zijn in P/i-positieve 
leukemie, hetgeen het veronderstelde verband tussen de normale cellulaire bcr functie en het onstaan van 
leukemie benadrukt. 
Van alle onderzochte weefsels komt bcr het hoogst tot expressie in de hersenen. Om andere 
biologische processen, waarin Bcr mogelijk een rol speelt, op te helderen, wordt het expressiepatroon van 
bcr in muizehersenen beschreven in hoofdstuk acht. Hiervoor zijn in situ hybridisatie technieken en 
Northern analyse gebruikt. Ofschoon niet direct relevant voor het onstaan van leukemie, wordt een 
potentieel interessante rol voor het Bcr eiwit in de hersenen besproken: het expressiepatroon van bcr 
overlapt de functionele organisatie van sterk gespecialiseerde structuren in de hersenen. 
Met de beschikbaarheid van goed gedefinieerde transgene diermodellen voor BCR/ABL-positieve 
leukemie, is de mogelijkheid gecreëerd om cellulaire eiwitten en processen, die bijdragen aan het onstaan 
en de ontwikkeling van Philadelphia-positieve leukemie in het dier, te bestuderen. Uiteindelijk is dit 
onderzoek gericht op het ontwikkelen en testen van effectieve medicijnen tegen deze vormen van leukemie 
in de mens. 
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